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1. INTRODUCTION 
1.1 Atherosclerosis 
Atherosclerosis is the leading cause of death worldwide1. The disease can be viewed as 
a chronic inflammatory condition of the arterial wall2. Atherosclerosis is mainly located 
in the intima of middle- and large-sized arteries. Atherosclerosis affects all three layers 
of the arterial wall, i.e., the intima, the media, and the adventitia. The adventitia 
constitutes the connective tissue coat that surrounds arteries3,4. Major features of the 
advanced atherosclerotic plaque are foamy macrophages, smooth muscle cells (SMCs), 
T cells, extracellular lipid, and necrotic cores5. Atherosclerosis leads to plaque 
formation and - if the disease becomes clinically significant - subsequent fissure, 
erosion or rupture of the plaque. In its late stages, atherosclerosis is associated with 
intraluminal thrombosis, resulting in oxygen depletion in the downstream territory 
leading to tissue infarcts2,6. Smoking, obesity, hypertension, stationary way of life, 
diabetes mellitus, and hyperlipidemia are well-recognized risk factors of 
atherosclerosis1. 
1.1.1 The healthy artery  
A normal large- or medium-sized artery consists of three layers, i.e., the intima, the 
media, and the adventitia. The innermost layer is known as the intima, which is 
composed of a single layer of endothelial cells and a sheet of elastic fibers named the 
internal elastic lamina. The media, i.e., the middle layer, is made up of SMCs and elastic 
fibers7. The outermost layer is the adventitia consisting of connective tissue harboring 
blood vessels, lymph vessels, tissue macrophages, mast cells, T cells, conventional or 
classical dendritic cells, and myofibroblasts8. The inner elastic lamina separates the 
intima from the media, while the outer external lamina isolates the media from the 
adventitia (Fig. 1.1).  
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Figure 1.1 Schematic graph of a normal and diseased artery8. Reproduced from Mohanta, S.K., et al. 
2014, Circulation Research. Normal and diseased arteries contain three layers: the intima, the media, and 
the adventitia. The normal intima contains a monolayer of endothelial cells. The normal media consists 
of several layers of smooth muscle cells (SMCs). Underneath the endothelial cell monolayer, few T cells 
together with conventional dendritic cells can be observed, while the adventitia harbors mast cells, 
macrophages, T cells, and myofibroblasts. During atherosclerosis progression, macrophages take up lipid 
to form foam cells, and SMCs migrate into the intima and proliferate. Thus, the atherosclerotic plaque 
consists of several inflammatory leukocytes, proliferating SMCs, and activated endothelial cells. 
Moreover, the adventitia adjacent to atherosclerosis contains a large number of T- and B-cells, other 
immunocytes, and newly formed high endothelial venules (HEVs) and conduits as well as aberrant 
lymphatic vessels. mDC designates monocyte-derived DC. 
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1.1.2 Progress in the field of atherogenesis 
Atherosclerosis is initiated by an accumulation of cholesterol in the arterial wall. 
Oxidized lipids and low-density lipoprotein (LDL) cause endothelial cells to express 
adhesion factors and chemokines. Subsequently, blood leukocytes adhere to the 
activated endothelium, then migrate into the intima9. Many macrophages in 
atherosclerotic plaques originate in blood-born monocytes, take up lipid to become 
lipid-laden foam cells10. The development of atherosclerotic plaque includes the 
migration of SMCs from the media to the intima, proliferation of SMCs, and an increase 
of extracellular matrix components such as collagen, elastin, and proteoglycans11. The 
macrophages and SMCs sustain apoptosis in advanced plaques. Extracellular lipid 
released by dead cells locates in the center of a plaque. Advanced plaques contain 
cholesterol crystals and microvessels as well. The last and clinically phases of 
atherosclerosis are associated with rupture of the plaque and intraluminal thrombus 
formation, which ultimately clog the artery leading to tissue infarcts, including 
myocardial infarcts and stroke12. 
1.1.3 Immunocytes in atherosclerotic plaques 
Atherosclerotic plaques consist of various immunocytes, characteristically 
macrophages, and T cells13-14. However, the roles for each cell type and the sequence 
of events leading to advanced atherosclerosis are not entirely clear.  
Foamy macrophages accumulate in the plaque and are pathological hallmarks of 
atherosclerosis. In 1979, Goldstein’s group first found that macrophages express 
scavenger receptors for acetylated LDL uptake and degradation15. This discovery 
revealed that scavenger receptor-expressing macrophages promote foam cell formation 
and atherogenesis.  
Ralph M. Steinman, in 1973, discovered dendritic cells (DCs) and characterized some 
general features of T cell responses that are initiated by DCs16. DCs were described in 
atherosclerosis for the first time in 1995 by Bobryshev13. DCs are found in the normal 
healthy artery wall and in all stages of atherosclerosis, indicating that DCs play 
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important roles in atherosclerosis. Subramanian et al. reported that Myd88-deficient 
CD11c+ DCs reduced regulatory T cells (Treg cells) in atherosclerotic arterial walls and 
thereby promoted atherosclerotic lesion formation in aortic roots17. DCs can also 
influence atherosclerosis by secreting inflammatory cytokines, i.e., interleukin-6, tumor 
necrosis factor, interleukin-2, interleukin-23, granulocyte-macrophage-colony- 
stimulating factor with potent effects on T cells and other immune cells18. 
T cells, one of the two major lymphocyte subtypes, play a significant role in the immune 
response. The T cell repertoire is formed in the thymus, and subsequently, T cells 
become activated and proliferate in secondary lymphoid tissues, including lymph nodes 
and spleen. T cells are heterogeneous. There are different stages and functional 
activation stages of T cells. These can be identified on the basis of surface activation 
markers. CD44 and Selectin-L (also known as CD62L) are well-recognized lymphocyte 
homing receptors, which mediate the interaction of lymphocytes with endothelial cells 
of high endothelium venules in secondary lymphoid tissues mediating recirculation 
events. Conventional murine T cells can be divided into three major populations, 
CD62LhiCD44lo naïve T cells (Th0), CD62LhiCD44hi central memory T cells (TCM), 
and CD62LloCD44hi effector memory T cells (TEM). Naïve T cells refer to T cells that 
leave the thymus but are not yet activated by antigens in secondary lymphoid organs. 
These T cells perform immune surveillance by recirculating between the blood and 
secondary lymphoid organs. In contrast, memory T cells have encountered a specific 
antigen and have been activated, resulting in proliferation.  
In 1986, Jonasson et al. discovered that T cells were present in atherosclerotic fibrous 
caps14. Since then, adaptive immune responses became a focus of atherosclerosis 
research. Wick et al. also observed that lymphoid cells were critical cellular constituents 
of atherosclerotic plaques19. Moreover, van der Wal et al. showed that CD4+ T cells 
were more abundant than CD8+ T cells in the early lesions and that the CD8+/CD4+ 
ratio increased in both early and late human plaques20. In the lesion, 95% of the T cells 
express TCR α and β subunits, and approximately 5% of T cells carry the TCR γδ in 
fatty streaks, and 4.3% in plaque21 (only 1-2% T cells carry the TCR γδ in peripheral 
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blood)22. These data indicated that T cells might contribute to atherogenesis. 
1.1.4 Mouse models of atherosclerosis 
Atherosclerosis is a complex, chronic, and multi-factorial disease. Because of the 
generation and use of genetically modified mice and their use for atherosclerosis 
research, the current understanding of the mechanisms of the disease has grown 
rapidly23-26. 
Genetically modified mice such as Apolipoprotein E-deficient mice, when maintained 
on a normal chow diet develop atherosclerosis because these mice are constitutively 
hyperlipidemic27,28. When maintained on a high-fat diet, some strains of mice, such as 
the C57BL/6 strain, develop atherosclerosis even more rapidly over time29,30.  
In 1992, the Apolipoprotein E-deficient (ApoE-/-) mouse was generated by two 
independent research groups27,28. As mentioned above, ApoE-/- mice are constitutively 
hyperlipidemic when maintained under normal mouse chow29,30. The other most 
utilized model of atherosclerosis is the low-density lipoprotein receptor-deficient 
(LDLr-/-) mouse. This mouse was established in 1993 by Ishibashi et al31. In contrast to 
ApoE-/- mice, LDLr-/- mice require a high-fat diet such as a Western-type diet to become 
severely hyperlipidemic and to develop atherosclerosis. Both ApoE-/- and LDLr-/- mice 
generate atherosclerotic plaques, which are similar to their human counterparts, but the 
mice have different plasma lipid profiles30. In LDLr-/- mice, triglyceride and cholesterol 
levels are increasing because of the Western chow, while in ApoE-/- mice triglyceride 
levels do not significantly change32. ApoE-/- mice develop advanced lesions with an 
acellular necrotic core33, and in addition, atherosclerotic plaque ruptures rarely occur in 
the brachiocephalic artery of the long-term high-fat diet fed ApoE-/- mice34. However, 
plaques instability in the normal diet fed ApoE-/- mice does not regularly form occlusive 
thrombi revealing differences between humans and mice35. However, ApoE-/- mice are 
of great interest in performing longitudinal studies of plaque development, vascular 
fibrosis, and calcification, but not plaque rupture. 
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1.1.5 Atherosclerosis in ApoE-/- mice 
Compared to wild type C57BL/6 mice, which have mean total cholesterol (TC) of 2.1 
mg/dl, ApoE-/- mice show substantial elevations, with mean TC at 19 mg/dl36. And this 
TC level will further increase 3-4 times on a high-fat diet (15% fat, 1.0% cholesterol, 
and 0.5% cholate)36.  
In a normal diet fed ApoE-/- mice, early atherosclerotic lesions, fatty streaks are 
regularly observed at 3 months27,37. More complex lesions will be formed after 20-30 
weeks, with many characteristics similar to human lesions, such as macrophages and 
SMC infiltration, fibrous plaque formation, and wall thinning37. By 10 months, 
calcification may be seen37. The progression will speed up with a high-fat diet37. 
1.2 Complement system and activation 
1.2.1 Complement cascade 
Hans Ernst August Buchner found a "factor" or "principle which is capable of 
eliminating microbes in the blood. Later, in 1896, Jules Bordet found that blood 
contained two distinct molecules: a heat-stable and a heat-labile constituent. The heat-
labile component was observed to be responsible for the general antimicrobial action 
of normal serum, and this is now termed the so-called "complement"38,39. 
The complement system constitutes a group of components in human and animal body 
fluids or on cell surfaces40-42. Complement is a significant part of the innate immune 
system, which is the first line of defense/protection against pathogen-triggered diseases. 
Recent studies further showed that complement connects the innate and adaptive 
immune response, and removes antibody-antigen complexes (immune complexes)41-43. 
The system contains more than 30 components41-43, which are largely produced and 
maintained by hepatocytes43. Additionally, immune cells and endothelial cells 
synthesize several complement components locally44. 
1.2.2 Activation of the complement system  
The complement system senses foreign pathogens and injured host cells by activating 
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the classical complement pathway (which is also termed the classical complement 
cascade, i.e., the CCC), the alternative complement pathway, and the mannan-binding 
lectin (MBL) complement pathway38. 
The CCC can be activated by binding of antibody-antigen complexes to C1q during 
innate immune responses, and therefore the CCC bridges the innate and adaptive 
immune systems. Binding of the MBL to mannose-containing carbohydrates on 
bacteria or viruses initiates the MBL pathway. The alternative pathway is initiated by 
the spontaneous hydrolysis of C3 into C3a and C3b. Because of the inhibitors and 
regulators represented on the surface, i.e., factor H, factor I, CD59, C3b deposits on all 
normal cells does not lead to cell damage. The pathway is only triggered by the direct 
binding of the C3b protein to a microbe, foreign materials, and damaged cells. 
Both the classical and MBL pathways require the C2 and C4 complement proteins for 
the formation of C3 convertase, which is formed from C4b-C2b complexes. In the 
alternative pathway, factor B can bind to C3b, which is produced by the CCC. D factor 
cleaves the C3bB complex into C3bBb and Ba. C3bBb, as a C3 convertase, includes 
the Bb component which can cleave C3 into C3a and C3b. C3bBb can be stabilized 
with binding to properdin (P factor), or it will hydrolyze rapidly (see Fig. 1.3).  
Complement pathway activation leads to the generation of a protease called a C3 
convertase that cleaves C3 to C3a and C3b. The C3b molecule contributes to generating 
a C5 convertase that produces the small key peptide mediators of inflammation, the 
products of C5, i.e., C5a and C5b. Following C6 binding site exposure by C5b, the 
C5bC6 binds to the target surfaces and initiates the formation of C5b-9 (MAC or 
TCC)45, which forms a pore in the cell membranes of pathogens or other target cells 
and induces the cells’ lysis. Whether cell death is apoptotic or necrotic seems to be a 
function of C5b-9 quantity45. 
Complement cascade activation results in lysis of the pathogen, opsonization, and pro-
inflammatory activity by producing a large number of biologically active components.  
C3b plays an important role in opsonization. It deposits on the surface of a target to 
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mark the target such a microorganism and then promotes the recognition and uptake by 
phagocytes46.  
C3a and C5a can also recruit and activate inflammatory cells by potent chemotactic 
activity towards several innate and adaptive immune cells. C5a receptor (C5aR) is 
involved in chemotaxis, oxidative burst, and other inflammatory mechanisms. 
Moreover, it is highly expressed in myeloid cells, granulocytes, 
monocytes/macrophages, mast cells, DCs, T and B cells47, 48. C5aR was also found to 
be expressed in most organs and many different cell types like endothelial cells, neurons, 
astrocytes, microglia, and other tissue cells, including those of the kidney, lung, liver, 
spleen, intestine, and heart46,47. Using C5aR-/- mice or C5a/C5aR-inhibition in animal 
models, it has been shown that C5a plays an important role in various diseases, i.e., 
Alzheimer’s disease, sepsis, Arthus reaction, asthma, in several models of ischemia-
reperfusion injury47, and in atherosclerosis48.  
C5a regulates neutrophil and monocyte activity and enhances cell adhesion, resulting 
in granulocyte degranulation and release of intracellular enzymes, generate toxic 
oxygen metabolites and initiating other cellular metabolites.  
The complement component also has a variety of other immune functions via 
complement receptors (CR) expressed by immune cells. C3b/C4b receptor, CR1, 
known as CD35, promotes antigen presentation on B cells49, and transfers and eliminate 
immune complexes on red blood cells50. CR2 (CD21) regulates B cell activation by 
binding to CD1951 and serves as a receptor for Epstein Barr virus, which is an important 
facilitator of T cell lymphomas and autoimmune diseases52. CR3 (CD11b/ 
CD18)regulate T cell proliferation and IL-2 production53. CR3 and CR4 (CD11c / CD18) 
contribute to phagocytosis54. Activation of complement cascades generates C3a, C4a, 
and C5a, which in return lead to mast cell degranulation, vascular leakage, and smooth 
muscle contraction. 
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Figure 1.2 Complement activation cascades46. This schematic representation was taken from reference 
(Zipfel, P.F et al., 2009, Nat Rev Immunol). The complement pathways contain alternative, classical, and 
lectin pathways. The alternative pathway is activated by C3 hydrolysis spontaneously, which is modified 
by factor B and factor D. The CCC is activated by C1q binding to immune complexes, and the lectin 
pathway is initiated by MBL. Activation of C3 leads to the C5 activation and TCC formation, which is 
formed with C5a, C6, C7, C8, and multiple C9 molecules. C3b can serve as an opsonin when bound to 
an antigen’s surface. C3a and C5a cause inflammation by activating and recruiting inflammatory cells. 
Mannan-binding lectin serine protease (MASP) indicates MBL-associated serine protease. 
1.3 Complement cascade and atherosclerosis 
While initial events in the pathogenesis of atherosclerosis remain to be fully understood, 
it is well accepted that lipid accumulation beneath endothelial cells is associated with 
major inflammatory tissue reactions, which in turn trigger additional inflammatory 
cascades to form an advanced plaque. However, how lipid triggers vascular 
inflammation is still unclear. 
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Complement might influence the progression of atherogenesis, as shown in human 
studies. Vlaicu's group showed that C5b-9 is present in the normal intima and the media 
but is induced significantly in the thickening intima, media, and the fibrous plaque55. 
Moreover, Cristea and Vlaicu’s group reported that C5b-9 deposition was frequently 
associated with other complement components such as C1q, C3c, and C4 and 
immunoglobulins such as IgM, IgG, IgA56. In 1990, Rus and Vlaicu’s group showed 
that decay-accelerating factor deposition in human thickened intima and fibrous 
plaques were significantly higher than those in fatty streaks or healthy blood vessel 
areas. Decay-accelerating factor and C5b-9 proteins were co-localized on nucleated 
cells and cell debris57. In 1989, factor H, factor B, and C3 were found at the same 
location as C5b-9 by Hansson’s group, but not in normal arteries. The same 
investigators observed complement C3b receptor (CR1) and the iC3b receptor (CR3) 
to be expressed by approximately 20% of the total cells in complex human carotid 
lesions58. The mRNA levels for complement components were also increased in fibrous 
plaques when compared with normal arteries indicating local production of 
complement components. Yasojima observed that mRNAs for C1r, C1s, C4, C7, C8, 
and CD59 were increased in human aortic atherosclerotic plaques compared with 
normal artery59.  
Previous functional studies in mice have, however, shown that the role of complement 
activation in atherosclerosis remains controversial. C6-/-ApoE-/- mice on a high-fat diet. 
develop fewer plaques in the innominate artery compared to control ApoE-/- mice60. 
Inhibition of the C5a receptor in ApoE-/- mice on a normal diet decreased innominate 
artery plaque size48. These data indicated that complement system activation promotes 
atherosclerosis. However, C1q-/-LDLr-/- mice on normal diet developed more aortic root 
plaque61, and C3-/-ApoE-/-LDLr-/- mice have more plaques in total aorta when stained 
with en-face staining62, indicating that complement cascade activation protects the 
arterial wall from atherosclerosis. Finally, knockout of C5 does not appear to affect 
atherosclerosis in ApoE-/- mice on high fat diet63. Therefore, studies on the role of the 
complement cascades in atherosclerosis using animal models have so far produced 
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conflicting results, and thus the role of complement activation in atherosclerosis 
remains unclear. 
1.4 Complement-based therapies  
1.4.1 Complement-system-associated diseases 
The immune system employs inflammation to protect the host from microbial damage, 
repair damaged tissue, and to remove dead cells and immune complexes. However, 
when inflammation becomes chronic, inflammation can cause disease. Complement 
system activation seems to drives a significant number of chronic inflammatory, 
autoimmune64, neurodegenerative65, and ischemia/reperfusion (I/R) injury-related 
diseases66. It is well established that complement constituents are increased in inflamed 
tissues and complement is involved in various autoimmune diseases, e.g., systemic 
lupus erythematosus (SLE)67, Alzheimer’s disease plaques68, age-related macular 
degeneration (AMD)69, atypical hemolytic uremic syndrome (aHUS)70, paroxysmal 
nocturnal hemoglobinuria (PNH)71, rheumatoid arthritis (RA)72, myasthenia gravis 
(MG)73 and others.  
PNH is a rare and acquired fatal blood disease. Patients with PNH present somatic 
mutations in the PIG-A gene on the X chromosome in hematopoietic bone marrow stem 
cells, and deficiency of CD55 and CD59, which are surface proteins and inhibit the 
formation and function of the TCC. Therefore, red bloods are susceptible to damage by 
the complement system, resulting in chronic hemolytic anemia74.  
aHUS is a disease characterized by microvascular hemolytic anemia, thrombocytopenia, 
and acute renal failure. The main pathogenesis of aHUS is the excessive activation of 
the alternative pathway, which forms MAC on the membrane of the host cells, resulting 
in cell lysis75.  
AMD is an age-related disease, characterized by ocular nerve degeneration, and 
associated with several complement gene variations, including C2, C3, FB, Factor H, 
and Factor I69. Nozaki et al76 found deposition of C3a and C5a in the drusen (the earliest 
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clinic pathologic feature of AMD, extracellular deposits under the retinal pigmented 
epithelium) of AMD patients and in a mouse model. And in the C3a and C5a knockout 
AMD mouse model, the expression of vascular endothelial growth factor decreased 
implicating complement in the pathogenesis of AMD.  
SLE and SLE like disease are chronic, complex autoimmune diseases. In SLE patients, 
many organs, including the joints, skin, and kidneys77, are affected by complement 
activation. The deficiencies of C1q, C1r, C1s, C2, and C478 can increase the risk of 
these diseases in the patients. Only a small number of these patients exist with C379 and 
C5b-975 deficiency. Clinical data show that atherosclerosis is more prevalent in patients 
with SLE80. The complement protein deposition is easily observed in the inflamed 
tissues of the patients, such as C3, C481 and C5b-982, supporting the complement system 
activation in SLE pathology. 
1.4.2 Complement therapeutics 
The purpose of clarifying the association between complement activation and the 
pathogenesis of many diseases is not only to assist in clinical diagnosis but also to 
develop novel treatments. In recent years, targeted therapeutics related to complement 
components or their receptors have also made considerable progress.  
The first approved adjuvant therapy for clinical use is Eculizumab (Alexion), i.e., a 
humanized recombinant anti-C5 monoclonal antibody that specifically binds to 
complement C5 blocking the release of C5a and the C5b-9 complex. In PNH patients, 
anti-C5 treatment improves the quality of life but does not appear to affect mortality71,83. 
The anti-C5 antibody has also been successfully used to treat aHUS patients who 
developed C3 glomerulopathy84.  
Pexelizumab (Alexion) is a humanized, monoclonal, single-chain antibody fragment 
targeting C5. It shows promising therapeutic benefits by reducing inflammation and 
organ dysfunction both in acute myocardial infarction and in patients undergoing 
coronary artery bypass graft with cardiopulmonary bypass85. 
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1.4.3 Liver-specific C5 small interfering RNA (siRNA) from Alnylam 
Pharmaceuticals, Inc.  
Alnylam Pharmaceuticals, Inc. was founded in 2002 to develop next-generation drugs 
based on the RNA interference technology (Andrew Fire and Craig Mello received the 
Nobel prize for Physiology or Medicine for the discovery of the technology). Alnylam 
has developed an RNAi therapeutics to target the liver-specific C5, currently under 
phase 2 clinical study in the USA. It features an attachment resulting in N-
acetylgalactosamine (GalNAc)-tagged siRNA to target the liver specifically. It was 
demonstrated that ALN-CC5 targets hepatocytes to block the synthesis of C5 mRNA 
levels and subsequent dramatic lowering of C5 protein in mice, rats, and non-human 
primates73. In vivo, the highest dose reduces the circulating C5 concentration by 99%, 
and as reported by Alnylam that C5 knockdown is associated with up to 96.8% 
inhibition of serum complement activity86. In Phase I clinical trial for healthy people, 
subcutaneous injection of the drug can reduce complement hemolysis by more than 90% 
and can last for more than 2 months87. Clearly, this is an advantage for the 
pharmacokinetics and pharmacodynamics of siRNA in patients who require long-term 
acceptance of complement inhibition therapy. 
1.4.4 Complement component C5 and autoimmune diseases studies 
The role of complement component C5 in complement system activation in the context 
of autoimmune diseases, i.e. RA88, AMD, SLE89, MS90, MG73, was studied in C5-/-
(DBA/2) hybrid mice90 or the use of anti-C5 specific antibody89 and C5 siRNA73,88 
treatment. The anti-C5aR (anti-CD88)91 antibody was also used for studying the effect 
of the C5a receptor in autoimmune disease. 
In 1996, Yi Wang studied the role of C5 in SLE with the New Zealand black crossed 
New Zealand white F1 mice, which develop a notable syndrome similar to human SLE 
spontaneously. In the mice, chronic treatment with C5 antibody for 6 months 
significantly reduced the development of glomerulonephritis and increased survival, 
supporting the role of complement activation in the SLE mouse model89. 
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Figure 1.3 GalNAc-siRNA C5 conjugate is an RNAi therapeutics targeting C586. This schematic 
representation was taken from Borodovsky. et al. (2014)86. Asialoglycoprotein receptor (ASGPR) is 
highly and specifically expressed in hepatocytes. siRNA conjugated to N-acetylgalactosamine (GalNAc) 
ligand, which binds to the ASGPR specifically, was efficiently delivered to hepatocytes by clathrin-
coated pit-mediated uptake. siRNA binds to a helicase, ATP, and multiple proteins to form RNA-induced 
silencing complexes (RISCs). After specific binding to the C5 messenger RNA (mRNA), RISC cleaves 
the mRNA, eventually leading to C5 protein silencing. ASGPR is released from the endosome and 
recycled to the cell membrane. 
Experimental autoimmune encephalomyelitis (EAE) is a mouse model for studying 
multiple sclerosis (MS). C5 deficiency in the EAE mouse model reduced the lesion 
areas and immune cell infiltration90, indicating that complement activation plays a role 
in the development of the course of the disease in the EAE model.  
The C5 siRNA treatment significantly reduced the serum C5 level and the disease 
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symptoms in the two MG rat model73, demonstrating the liver-specific C5 plays a part 
in the development of MG. 
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1.5 Aims 
Atherosclerosis is a prototypic chronic inflammatory disease of major clinical 
importance. Complement cascades play multiple roles in several inflammatory diseases, 
such as PNH and the aHUS. Complement proteins (i.e., C1q, C3, C5, C5b-9) were 
discovered in both the human and the mouse atherosclerotic plaque. However, the roles 
of complement cascades in atherosclerosis remain controversial. To understand the 
roles of complement cascades on atherosclerosis better, I chose N-acetylgalactosamine- 
conjugated C5 siRNA to examine liver-derived C5 on atherosclerosis in different 
dietary conditions as well as at various disease stages. In my Ph.D. thesis, the following 
questions will be addressed: 
1) Are transcripts coding for complement cascades altered during atherosclerosis 
development?  
2) Does liver-specific C5 control atherosclerosis in young ApoE-/- mice maintained 
under a normal chow diet? 
3) Does liver-derived C5 affect atherosclerosis in young ApoE-/- mice maintained under 
a high-fat diet? 
4) Does liver-derived C5 affect atherosclerosis development in aged ApoE-/- maintained 
under a normal mouse chow?  
5) Are complement proteins expressed in human plaques?
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2. MATERIALS & METHODS 
The general reagents were purchased from Fluka (Buchs, Switzerland), Sigma 
(Deisenhofen, Germany), and Carl Roth (Karlsruhe, Germany) in analytical grade 
quality unless stated otherwise. All solutions were prepared with Millipore H2O (Milli-
Q Plus ultrapure purification, Millipore, MA). 
2.1 Materials  
2.1.1 Equipment 
Table 2.1 List of equipment
Equipment Type Manufacturer 
Balance Analytical Plus Ohaus 
Black dissection wax C3541 CR Scientific 
Centrifuge Centrifuge5415 R Eppendorf 
Heraeus®Multifuge®3S-R Thermo Scientific 
Complete blood cell counter scil Vet abc scil animal care 
company GmbH 
Confocal laser scanning microscopy  True Confocal Scanner-SP8 Leica 
Cryostat microtome Leica RM2235 Leica Biosystems 
Digital camera DSLR-a580 Sony 
Leica DFC365 FX Leica Microsystems 
Dissection Stereo microscope  Stemi 2000 Leica 
Flow cytometers Canto-II BD 
Flourescence microscope  DM 6000 B Leica  
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Hematology analyzer ScilVet ABC Scil Animal Care 
Light microscope   DM LB Leica 
Minutien Pin 26002-15 Fine Scientific Tools 
pH-meter InoLab level 1 WTW 
Microplate reader SpectraFluor Plus Tecan 
Ultrapure purification Milli-Q Plus ultrapure 
purification 
Millipore 
Veroklav Laboratory Autoclave Ype:500 Thermo Scientific   
-80 °C freezer  C7736CD Miele 
2.1.2 Reagents and materials 
Table 2.2 List of reagents and materials 
General Reagents and 
materials 
Catalog 
number 
Manufacturer Storage or Specification 
10% bovine serum albumin 
(BSA)  
70411/1 Aurion 4 °C  
10% fetal calf serum (FCS) DE14-801F Lonza -20 °C 
4',6-diamidino-2-
phenylindole (DAPI) 
H-1500 Vector Labs -20 °C 
96 Well Polystyrene Plate Costar 9018 Corning Room temperature 
Acetone  K40718714 Merck Room temperature under 
the hood  
Ethylenediaminetetraacetic 
acid (EDTA)-coated tubes 
41.1504.005 Sarstedt Room temperature 
Fluorescence mounting 
medium 
S3023 DAKO 4 °C 
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Faramount mounting 
medium, Aqueous 
S3025 DAKO 4 °C 
Isopropanol     K40615718 Merck Room temperature under 
hood 
O.C.T. Compound 0827400006 Tissue-Tek 125mL 
O.C.T. Cryomold 25608-
922/924/916 
Tissue-Tek 10x10x5/15x15x5/25x20x
5mm 
Oil red O (ORO) S378 Romeis Room temperature  
Paraformaldehyde (PFA) P-6148 Sigma-Aldrich Room temperature 
Sarstedt Microtube 1.1ml Z-
Gel 
50-809-211 Sarstedt Room temperature 
Triton X-100 9002-93-1 Sigma-Aldrich Room temperature 
Tween® 20 P1379  Sigma-Aldrich Room temperature 
Western Type Diet (High-
fad diet) 
EF TD88137 
mod 
ssniff-Spezialdiaeten 
GmbH 
21.1% crude fat, and 
17.3% crude protein 
2.1.3 Standard solutions and buffers 
Table 2.3 List of standard solutions and buffers 
Solution  Composition Storage 
Ammonium-Chloride-Potassium 
(ACK) lysis buffer 
0.15 mM NH4Cl, 1 mM KHCO3, 0.1 
mM Na2EDTA, adjust to pH 7.3 
Room 
temperature 
Phosphate buffered saline (PBS) (10x) 80 g NaCl, 2 g KCl, 27 g 
Na2HPO4∙7H2O, 2.4 g KH2PO4 into 800 
mL ddH2O, then, adjust the pH to 7.4, 
add ddH2O to 1000 mL 
Room 
temperature 
PBS (1x) Dilute PBS (10x) in 10 times with 
ddH2O 
Room 
temperature 
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Fluorescence-activated cell sorting 
(FACS) buffer 
PBS with 2% fetal calf serum (FCS) Fresh prepared 
0.05 M sodium Micarbonate buffer 0.015 M Na2CO3, 0.035 M NaHCO3, 
adjust to pH 9.6 
Room 
temperature 
4% PFA    Dissolve 40 g paraformaldehyde in PBS 
(1000 ml final), pH 7.2-7.4 
4 °C 
PFA-sucrose solution Dissolve 50 g sucrose into 1000mL 4% 
PFA 
Room 
temperature 
Sudan IV-staining solution 
 
Dissolve 500 mg Sudan IV in a mixture 
of 35 mL ethanol, 50 mL acetone, and 
20 mL ddH2O 
Room 
temperature 
Oil red O stock solution Dissolve 1 g Oil red O powder in 200 
mL 99% isopropanol 
Room 
temperature 
Oil red O working solution Dilute 400 mL Oil red O stock solution 
with 300 mL of ddH2O. Stored at room 
temperature overnight, filtered before 
use. 
Room 
temperature 
2.1.4 Antibodies for Immunofluorescence Microscopy 
Table 2.4 List of antibodies for immunofluorescence staining 
Primary Antibodies 
Antibody Target Clone Host Reactivity Manufacture 
Anti-C1q Complement protein 
C1q 
9A7 Human Mouse abcam 
Anti-C3 Complement protein 
C3 
Polyclonal Goat Human Complement 
Technologies 
Anti-C4 Complement protein 
C4 
16D2 Rar Mouse Hycult 
Anti-C5 Complement protein Polyclonal Rabbit Human Complement 
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C5 Technologies 
Anti-C5 Complement protein 
C5 
Polyclonal Rabbit Mouse abcam 
Rabbit IgG Isotype control Polyclonal Rabbit Mouse abcam 
Anti-CD68 Macrophages, 
microglia cells, 
some DCs 
FA-11 Rat Mouse Serotec 
Anti-CD3e Naïve or primed T 
cells 
145-2C11 A. Hamster Mouse BD 
PharMingen 
Anti-CD31 Endothelial cells, 
some peripheral 
leukocytes, platelet, 
bone marrow- 
derived 
hematopoietic stem 
cells and embryonic 
stem cells 
MEC13.3 Rat Mouse BD 
PharMingen 
SMA-Cy3 Smooth Muscle cells 1A4 Mouse Mouse Sigma 
Secondary Antibodies 
Antibody Host  Format  Manufacture 
Anti-rat IgG Donkey Alexa 488 Molecular Probes 
Cy3 Dianova 
 
Cy5 
Goat Cy3 
Anti-rabbit IgG Donkey Cy3 
Cy5 
Goat Alexa 488 Invitrogen 
MATERIALS & METHODS 
22 
 
Cy3 Dianova 
 
Cy5 
Anti-mouse IgG Goat Cy3 
Cy5 
Donkey Cy3 
Cy5 
Anti-goat IgG Donkey FITC 
Cy3 
Cy5 
Anti-A. Hamster 
IgG 
Donkey Cy3 
Cy5 
Table 2.5 List of antibodies for Enzyme-linked immunosorbent assay (ELISA) 
Primary Antibodies 
Antibody  Target Clone Host Reactivity Manufacture 
Anti-C5 Complement protein 
C5 
Polyclonal Goat  Human  Complement 
Technologies 
Secondary Antibody 
Antibody  Clone Conjugate Format Host Reactivity Manufacture 
Bovine Anti-
Goat IgG-
HRP (H+L) 
Polyclonal Horseradish 
Peroxidase 
IgG 
(H+L) 
Bovine Goat Jackson 
ImmunoResearch 
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2.2 Mouse strains and husbandry 
Male ApoE-/- mice (on C57BL/6J background) were housed in the animal laboratory 
facility of the Ludwig-Maximilians-University München (LMU), the Zentrale 
Versuchstierhaltung (ZVH), Klinikum Universität München (KUM). Mice were kept 
on a 12-hour light-dark cycle. Mice had free access to water and mouse chow. 
Depending on experiment objectives, mice were fed a normal diet (ssniff Spezialdiäten 
GmbH) or the high-fat diet (21.1% crude fat, 17.3% crude protein, 5% crude fiber with 
4.3% crude ash; E15721-347, EF TD88137 mod, ssniff Spezialdiäten GmbH, 
Germany). According to the German animal protection law, animal experiments were 
reviewed and approved by the government of Upper Bavaria (Regierung von 
Oberbayern). 
2.3 Mouse models 
2.3.1 siRNA preparation and injection 
In order to block the complement pathways, GalNAc conjugated siRNA targeting C5 
(C5 siRNA; AD-61679.7, 20 mg/mL in DPBS) and GalNAc conjugated siRNA 
targeting luciferase (control siRNA; AD-48349.3, 20 mg/mL in DPBS) as control 
(received from Alnylam Pharmaceuticals) were used for C5 protein knockdown in the 
circulation. The control siRNA, luciferase siRNA, was chosen as a control because it 
targets the luciferase protein, which does not exist in the vertebrate transcriptome. The 
dose of siRNA for injection was 0.15 mg/g body weight. These siRNAs were applied 
immediately after 20 times dilution with PBS. Mice were injected with subcutaneous 
injection (s.c.). The site for injection was s.c. in the neck area.  
2.3.2 Experimental protocol 
1. 23 ApoE-/- mice (12-13 weeks old) were randomized for treatment with C5 siRNA or 
control siRNA every two weeks for 20 weeks. There were 12 mice in the C5 siRNA 
group, and others in control. 
2. 18 ApoE-/- mice (58-59 weeks old) were randomized for treatment with C5 siRNA or 
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control siRNA every two weeks for 18 weeks. There were 9 mice in each group. 
3. 21 ApoE-/- mice (12-13 weeks old) were randomized for treatment with C5 siRNA or 
control siRNA every two weeks for 20 weeks. They were fed a high-fat diet for 16 
weeks, starting at 14-15 weeks old. There were 10 mice in the C5 siRNA group, and 
others in control. 
4. Six ApoE-/- mice (8-9 weeks old) were randomized for treatment with C5 siRNA or 
control siRNA every two weeks for four weeks. They were fed a high-fat diet for 3.5 
weeks. There were three mice in each group. 
2.4 Serum collection and body weighing 
Serum was collected every two weeks before and after siRNA treatment at different 
time intervals, for the C5 concentration in circulation detecting. After fixing the mouse 
in a fixture, approximately 20-30 μl of blood from the tail vein was collected in serum-
separating tubes. After the centrifugation, serum in the supernatant was transferred into 
new tubes and stored at -80 °C. Mice were weighed every two weeks before and after 
siRNA treatment regularly. 
2.5 Blood and organ collection 
Mice were anesthetized by i.p. injection of Ketamine Hydrochloride (80 mg/kg) and 
Xylazine (5 mg/kg), and 700-1000 μl of blood were drawn by cardiac puncture. 20-30 
μl of blood was kept in serum-separating tubes, and serum was prepared for determining 
the C5 concentration in circulation using ELISA. About 100-200 μl of blood was 
collected in EDTA tubes, and plasma was prepared from different blood cells counting 
with animal blood counter and for determination of concentrations of total cholesterol, 
Cholesterol (Chol) and triglyceride (TG) (in collaboration with Institute of Laboratory 
Medicine, Clinical Chemistry and Molecular Diagnostics, Universitäts Klinikum 
München). 400-500 μl of blood was collected in 10mL tubes with 5 ml 5 mM EDTA, 
and single blood cells were prepared for FACS. 
Subsequently, mice were perfused with 5 ml 5 mM EDTA and followed by 10 ml PBS 
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to ensure the removal of blood from the aorta and other organs. The aortic roots were 
then collected and immersed in Tissue-Tek® O.C.T. compound and frozen in N-pentane 
to prepare fresh-frozen tissue blocks. These blocks were stored at -80 °C. The total 
aortas were collected for en-face Sudan IV staining. 
2.6 Assessment of atherosclerosis in mice 
In order to assess atherosclerosis progression, the area of plaques may be quantified 
throughout the arterial tree. Previous studies already identified areas of atherosclerosis, 
which developed faster than others, such as the aortic valve leaflet and the root of the 
aortic arch92 implicating that the location for assessing atherosclerosis within the aorta 
determines the outcome of the analyses.  
Cross-section and en-face staining techniques are applied to determine the degree of 
atherosclerosis. Cross-sections can be used for histological staining or 
immunohistochemistry of different markers, which could be quantified for specific 
purposes of the atherosclerosis study. The en-face assay requires to open the aorta, then, 
fixing it onto a flat black wax dish, followed with Sudan IV staining. Imaging software, 
such as ImageJ, is used for plaque development quantification and plaque structure 
evaluation. 
2.6.1 en-face preparation and Sudan IV staining 
The total plaque load in the thoracic and abdominal aorta were analyzed using the 
Sudan IV staining of en-face prepared tissues. The adventitia was carefully removed, 
and the entire aorta was dissected under a dissection microscope. The outer curvature 
of the aortic arch and the inner curvature of the entire aorta was cut open along 
longitudinally to expose the intimal surface. The aortas were pinned down with the 
luminal surface upside with needles onto a black wax plate for fixation in PFA-sucrose 
solution overnight at 4 °C. The consistency in the pinning of the aorta was ensured. 
Then, pinned aortas were rinsed three times with PBS for 10 min, followed by 
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incubation in Sudan IV solution for 10 min. The aortas were then rinsed two times with 
70% ethanol, and covered with PBS. 
In order to quantify the percentages of lipid deposition in the thoracic, abdominal, and 
entire aorta, images were taken using a digital camera (Sony, DSLR-a580) with a 
standard bar.  
The Sudan IV positive area in the aorta was quantified using Java-based image 
processing software ImageJ. The percentage area of the lesion was calculated using the 
Sudan IV positive area and area of the thoracic, abdominal and total aorta. The images 
to be measured were opened with the software ImageJ. Then, the image scale was set 
with the standard bar on the images. After the calibration for the image, on the 
measurement toolbar ‘polygon selections’ icon was used to outline and measure the 
area of the thoracic aorta and abdominal aorta. The aorta was separated into the thoracic 
and abdominal aorta at the level of the diaphragm93. The Sudan IV positive lesion areas 
on each part were outlined and traced with ‘polygon selections’. Then the selected 
lesions were checked through the microscope. The selections were saved to the ‘ROI 
Manager’. The data were exported using the ‘measure’ in the ROI Manager.  
The percentage of the area of the lesion in the aorta area was calculated respectively. 
The sum of the thoracic aorta area and abdominal aorta area together is total aorta area. 
And the percentage of lesions in the total aorta was calculated with the total lesion area 
and the total aorta area. 
2.6.2 Tissue sectioning 
The tissue blocks were sectioned in a cryotome maintained at -20 °C. 10 μm thick aortic 
root serial sections were collected on glass slides. The slides were stored at -80 °C until 
further use. 
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2.6.3 Oil-Red-O Hematoxylin (ORO/HE) staining and atherosclerotic lesion 
quantification 
Frozen aortic root cryosections (10 μm) were warmed on a hot plate maintained at 37 °C 
for one min immediately followed by air-dry for 30-60 min at room temperature. The 
sections are serial and in 100 μm intervals, respectively, starting from the origin of the 
aortic roots. In total, 6-8 sections per mouse heart were stained in ORO working 
solution for 10 min, then immersed in 60% isopropanol and washed with tap water 
briefly. They were then stained with hematoxylin for 6 min, followed by washing in 
running water (pH>7) for 10 min. The cover slides were mounted on tissue sections 
with an aqueous Faramount Mounting Medium. Images were taken with a microscope 
(Leica DM6000B, Leica Microsystems) connected to a camera (Leica DFC295, Leica 
Microsystems). All pictures of sections were taken with a 10x objective and 10x ocular 
lens.  
Atherosclerotic plaque areas were quantified with the ORO pictures using ImageJ 
software. The ORO images were opened with the software ImageJ. The image scale 
was set with the standard bar on the images. After the calibration for the image, the 
measurement toolbar ‘polygon selections’ icon was selected to encircle the intimal layer 
area of the aortic root by repetitive clicks. The intimal layer was defined by the internal 
elastic lamina and the lumen. The intima area was saved to the ‘ROI Manager.’ The 
data were exported using the ‘measure’ in the ROI Manager. 
2.6.4 Immunofluorescence staining 
Immunofluorescence staining was performed for CD68+ macrophage/DC, CD3e+ T 
cells, SMA+ SMC, CD31+ EC, and complement components C3, C4, and C5. 10 µm 
fresh frozen tissue sections were prepared by microtome and stored at -80 °C. In total, 
6-8 sections per mouse heart were thawed on a 37 °C hot plate for 30 seconds, followed 
by 30-60 min air-dry at room temperature. For fixation, sections were incubated with a 
pre-cooled 4% PFA solution for 5 minutes at 4 °C, then rinsing with PBS. Before and 
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after the fixation in 100% acetone for 2 min, sections were submerged in 50% acetone 
and then rehydrated in PBS for 10 min.  
After fixation, sections were incubated overnight with primary antibodies diluted at the 
appropriate dilution in PBS with 0.25% BSA at room temperature. Sections were 
washed three times with PBS for 5 min, followed by incubation with the fluorescent-
labeled secondary antibodies diluted in PBS with 0.25% BSA and 0.2% DAPI nuclear 
stain for one hour in the dark. After three times washes, slides were mounted with 
Flouromount-G mounting media. For negative controls, primary antibodies were 
omitted, whereas the rest of the procedure was done as described. No specific 
immunostaining was observed in the control sections.  
2.6.5 Quantification of CD68+ macrophage and CD3e+ T cell infiltration in the 
plaque areas  
The serial aortic root cryosections (10 μm), which are in 100 μm intervals respectively, 
were stained with CD68 and CD3e antisera with the immunofluorescence staining 
method above. A total of 6-8 sections per mouse heart was used for analysis. Stained 
sections were examined using a confocal laser scanning microscope TCS SP8 (Leica, 
Germany) with appropriate excitation and emission filters. All pictures of sections were 
taken with a 20x objective and a 10x ocular lens. 
The CD68+ macrophage and CD3e+ T cell infiltration in the plaque areas were 
quantified with CD68 and CD3e antibody stained pictures using the software ImageJ. 
The images were opened with the software ImageJ. The image scale was set with the 
standard bar on the images. After the calibration for the image, the intimal layer was 
encircled using the ‘polygon selections’ tool. The intimal layer was defined by the 
internal elastic lamina and the lumen. The intima area was saved to the ‘ROI Manager.’ 
Then the immunofluorescence pictures of CD68 were segmented by thresholding to 
create binary images94. The ‘area fraction’ of CD68+ macrophage in plaque area and the 
plaque area can be exported with the ‘measure’ tool in the ‘ROI Manager.’ 
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In order to count the CD3e+ T cell numbers in the plaque area, the CD3e antibody and 
DAPI stained pictures were merged into one picture. The CD3e and DAPI double-
positive cells were counted as the CD3e+ T cells.  
2.7 ELISA for C5 protein in the circulation 
In order to obtain an estimate of C5 levels in circulation, approximately 20-30 μl of 
mouse blood, which was collected in 2.4 and 2.5, was centrifuged at 10,000 rpm for 15 
min. The serum was then collected, and the C5 level was measured by ELISA, 
described below. 
10 serum samples from 8 weeks old ApoE-/- mice without siRNA treatment were pooled 
as a positive control and standard curve sample. Pooled serum was frozen in 10 μl 
aliquots. A new aliquot was thaw for every assay.  
96 wells flat plates were first coated with 100 μl diluted samples at the dilution of 
1:5000 in dilution buffer. Pooled serum was used as a positive control and no serum as 
a negative control. As a non-specific background C5 negative control, serum from C5-
/- mouse (DBA/2) to show the specificity of the assay. They were diluted at the same 
dilution as samples. For the standard curve, pooled serum was initially diluted at a 
dilution of 1:1000 and then eight serial 2x dilutions in sample dilution buffer.  
ELISA plates were first coated with mouse serum (including all samples, controls, and 
standards curve dilutions) overnight at 4 °C, then blocked with 350 μl per well of 
blocking buffer (2% (w/v) BSA in PBS, filter through a 0.2 μm filter prior to use), 
incubated at room temperature for 2 hours. Subsequently, 100 μl per well of primary 
antibody (Gout anti-human C5 Antibody), diluted in antibody buffer at a dilution of 
1:1000 and incubated at room temperature for 60 min, was used to detect bound C5 
protein. 
Following this step, 100 μl per well of secondary antibody (Bovine anti-goat IgG-HRP) 
diluted into an Antibody Buffer at a dilution of 1:500 and incubated for 1 hour at room 
temperature in the dark. Last, 100 μl per well of TMB mixed equal parts substrate A 
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and B before use and incubated for 3-5 min at room temperature in the dark. The ELISA 
reaction was stopped with 100 μl per well of 2 N sulfuric acid. The reaction was stopped 
at an OD value between 0.7 and 0.9 for the highest signal wells. Absorbance was read 
at 450 nm using a plate reader. Between incubations, plates were washed five times 
with 300 μl per well of wash buffer (0.05% (v/v) Tween 20 in DPBS).  
OD values were first subtracted from background value (no serum background), and 
these values were then transferred in GraphPad Prism 8, and a standard curve was 
plotted with known C5 values (dilution fold) on the x-axis against absorbance values 
on the y-axis. Fit standard curve in GraphPad Prism 8 using a Sigmoidal 4-parameter 
fit. Input background-subtracted OD values for samples and controls into Prism and 
interpolated arbitrary values for C5 protein concentration. The data were normalized to 
the pre-dose values.  
2.8 Human carotid artery tissues and atherosclerotic lesion analyses 
Human carotid atherosclerotic plaques were analyzed and quantified95. Briefly, 
atherosclerotic plaques were obtained from patients with high-grade carotid artery 
stenosis (>70%) after carotid endarterectomy. Healthy control carotid arteries were 
obtained from the Forensic Medicine Institute (type 0–I). The study was performed 
according to the Guidelines of the World Medical Association Declaration of Helsinki. 
The ethics committee of the Faculty of Medicine, Technical University of Munich 
(TUM) approved the study. 
Human carotid plaques were segmented in blocks of 3 to 4 mm, fixed in formalin 
overnight, decalcified in 0.5 M EDTA (pH 7.2), and formalin-fixed paraffin-embedded 
(FFPE), or fresh frozen in Tissue-Tec (Sakura Finetek) for immunofluorescent staining 
of lipid. Hematoxylin-eosin and Elastic van Gieson (EvG) staining were performed to 
assess atherosclerosis. Specimens were divided into early (II-III) and advanced stages 
of atherosclerosis (V–VII) according. After staining, the stained slides were scanned 
by a ScanScope microscope (Leica) to obtain digital histological images of the whole 
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aorta sections. By ScanScope, each aorta section was translated into a TIF file. The TIF 
images were opened with the software ImageJ. The image scale was set with the 
standard bar on the images. After the calibration for the image, atherosclerotic plaques 
and media layers were encircled using the ‘polygon selections’ tool. The intimal layer 
was defined by the internal elastic lamina and lumen. The intima area and media were 
saved to the ‘ROI Manager.’ Immunohistochemical pictures of CD68 or C1q or ApoE 
or C5 were segmented by thresholding to create binary images94. Then the ‘area fraction’ 
of CD68+ macrophage or C1q+ area or ApoE+ area or C5+ area within intima or media 
layers was quantified by click “measure” tool in the ‘ROI Manager.’ 
2.9 Statistical analysis 
Measurements are expressed as means of n samples ± SEM. All calculations were 
carried out using Microsoft Excel and/or GraphPad Prism 8 software. Significance was 
analyzed using two-tailed unpaired Student’s t-test, one-way analysis of variance 
(ANOVA), and two-way ANOVA, with statistical significance, assumed at p 
value<0.05, and statistically highly significant assumed at p value<0.001.
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3. RESULTS 
3.1 mRNA Microarrays of Wt and ApoE-/- aortas of various ages reveal 
the presence of transcripts of complement cascade constituents in 
atherosclerotic plaques 
Multicellular organisms develop into different tissues, each with various functions due 
to specific gene expression profiles at different times and territories. If a certain gene is 
abnormally expressed, it may affect the body's normal physiological activity or even 
lead to disease. Similarly, if the body encounters certain injuries, it will usually respond 
with distinct gene expression patterns. Whole transcriptome mRNA expression arrays 
were examined by microarray, which is based on a Gene chip to study gene expression 
changes, and such tissues can then be compared and analyzed for differences in gene 
expression between physiological and pathological conditions.  
Recently, Skerka and Zipfel observed through in vitro studies that ApoE is a CCC 
inhibitor by binding to activated C1q95. We found that C1q-ApoE complexes emerge in 
choroid plexus inflammation in Alzheimer's disease and in atherosclerosis, and that 
pharmacological targeting the complement component C5 alleviates choroid plexus 
inflammation, atherosclerosis and intermediate-sized Alzheimer plaque loads as well as 
Alzheimer plaque-associated inflammation in several mouse models95. Here, I 
examined the functional impacts of C1q-ApoE complexes in atherosclerosis. 
ApoE-deficient mice on normal mouse chow develop atherosclerosis during aging. We 
hypothesized that complement cascades might be induced in atherosclerotic plaques of 
ApoE-/- mice due to the lack of its endogenous complement inhibitor (ApoE). We 
examined whether complement activation controls atherosclerosis development in this 
mouse model during aging.  
In order to validate this hypothesis, members of our group had earlier harvested the 
whole aorta from Wt and ApoE-/- mice of various ages. These plaques were prepared 
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for microarray analyses in the previous studies95-97. Total aortas were from 6w, 32w, 
and 78w old Wt and ApoE-/- mice. Microarray analyses were performed by Michael 
Beer and Markus Hildner at the Friedrich-Schiller University of Jena Medical School. 
This approach allowed me to mine the transcriptomes for the complement pathway- 
associated molecules. We examined differentially expressed genes of interest by using 
several gene ontology (GO) terms involved in complement cascades, that is an innate 
immune response (GO: 0045087), classical complement pathway (GO: 0006958), 
alternative complement pathway (GO: 0006957), regulation of complement activation 
(GO: 0030449). 
There are few immune response-related genes that are up- and down-regulated in the 
Wt aorta during aging (Fig. 3.1 A: innate immune response GO term). However, 
immune response-related genes were dramatically upregulated in the aortas of adult and 
aged ApoE-/- mice. There are no significant differences observed between Wt and ApoE-
/- aortas at 6 weeks of age, but large differences were noted in ApoE-/- aortas at 32 weeks 
and 78 weeks of age when compared with age-matched Wt aortas (Fig. 3.1 A).  
We specifically focused on the GO term of the CCC, the alternative complement 
pathway, and the regulation of complement activation (Fig. 3.1 B).  
Atherosclerosis plaques begin to form in the aorta during the time window of 8-12 
weeks when maintained on a normal chow diet though 6-weeks old ApoE-/- mice do not 
develop atherosclerosis plaques in the aorta. The CCC-related genes, i.e., C1qa, C1qb, 
C1qc, C4b, were strongly upregulated in the diseased aorta, but not in 6-week old  
ApoE-/- mice (Fig. 3.1 C). Complement C3 and complement receptors expressed by 
leukocytes (C3ar1, C5ar1) were also strongly induced during atherosclerosis (Fig. 3.1 
C). Following CCC activation, C3b will initiate a constitutive amplification loop of the 
alternative complement cascade, also referred to as C3-triggered amplification loop. In 
addition, Factor H mRNA was detectable without differences between groups. Some of 
these data were represented in my previous publication95. 
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Figure 3.1 Transcriptomes of Wt and ApoE-/- aorta 
during aging Microarray heatmaps of the whole aorta 
from different age groups of Wt and ApoE-/- mice. A-B. 
Heatmaps of differentially regulated genes in total aorta 
RNA extracts. Gene expression in aortas was displayed 
separately from 6, 32, and 78 weeks old Wt and ApoE-/- 
mice. The following GO terms were analyzed from total 
genes: innate immune response (GO: 0045087), classical 
pathway (GO: 0006958), alternative pathway (GO: 
0006957), regulation of complement activation (GO: 
0030449). C. Aorta complement gene mRNA expression 
(log2 value). Means ± SEM. One-way ANOVA with 
Bonferroni's post-hoc test; * P<0.5, ** P<0.01, *** 
P<0.005, ****P<0.001. 6 weeks Wt (n=3); 32 weeks Wt 
(n=3); 78 weeks Wt (n=3); 6 weeks ApoE-/- (n=3); 32 
weeks ApoE-/- (n=3); 78 weeks ApoE-/- (n=3). 
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Figure 3.2 Other transcriptomes of Wt and ApoE-/- aorta during aging Microarray heatmaps of the 
whole aorta from different age groups of Wt and ApoE-/- mice. Heatmaps of differentially regulated genes 
in total aorta RNA extracts. Gene expression in aortas was displayed separately from 6, 32, and 78 weeks 
old Wt and ApoE-/- mice. The following GO terms were analyzed from total genes: A. Leukocyte 
migration (GO: 0050900), meloid leukocyte migration (GO: 0097529), B. Phagocytosis (GO: 0006909), 
C. Cellular response to lipid (GO: 0071396). One-way ANOVA. 6 weeks Wt (n=3); 32 weeks Wt (n=3); 
78 weeks Wt (n=3); 6 weeks ApoE-/- (n=3); 32 weeks ApoE-/- (n=3); 78 weeks ApoE-/- (n=3). 
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These data supported our hypothesis that the CCC was strongly induced during 
atherosclerosis in ApoE-/- mice.  
Oxidized lipids can activate the CCC, which in turn will release anaphylatoxin C3a and 
C5a to recruit leukocytes to the injury sites. The deposition of C3b on the lipid surface 
will increase macrophage phagocytosis and cellular response to lipids98. We next 
examined the GO terms related to the functional impact of complement activation, i.e., 
leukocyte migration, myeloid cell migration, phagocytosis, and cellular response to 
lipid (Fig. 3.2). In conclusion, our data support the hypothesis that the CCC may be 
involved in atherosclerosis progression.  
3.2 Liver-specific C5 siRNA reduces atherosclerosis burden in young 
ApoE-/- mice maintained on normal mouse chow 
In order to examine whether complement cascades control atherosclerosis development, 
we chose to specifically target complement C5, which is a biologically inactive 
proprotein resulting in the generation of the potent downstream inflammatory mediators 
of all three complement cascades, C5a and C5b. Complement C5 is expressed mainly 
by hepatocytes, but a small amount can also be produced by locally infiltrating 
leukocytes under distinct physiological and disease conditions99. However, we did not 
detect complement C5 mRNA expression in the aorta transcriptomes in our microarray 
data analyses (see above), indicating that locally expressed C5 was under the detection 
threshold of the microarray.  
The deficiency of ApoE in mice leads to spontaneous hyperlipidemia. These mice 
develop visible atherosclerotic plaques in the aorta at the age of 8-12 weeks, and 
atherosclerotic plaque progression can be observed during aging30. Oxidation-specific 
epitopes in extracellular lipid activate complement cascades and result in surface 
opsonization by C3b, generation of locally acting anaphylatoxins C3a and C5a, which 
in turn recruit leukocytes and elicit tissue inflammation47,100. In order to test the 
possibility that lipid accumulated underneath the dysfunctional endothelial cells 
triggers complement activation and leads to leukocyte infiltration and inflammation 
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during atherosclerosis in ApoE-/- mice, we first treated 12 weeks old ApoE-/- mice with 
C5 siRNA for 20 weeks. Then, we harvested tissues at the age of 32 weeks (Fig. 3.3). 
23 mice were randomly separated into two groups: 12 ApoE-/- mice were treated with 
C5 siRNA every two weeks for 20 weeks and 11 ApoE-/- mice, as a control group, were 
injected with siRNA targeting luciferase. In order to examine the effect of C5 siRNA 
on atherosclerosis, a series of measurements were performed: a) blood was taken 
throughout the whole injection period: before treatment, at 2 weeks, at 12 weeks, and 
at 20 weeks after treatment to determine the concentration of C5 in the circulation; b) 
body weight was measured every two weeks; c) blood parameters were measured with 
complete blood leukocyte counts after 20 weeks treatment; d) leukocytes percentages 
were examined by FACS after 20 weeks treatment; e) atherosclerotic plaque burden 
was determined by en-face staining, and aortic root plaque areas were determined with 
ORO/HE-stained sections; f) plaque complement proteins were examined by 
immunofluorescence staining (see below Fig. 3.4 - Fig.3.9). The work introduced in 
this section was published95. 
 
Figure 3.3 Experimental design. 12 weeks old male ApoE-/- mice (C5 siRNA treated mice: n=12; 
control siRNA treated mice: n=11), were treated with C5 or control siRNA every two weeks for 20 weeks 
and were given water and normal chow ad libitum. They were tail-bled at the age of 12 weeks, 14 weeks, 
24 weeks, and 32 weeks. 
3.2.1 Liver-specific C5 siRNA reduces serum C5 protein level in 32 weeks old 
ApoE-/- mice on a normal diet 
Complement protein C5 concentration in serum was quantified by ELISA. Complement 
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protein C5 levels were determined before treatment and 2 weeks, 12 weeks, and 20 
weeks after treatment. Serum C5 levels decreased dramatically up to 93% after 2 weeks 
of treatment, and the low levels were maintained throughout the treatment period (Fig. 
3.4). By contrast, the levels of serum C5 in control siRNA-treated mice remained 
unaffected (Fig. 3.4). These data demonstrated that liver-specific C5 siRNA effectively 
silences serum C5 protein, and indicated that circulating C5 protein was mainly derived 
from the liver (Fig. 3.4).  
 
Figure 3.4 Liver-specific C5 siRNA effectively silenced C5 in the circulation of young ApoE-/- mice 
on a normal mouse chow. Blood was collected before injection, 2 weeks, 12 weeks, and 20 weeks after 
injection from the caudal vein. Complement C5 levels were measured by ELISA. Serum of C5-deficient 
mice (DBA/2) was used as a non-specific background negative control. The line graph shows group 
means ± SEM; two-tailed Student’s t-test; *** p<0.005 versus before injection; liver-specific C5 siRNA 
treated mice: n=12 mice; control siRNA treated mice: n=11 mice. 
3.2.2 Liver-specific C5 siRNA does not change blood lipid levels, body weight, 
blood cell numbers, and leukocyte percentages in 32 weeks old ApoE-/- mice on a 
normal mouse chow 
We next examined whether C5 siRNA impacts body weight, blood lipid levels, and 
blood cells. 
3.2.2.1 Lipid metabolism 
Atherosclerosis is thought to involve passive lipid, specifically LDL, deposition in the 
RESULTS 
40 
 
vessel wall. In order to study whether the C5 siRNA injection influences the blood lipid 
levels, plasma lipid levels were determined in the plasma of 32 weeks old ApoE-/- mice 
after 20 weeks C5 or control siRNA treatments. LDL, HDL, and total cholesterol levels 
and LDL, HDL, and total triglyceride levels between C5 siRNA-treated mice and 
control mice were not different (Fig. 3.5 A, B). 
3.2.2.2 Body weight 
Mice were weighed before treatment and every 2 weeks after injection. Body weight of 
mice in both of the groups increased over time, but there was no statistically discernable 
alteration between the two different groups (p=0.6175) (Fig. 3.5 C). This data indicated 
that C5 inhibition did not affect the body weight in young ApoE-/- mice.  
3.2.2.3 Blood cell counts 
In order to study whether C5 siRNA affects other blood parameters, the blood of 32 
weeks old ApoE-/- mice treated with siRNA for 20 weeks was analyzed with a complete 
blood cell counter. There are no differences in white blood cells (WBCs), red blood 
cells (RBC), platelets (PLT), lymphocytes (LYM), monocytes (MO), and granulocytes 
(GRA) between C5 siRNA and control groups (Fig. 3.5 D). Hence, C5 protein knock-
down in the circulation did not alter the number of white blood cells. Other red blood 
cell parameters including total RBC, hemoglobin (HGB), hematocrit (HCT), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), and red blood cell distribution width (RDW), were 
not statistically significantly different between the C5 siRNA group and control siRNA 
group (Fig. 3.5 E). 
Platelet parameters, including total platelet number (PLT) and mean platelet volume 
(MPV), were also not statistically different between C5 siRNA-treated and the control 
siRNA-treated groups (Fig. 3.5 E). 
Liver-specific C5 inhibition did not affect the percentages of LYM, MO, and GRA 
within total white blood cells (Fig. 3.5 F). 
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Figure 3.5 Liver-specific C5 siRNA does not impact blood lipid, body weight, blood cell 
concentration and leukocyte percentages of 32 weeks old ApoE-/- mice. (A-B) Blood lipid. Plasma 
was collected after 20 weeks of siRNA treatment. Chol and triglyceride TG levels were measured. I 
greatly acknowledge the help of Prof. Daniel Teupser and Dr. Wolfgang Wilfert (Institute of Laboratory 
Medicine, Clinical Chemistry and Molecular Diagnostics, Universitätsklinikum München). Chol: 
cholesterol; TG: triglyceride. HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very 
low-density lipoprotein. C. Body weight. Body weight was determined before treatment and every 2 
weeks thereafter. (D-F) Blood cell concentration and leukocyte percentage. Data represent means ± 
SEM; two-tailed Student´s t-test, n.s.: no significant difference; liver-specific C5 siRNA-treated mice: 
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n=12 mice; control siRNA-treated mice: n=11 mice. HGB: hemoglobin; HCT: hematocrit; MCV: mean 
corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin 
concentration; RDW: red blood cell distribution width; MPV: mean platelet volume. WBCs: white blood 
cells; RBC: red blood cells; PLT: platelets; LYM: lymphocytes; MO: monocytes; and GRA: granulocytes. 
 
Figure 3.6 Effects of liver-specific C5 siRNA on leukocyte subsets in the circulation of 32 weeks old 
ApoE-/- mice on normal mouse chow, part A. Flow cytometric analysis of leukocytes from 32 weeks 
old C5 siRNA and control siRNA treated ApoE-/- mice. A. Gating strategies: CD4+ T cells 
(CD45+CD4+ gate), CD8+ T cells (CD45+CD8+ gate), CD4+ Th0 (CD45+CD4+CD62LhiCD44lo gate), 
CD4+ TCM (CD45+CD4+CD62hiCD44hi gate), CD4+ TEM (CD45+CD4+CD62LloCD44hi gate), CD8+ 
Th0 (CD45+CD8+CD62LhiCD44lo gate), CD8+ TCM (CD45+CD8+CD62hiCD44hi gate), CD8+ TEM 
(CD45+CD8+CD62LloCD44hi gate), B cells (CD45+B220+ gate). B. The frequencies of CD4+ T cells, 
CD8+ T cells, and B cells were compared in circulation in the normal diet fed 32 weeks old ApoE-/- mice 
treated with C5 siRNA and control siRNA. C. The frequencies of CD4+ Th0, TEM and TCM were 
compared in circulation in the normal diet fed 32 weeks old ApoE-/- mice treated with C5 siRNA or 
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control siRNA. D. The frequencies of CD8+ Th0, TEM and TCM were compared in circulation in normal 
chow-fed 32 weeks old ApoE-/- mice treated with C5 siRNA or control siRNA. Data represent means ± 
SEM; Student’s-t test, n.s.: no significant difference, * p<0.05; C5 treated mice: n=6 mice; control siRNA 
treated mice: n=6 mice.  
 
Figure 3.7 Effects of liver-specific C5 siRNA on leukocyte subsets in the circulation of 32 weeks old 
ApoE-/- mice, part B. Flow cytometric analyses of leukocytes from 32 weeks old ApoE-/- mice treated 
with C5 siRNA or control siRNA. A. Gating strategies: Treg cells (CD45+CD4+Foxp3+ gate), 
CD11c+CD11b- cells (CD45+CD4-CD11c+CD11b- gate), CD11c+CD11b+ cells (CD45+CD4-
CD11c+CD11b+ gate), CD11c-CD11bint cells (CD45+CD4-CD11c-CD11bint gate), CD11c-CD11bhi 
(CD45+CD4-CD11c-CD11bhi gate). B. The frequencies of Treg cells were compared in the circulation of 
32 weeks old ApoE-/- mice treated with C5 siRNA or control siRNA. C. The frequencies of 
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CD11c+CD11b- cells, CD11c+CD11b+ cells, CD11c-CD11bint cells, and CD11c-CD11bhi cells were 
compared within circulation in 32 weeks old ApoE-/- mice treated with liver-specific C5 siRNA or control 
siRNA. Data represent means ± SEM; Student’s t-test, n.s.: no significant difference; Liver-specific C5 
siRNA treated mice: n=6 mice; control siRNA treated mice: n=6 mice.  
3.2.3 Liver-specific C5 inhibition does not change blood leukocyte subsets in young 
ApoE-/- mice on normal mouse chow 
In order to examine whether liver-specific C5 siRNA influences circulating leukocyte 
subsets, blood leukocytes were examined using quantitative FACS analyses. 
20 weeks of liver-specific C5 siRNA treatment does not change the percentage of CD4+ 
T cell and CD8+ T cell subpopulations (Fig. 3.6 B), and B220+ B cells (Fig. 3.6 B). 
We next examined T cell activation and differentiation markers. Conventional murine 
T cells can be divided into three major populations, CD62L+CD44- Th0, CD62L+CD44+ 
TCM, and CD62L-CD44+ TEM. In CD4+ T cells, Th0 cells comprised the majority, 
whereas TEM cells were minor populations. C5 siRNA treatment does not change the 
percentages of either subset (Fig. 3.6 C). In CD8+ T cells, Th0 cells were the major 
subset. Otherwise, the ratio of TCM cells was low. The proportion of TEM cells in 
CD8+ T cells was slightly higher in the C5 inhibition group compared to the control 
group (Fig. 3.6 D). Forkhead box P3+ (Foxp3+) Treg cells ratio among CD4+ T cells did 
not differ between C5 siRNA-treated mice and control mice (Fig. 3.7 B). The 
frequencies of CD11c+CD11b- cells, CD11c+CD11b+ cells, CD11c-CD11bint cells, and 
CD11c-CD11bhi cells were compared within the circulation in 32 weeks old ApoE-/- 
mice treated with C5 siRNA and control siRNA, and there was no significant difference 
between these two groups (Fig. 3.7 C).  
3.2.4 Liver-specific C5 siRNA reduces atherosclerotic plaque burden in young 
ApoE-/- mice on a normal mouse chow  
In order to evaluate the effect of liver-specific C5-mediated complement cascade 
activation in plaque burden, en-face analysis of the whole aorta was examined101. Sudan 
IV was used to label lipids in red, and the main arterial trunk was stained (Fig. 3.8 A).  
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Liver-specific C5 siRNA-treated mice revealed markedly reduced atherosclerosis 
plaque burden as evidenced by decreased en-face staining. The 32 weeks old control 
siRNA mice developed 2.876 ± 0.735% Sudan IV-positive plaque in the total aortas, 
4.184 ± 1.148% in the thoracic aortas and 0.688 ± 0.120% in the abdominal aortas. The 
age-matched C5 siRNA treated ApoE-/- mice developed 0.9997 ± 0.164% plaque in the 
total aortas, 1.367 ± 0.246% in the thoracic aortas, and 0.3571 ±0.097% in the 
abdominal aortas. C5 siRNA-treated mice showed significantly reduced total lesion 
sizes of the whole aortas (65.24% reduction; P=0.030). The mean lipid-positive area in 
the thoracic aorta was also significantly less (69.21% reduction, P=0.035) in C5 siRNA-
treated mice compared with controls, and 48.10% reduction in abdominal aorta lesion 
sizes in C5 siRNA-treated mice vs. control siRNA-treated mice (P= 0.045). 
Hence, by 32-weeks of age, the administration of C5 siRNA resulted in a dramatic 
decrease in plaque formation in ApoE-/- mice.  
 
Figure 3.8 Liver-specific C5 mediate reduced atherosclerotic lesions in the aortas of 32 weeks old 
normal diet fed ApoE-/- mice. A. en-face Sudan IV staining. The total aortas were pinned and stained 
with Sudan IV. Representative aorta from mice treated with control siRNA or liver-specific C5 siRNA. 
Scale bar: 500 μm. B. The percent Sudan IV staining of the total aortic surface. C. The percent Sudan IV 
staining of the thoracic aorta. D. The percent Sudan IV staining of the abdominal aorta. Data represent 
means ± SEM; Student’s t-test, n.s.: no significant difference, * p<0.05; liver-specific C5 siRNA-treated 
mice: n=12; control siRNA-treated mice: n=11.  
In order to analyze whether C5 siRNA impact on plaque composition, fresh frozen 
aortic root sections were prepared for further studies. Lipid content in the plaques was 
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determined by ORO/HE staining of the fresh-frozen cross-sections. Lesions at the aortic 
root were quantified at 6-8 sections, which were located 300, 400, 500, 600, and 700 
μm proximal from its bottom side. As shown in Fig. 3.9 A, the lesion area was 
dramatically reduced (p value=0.0092) in C5 siRNA treated ApoE-/- mice when 
compared to the controls (Fig. 3.9 B). 
 
Figure 3.9 Liver-specific C5 treatment led to a marked reduction of atherosclerotic lesions in aortic 
roots of 32 weeks old normal diet fed ApoE-/- mice. A. Aortic root plaques from normal chow-fed 32 
weeks old C5 siRNA and control siRNA-treated ApoE-/- mice. 10 μm fresh frozen sections of the aortic 
root were stained with ORO/HE staining. Scale bar:100 μm. B. Mean plaque sizes of the individual cross-
sections of the aortic root. Data are represented as the mean ± SEM, two-way ANOVA, * * * p<0.005; 
liver-specific C5 siRNA-treated mice: n=4; control siRNA-treated mice: n=4.  
3.2.5 Liver-specific C5 siRNA inhibits macrophage/dendritic and T cell infiltration 
in atherosclerosis in young ApoE-/- mice on a normal chow 
Foamy macrophages accumulate in the plaque and are the pathological hallmark of 
atherosclerosis15. CD68 is highly expressed on macrophages, as well as DCs in the 
plaque. Aortic root sections were stained for CD68 antibody using immunofluorescence 
staining (Fig. 3.10 A).  
The CD68+ area in atherosclerotic plaques was higher in control siRNA-treated mice 
compared to C5 siRNA-treated mice (Fig. 3.10 B). Our data indicated that liver-specific 
C5 inhibition inhibits CD68+ macrophage/DC infiltration in atherosclerotic plaque of 
32 weeks ApoE-/- mice fed with a normal diet. 
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Figure 3.10 Liver-specific C5 reduced CD68+ macrophage/DC infiltration in atherosclerotic 
plaques of 32 weeks old ApoE-/- mice on a normal diet. A. Aortic root plaques from 32 weeks old liver-
specific C5 siRNA or control siRNA treated ApoE-/- mice. 10 μm fresh-frozen sections of the aortic root 
were stained for CD68+ macrophages/DCs. Scale bars: 100 μm. B. Quantification of CD68+ area in aortic 
root plaque. Data are representative for the means ± SEM, Two-way ANOVA, *: p <0.05; Liver-specific 
C5 siRNA-treated mice: n=4; control siRNA-treated mice: n=4. 
 
Figure 3.11 Liver-specific C5 reduced CD3e+ T cell numbers in atherosclerotic plaques of normal 
mouse chow-fed 32 weeks old ApoE-/- mice. A. Aortic root plaques from normal chow-fed 32 weeks 
old liver-specific C5 siRNA- and control siRNA-treated ApoE-/- mice. 10 μm fresh-frozen sections of the 
aortic root were examined by CD3e+ T cell immunofluorescence staining. The red arrows in the images 
show the CD3e+ T cells. Scale bars: 100 μm. B. Quantification of CD3e+ numbers in aortic root plaque. 
Data are representative for the means ± SEM, Two-way ANOVA, *: p <0.05; Liver-specific C5 siRNA-
treated mice: n=4; control siRNA-treated mice: n=4.  
The role of T cells in the development and progression of atherosclerosis has been 
intensively studied for many years. We next examined whether liver-specific C5 siRNA 
impact T cell infiltration in atherosclerosis. The accumulation of T cells in aortic root 
lesions was counted by combined CD3e immunostaining (Fig. 3.11 A). The lesional 
CD3e+ T cells content in liver-specific C5 siRNA-treated mice was less than the control 
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group (Fig. 3.11 B), indicating that liver-specific C5 siRNA reduced CD3e+ T cell 
infiltration in 32 weeks old ApoE-/- mice on a normal diet.  
3.2.6 Effect of C5 siRNA on complement protein activation and deposition in 
normal chow-fed 32 weeks old ApoE-/- mice 
We hypothesized that attenuation of plaque progression observed in liver-specific C5 
treated ApoE-/- mice was due to the absence of complement proteins, including C3, C4, 
and C5 activation within the plaque. To test this hypothesis, we next stained 
complement proteins in atherosclerotic plaques. 10 μm fresh-frozen sections of the 
aortic roots from the liver-specific C5 siRNA and control groups were stained with 
immunofluorescence. Complement was assessed by staining for C3, C4 (Fig. 3.13), and 
C5 (Fig. 3.12) deposition.  
C3 and C4 deposition were detected strongly in plaques from both mice groups (Fig. 
3.13). C5 deposition was detected weakly in the aortic root plaques of C5-treated mice, 
though strongly in plaques from the control mice (Fig. 3.12). These results indicated 
that complement cascades are activated during the initiation of atherosclerosis; C5 
inhibition did not affect the C3, C4 deposition; however, C5 inhibition influenced the 
C5 deposition in the plaque in the initiation period of atherosclerosis.  
 
Figure 3.12 Liver-specific C5 reduced C5 deposition in atherosclerotic plaque of normal diet fed 
32 weeks old ApoE-/- mice. (A-B) Aortic root plaque from normal chow-fed 32 weeks old C5 siRNA- 
or control siRNA-treated ApoE-/- mice. 10 μm fresh frozen sections of aortic roots were examined by C5 
antibody immunofluorescence staining (right). Left pictures show the ORO/HE-stained sections next to 
the sections stained with C5-antibody. Scale bars: 100 μm.  
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Figure 3.13 C3 and C4 deposition in atherosclerotic plaques of normal chow-fed 32 weeks old 
ApoE-/- mice. (A-B) Aortic root plaque from normal chow-fed 32 weeks old C5 siRNA- and control 
siRNA-treated ApoE-/- mice. 10 μm fresh-frozen sections of the aortic root were examined by C3 and C4 
antibody immunofluorescence staining. Left pictures show the ORO/HE-stained sections next to the 
sections stained with C3 and C4 antibody. Scale bars: 100 μm. The green area in the pictures shows the 
autofluorescence. 
3.3 The role of liver-specific complement C5 in atherosclerosis in aged 
ApoE-/- mice maintained on a normal mouse chow 
Our data indicated that complement activation plays an important role in the formation 
of atherosclerotic plaques because, in the absence of complement C5 mice, the rate of 
progression of atherosclerosis was greatly decreased in young ApoE-/- mice. To further 
explore whether complement activation plays a role in atherosclerotic plaque 
development, complement activation inhibition was studied in aged ApoE-/- mice, 
which harbor advanced atherosclerotic plaques after maintaining them on a normal 
mouse chow. 58 weeks old ApoE-/- mice were treated with C5 siRNA every two weeks 
for 18 weeks. They were fed with a normal mouse chow throughout their lives (Fig. 
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3.14). 
 
Figure 3.14 Experimental design. 58 weeks old male ApoE-/- mice (C5 siRNA treated mice: n=9; 
control siRNA-treated mice: n=9), were treated with C5 or control siRNA every two weeks for 18 weeks 
and were given water and normal chow ad libitum. They were tail-bled at the age of 58 weeks, 60 weeks, 
70 weeks, and 76 weeks. 
Figure 3.15 C5 siRNA effectively silenced C5 in the circulation of aged ApoE-/- mice on a normal 
chow for 4 months. Blood was collected before injection and 2, 12 and 18 weeks thereafter. Complement 
C5 levels were measured by ELISA. Serum of C5-deficient mice (DBA/2) was used as a negative 
background control. The line graph shows group means ± SEM, two-tailed Student’s t-test, *** P<0.005 
versus before injection; liver-specific C5 siRNA-treated mice: n=9; control siRNA-treated mice: n=9. 
3.3.1 Liver-specific C5 siRNA reduced serum C5 protein level in aged ApoE-/- mice 
on a normal chow 
The serum of C5 siRNA and control groups were collected before siRNA application 
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and 2, 10, and 18 weeks thereafter. In order to determine the effect of C5 siRNA 
knockdown on aged ApoE-/- mice, C5 levels in serum were quantified by ELISA. 2 
weeks after siRNA application, serum C5 levels decreased more than 99% in the C5 
siRNA group, but no change was observed in the control group (Fig. 3.15). C5 levels 
in serum were maintained steadily throughout the experiment indicating that C5 siRNA 
silenced C5 level effectively in the circulation of aged ApoE-/- mice for extended 
periods of time. 
3.3.2 Liver-specific C5 siRNA does not change body weight and blood lipid level 
in aged ApoE-/- mice 
3.3.2.1 Lipid metabolism 
In order to study whether the C5 inhibition affects blood cholesterol and triglyceride 
levels, plasma lipid levels were studied in 76 weeks old C5 siRNA mice and control 
mice after 18 weeks of siRNA application. The cholesterol plasma levels, including 
HDL, LDL, and VLDL, and the total cholesterol levels were similar in these two groups. 
Further, plasma levels of triglycerides were unchanged by siRNA C5 treatment (Fig. 
3.16 A, B) indicating that C5 knockdown did not influence plasma cholesterol and 
triglyceride levels in aged ApoE-/- mice on normal chow. 
3.3.2.2 Body weight 
Body weights of mice were measured before and every 2 weeks after treatment. 
Compared to the body weight before injection, the body weight of both siRNA C5 and 
control mice was unchanged (Fig. 3.16 C). This data indicated that C5 inhibition did 
not affect the body weight in aged ApoE-/- mice. 
3.3.2.3 Blood cell counts 
In order to evaluate the overall health and a wide range of disorders following liver- 
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Figure 3.16 C5 siRNA does not impact blood lipid level, body weight, blood cell count, and 
leukocyte percentages of 76 weeks old ApoE-/- mice on normal chow. (A-B) Blood lipid level. Plasma 
was collected after 18 weeks of siRNA treatment. Chol and TG levels were determined by Prof. Daniel 
Teupser and Dr. Wolfgang Wilfert. Chol: cholesterol; TG: triglyceride. HDL: high-density lipoprotein; 
LDL: low-density lipoprotein; VLDL: very low-density lipoprotein. C. Body weight. Body weight was 
determined before treatment and every 2 weeks after treatment. (D-F) Blood cell concentration and 
leukocyte percentages. Data represent means ± SEM; Two-tailed Student´s t-test, n.s.: no significant 
difference; liver-specific C5 siRNA treated mice: n=9; control siRNA treated mice: n=9. HGB: 
hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; 
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MCHC: mean corpuscular hemoglobin concentration; RDW: red blood cell distribution width; MPV: 
mean platelet volume. WBCs: white blood cells; RBC: red blood cells; PLT: platelets; LYM: lymphocytes; 
MO: monocytes; and GRA: granulocytes. 
specific C5 siRNA treatment in aged ApoE-/- mice, the blood of 76 weeks old ApoE-/- 
mice treated with siRNA for 18 weeks was analyzed with a complete blood cell counter. 
WBC count, including LYM, MO, and the GRA were not affected by C5 inhibition (Fig. 
3.16 E, F). Red blood cell count and other parameters, including HGB,HCT, MCV, 
MCH, MCHC, and RDW, were not significantly different between the two mouse 
groups (Fig. 3.16 D). PLA counts and means of MPV were also not changed (Fig. 3.16 
D).  
Hence, liver-specific C5 inhibition did not alter major blood parameters of the aged 
ApoE-/- mice on a chow diet. 
3.3.3 C5 inhibition does not change blood leukocytes subsets in aged ApoE-/- mice 
on normal chow  
To study the impacts of C5 siRNA treatment on leukocyte subsets in independent assays, 
isolated blood cells from aged ApoE-/- mice fed with normal chow diet, which were 
treated with C5 siRNA or control siRNA for 18 weeks, were analyzed by flow 
cytometry.  
A considerable percentage of blood CD45+ leukocytes were B220+ B cells (Fig. 3.17 
B). Percentages of B220+ B cells and T cell receptor β (TCRb+) T cells in blood CD45+ 
leukocytes were not different between C5 siRNA-treated and control groups (Fig. 3.17 
B). Subtypes of CD4+ T cells and CD8+ T cells in total TCRb+ T cells were also similar 
in the two groups (Fig. 3.17 C). In CD4+ T cells, CD62LloCD44hi TEM T cells 
comprised the majority, whereas CD62LhiCD44hi TCM cells were a minor fraction.  
However, Th0 cells in CD4+ T cells were lower in the C5 inhibition group compared to 
the control group (Fig. 3.17 D). In CD8+ T cells, the percentages of each subset were 
unchanged by C5 inhibition (Fig. 3.17 E). Also, Foxp3+ Treg cells ratio per CD4+ T cells 
did not differ between C5-treated and control mice (Fig. 3.18 B). Percentages of 
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CD11b+CD11c+, CD11b+CD11c-, CD11b-CD11chi, CD11b-CD11cint cells in CD4- cells 
were not affected by C5 inhibition (Fig. 3.18 C). The Th0 T cell result requires 
confirmation and possibly further studies. 
 
Figure 3.17 Effects of C5 siRNA on leukocyte subsets in the circulation of 76 weeks old ApoE-/- mice 
on normal chow, part A. FACS analyses of leukocytes from 76 weeks old C5 siRNA- and control 
siRNA-treated ApoE-/- mice. A. Gating strategies: T cells (CD45+TCRb+ gate), B cells (CD45+B220+ 
gate), CD4+ T cells (CD45+TCRb+CD4+ gate), CD8+ T cells (CD45+ TCRb+CD8+ gate), CD4+ Th0 
(CD45+CD4+CD62LhiCD44lo gate), CD4+ TCM (CD45+CD4+CD62hiCD44hi gate), CD4+ TEM 
(CD45+CD4+CD62LloCD44hi gate), CD8+ Th0 (CD45+CD8+CD62LhiCD44lo gate), CD8+ TCM 
(CD45+CD8+CD62hiCD44hi gate), CD8+ TEM (CD45+CD8+CD62LloCD44hi gate). B. The frequencies of 
circulating T cells and B cells were compared in 76 weeks old ApoE-/- mice treated with C5 siRNA and 
control siRNA. C. The frequencies of circulating CD4+ T cells and CD8+ T cells were compared in 76 
weeks old ApoE-/- mice treated with C5 siRNA or control siRNA. D. The frequencies of circulating CD4+ 
Th0, TEM, and TCM were compared in 76 weeks old ApoE-/- mice treated with C5 siRNA or control 
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siRNA. E. The frequencies of circulating CD8+ Th0, TEM and TCM cells were compared in 76 weeks 
old ApoE-/- mice treated with C5 siRNA or control siRNA. Data represent means ± SEM; Student’s t-
test, n.s.: no significant difference, * p<0.05; C5 treated mice: n=6; control siRNA-treated mice: n=4.  
 
Figure 3.18 Effects of C5 siRNA on leukocyte subsets in the circulation of 76 weeks old ApoE-/- mice, 
part B. FACS analyses of leukocytes from 76 weeks old ApoE-/- mice treated with C5 siRNA or 
control siRNA. A. Gating strategies: Treg cells (CD45+CD4+Foxp3+ gate), CD11b-CD11c+ cells 
(CD45+CD4-CD11b-CD11c+ gate), CD11b+CD11c+ cells (CD45+CD4-CD11b+ CD11c+ gate), CD11b-
CD11c- cells (CD45+CD4-CD11b-CD11c- gate), CD11b+CD11cdim cells (CD45+CD4-CD11b+CD11cdim 
gate), CD11b+CD11c- cells (CD45+CD4-CD11b+CD11c- gate). B. The frequencies of Treg cells were 
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compared within circulation in 76 weeks old ApoE-/- mice treated with the liver-specific C5 siRNA and 
control siRNA. C. The frequencies of CD11b-CD11c+ cells, CD11b+CD11c+ cells, CD11b-CD11c- cells, 
CD11b+CD11cdim, and CD11b+CD11c- cells were compared within circulation in 76 weeks old ApoE-/- 
mice treated with the liver-specific C5 siRNA and control siRNA. Data represent means ± SEM; 
Student’s-t test, n.s.: no significant difference; liver-specific C5 siRNA-treated mice: n=6; control 
siRNA-treated mice: n=4.  
3.3.4 Liver-specific C5 siRNA did not affect atherosclerosis plaque burden in aged 
ApoE-/- mice on a normal chow 
Aortas were harvested after 18 weeks of siRNA application, then examined after en-
face staining and quantified (Fig. 3.19 A). Compared to the control group, 18 weeks C5 
siRNA silencing did not affect plaque sizes in the total aortas or in each thoracic and 
abdominal segment separately (Fig. 3.19 B-D).  
 
Figure 3.19 C5 did not affect atherosclerotic lesion sizes in aortas of 76 weeks old normal chow-fed 
ApoE-/- mice. A. en-face Sudan IV staining. Total aortas were pinned and stained with Sudan IV. 
Representative aortas from mice treated with control siRNA or C5 siRNA; Scale bar: 500 μm. B. The 
percent Sudan IV staining of the total aortic surface. C. The percent Sudan IV staining of the thoracic 
aorta. D. The percent Sudan IV staining of the abdominal aorta. Data represent means ± SEM; Student’s 
t-test, n.s.: no significant difference; liver-specific C5 siRNA treated mice: n=9; control siRNA treated 
mice: n=9.  
To examine whether C5 siRNA impacts plaque sizes, freshly prepared cross-sectional 
aortic root sections were stained with ORO/HE staining and quantified (Fig. 3.20 A). 
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There was no significant difference between the siRNA C5 group and the control group 
(Fig. 3.20 B) indicating that C5 inhibition did not influence atherosclerotic plaque sizes 
in aged ApoE-/- mice when compared to controls. In order to confirm these results in 
the small cohort of mice, future studies will have to analyze a higher number of mice. 
Moreover, the effects of the liver-specific C5 inhibition on stabilization of 
atherosclerotic plaque in normal chow-fed aged mice have not yet been examined. The 
major structural determinants of vulnerability, including the content of collagen, the 
size of the necrotic core, and the thickness of the fibrous cap, should be examined in 
the future. 
Figure 3.20 C5 siRNA did not affect plaque sizes in aortic roots of 76 weeks old normal chow-fed 
ApoE-/- mice. A. Aortic root plaques from 76 weeks old C5 siRNA-treated ApoE-/- mice or control 
siRNA-treated ApoE-/- mice. 10 μm fresh-frozen sections of the aortic root were stained with Oil-Red-
O/HE. Scale bar: 100 μm. B. Mean plaque sizes of the individual cross-sections of the aortic roots of C5 
siRNA-treated ApoE-/- mice or control siRNA-treated ApoE-/- mice. Data represent means ± SEM, two-
way ANOVA, n.s.: no significant difference; C5 siRNA-treated mice: n=4; control siRNA- treated mice: 
n=4.  
3.3.5 Liver-specific C5 siRNA did not affect CD68+ macrophage/DC infiltration in 
atherosclerosis in aged ApoE-/- mice on a normal chow 
Macrophages are pathological hallmarks of infiltrates in the advanced plaque of the 
aged ApoE-/- mice15. In order to examine whether the C5 inhibition influences the 
macrophage content in plaques of aged ApoE-/- mice, CD68+ macrophages were stained 
on aortic root sections of 76 weeks old ApoE-/- mice treated with C5 siRNA for 18 
weeks (Fig. 3.21 A). CD68+ macrophage area/plaque areas were not affected by C5 
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inhibition (Fig. 3.21 B). 
 
Figure 3.21 C5 did not affect CD68+ macrophage/DC infiltration in atherosclerotic plaque of 76 
weeks old ApoE-/- mice on normal chow. A. Aortic root plaques from 76 weeks old C5 siRNA- or 
control siRNA-treated ApoE-/- mice. 10 μm fresh-frozen sections of the aortic root were stained with 
CD68+ macrophages/DCs. Scale bars: 100 μm. B. Quantification of CD68+ area in aortic root plaque. 
Data represent means ± SEM, two-way ANOVA, n.s.: no significant difference; C5 siRNA treated mice: 
n=4; control siRNA treated mice: n=4. 
 
Figure 3.22 CD3e+ T cells in atherosclerotic plaques of 76 weeks old ApoE-/- mice on a normal diet. 
A. Aortic root plaques from 76 weeks old C5 siRNA and control siRNA treated ApoE-/- mice. 10 μm 
fresh frozen sections of the aortic root were stained with CD3e+ T cell immunofluorescence staining. 
Scale bars: 100 μm. B-E. Aggregates of CD3e+ T cell in aortic root sections of control siRNA treated 
ApoE-/- mice. 10 μm fresh frozen sections of the aortic root in control mice were stained with ORO/HE, 
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CD3e+ T cell, CD68+ macrophage/DC, SMA+ SMC, and CD31+ EC immunofluorescence staining. Scale 
bars: 100 μm. 
There were 3 in 9 mice in the control siRNA group, which contained aggregates of 
nuclei in the aortic root sections stained with ORO/HE (Fig. 3.22 B), but no C5 siRNA 
treated mice showed a similar structure (n=9). CD3e
+
 T cells were stained in aortic root 
sections (Fig. 3.22 A and C). CD3e+ staining showed a large number of cells in the 
aggregates in the aortic root sections, which were identified as CD3e+ T cells (Fig. 3.22 
C). Except for these 3 mice, CD3e+ T cell positive areas did not differ in C5 siRNA-
treated mice versus the other 6 control mice, showing in Fig. 3.22 A. The CD68, SMA, 
and CD31 staining pictures show the cells in the aggregations of nuclei in the aortic 
root are not CD68+ macrophage/DCs, SMCs and CD31+ ECs (Fig. 3.22 D and E). The 
structure of T cells aggregates in the aged aortic root plaques in the control group and 
whether the C5 inhibition affects the T cells infiltration is still unclear. 
3.3.6 Effect of C5 siRNA on complement protein deposition in normal chow-fed 76 
weeks old ApoE-/- mice 
In order to study the role of C5 inhibition on complement protein deposition within the 
plaque, we performed immunofluorescence staining for C3, C4, and C5. C5 siRNA 
treatment did not alter C3 and C4 levels within atherosclerotic plaques of normal chow-
fed 76 weeks old ApoE-/- mice when compared to their controls (Fig. 3.24). C5 
deposition in the plaques from C5 siRNA-treated aged mice was reduced when 
compared to the controls, however (Fig. 3.23).  
In conclusion, these data demonstrated that liver-derived complement C5 promotes 
atherosclerosis when ApoE-/- mice are fed with chow diet, and atherosclerosis plaque 
burden is reduced by C5 siRNA. Our data indicate new therapeutic treatment strategies 
for atherosclerosis. We next examined the roles of C5 on atherosclerosis when ApoE-/- 
mice were maintained on a high-fat diet.  
RESULTS 
60 
 
 
Figure 3.23 C5 deposition in atherosclerotic plaque of normal chow-fed 76 weeks old ApoE-/- mice. 
(A-B) Aortic root plaques from 76 weeks old C5 siRNA- or control siRNA-treated ApoE-/- mice. 10 μm 
fresh-frozen sections of the aortic root were examined by C5 antibody immunofluorescence staining 
(right). Left pictures show the ORO/HE-stained sections next to the sections stained for C5. Scale bars: 
100 μm.  
 
Figure 3.24 C3 and C4 deposition in atherosclerotic plaques of normal chow-fed 76 weeks old 
ApoE-/- mice. (A-B) Aortic root plaques from normal chow-fed 76 weeks old C5 siRNA- or control 
siRNA-treated ApoE-/- mice. 10 μm fresh-frozen sections of the aortic root were examined by C3 and C4 
antibodies immunofluorescence staining. Left pictures show the ORO/HE-stained sections next to the 
sections stained with C3 and C4 antibodies. Scale bars: 100 μm. The green area in the pictures shows the 
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autofluorescence. 
3.4 The role of liver-specific complement C5 in atherosclerosis in 
ApoE-/- mice with a high-fat diet 
Our data reported above demonstrated that complement activation promotes 
atherosclerosis initiation rather than affects the late stages of the disease. In contrast, an 
article published in 2001 indicated that C5 deficiency did not change atherosclerosis 
plaque load in the aortic root of ApoE-/- mice after 18 weeks on the high-fat diet when 
compared to the control group63. Importantly, the mice were fed with a high-fat diet, 
whereas in the majority of our experiments, we used a normal mouse chow. ApoE-/- 
mice fed with a high-fat diet will develop atherosclerosis faster compared to normal 
chow. However, atherosclerotic plaque formation becomes less dependent on the 
immune system. These experiments are, therefore not strictly comparable. We 
hypothesized that atherosclerotic plaque sizes would differ depending on the diet as 
immune mechanisms of mice on a high-fat diet are compromised when compared to a 
normal diet. Therefore, we repeated our experiments under high-fat diet conditions in 
our experimental system. 
 
Figure 3.25 Experimental design. 12 weeks old male ApoE-/- mice (C5 siRNA-treated mice: n=10; 
control siRNA-treated mice: n=11), were treated with C5 or control siRNA every two weeks for 20 weeks 
and were given water and high-fat chow ad libitum. They were tail bled at the age of 12 weeks, 14 weeks, 
24 weeks and 32 weeks. 
To examine the role of complement activation during atherosclerosis, ApoE-/- mice were 
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treated with C5 siRNA and subjected them (together with their controls) to a high-fat 
diet. These 2 groups of mice (C5 siRNA-treated group or control siRNA-treated groups) 
were then characterized and compared (Fig. 3.25).  
3.4.1 Liver-specific C5 siRNA reduces serum C5 protein levels in 32 weeks old 
ApoE-/- mice on a high-fat diet  
As the data mentioned above, C5 siRNA knocks down C5 levels (94%) in the serum of 
ApoE-/- mice on a high-fat diet and on normal chow (Fig. 3.26). 
 
Figure 3.26 Liver-specific C5 siRNA effectively silenced C5 in the circulation of young ApoE-/- mice 
on a high-fat diet. Blood was collected before injection, 2 weeks, 12 weeks, and 20 weeks after injection 
from the caudal vein. Complement C5 levels were measured by ELISA. Serum of C5-deficient mice 
(DBA/2) was used as a non-specific background negative control. The line graph shows group means ± 
SEM; two-tailed Student’s t-test; *** p<0.005 versus before injection; liver-specific C5 siRNA treated 
mice: n=10; control siRNA treated mice: n=11. 
3.4.2 Liver-specific C5 siRNA does not change blood lipid levels, body weight, 
blood cell numbers, and leukocyte percentages in 32 weeks old ApoE-/- mice on a 
high-fat diet 
In order to determine whether C5 siRNA affected blood cell counts in high-fat diet fed 
ApoE-/- mice, plasma lipid levels were determined. C5 siRNA did not influence the 
cholesterol and triglyceride levels in high-fat diet fed ApoE-/- mice (Fig. 3.27 A-B). As 
expected, their plasma lipid levels were significantly higher than the plasma lipid levels 
RESULTS 
63 
 
of mice on a normal diet (not shown).  
Two groups of mice were weighed every two weeks, and their body weight increased 
steadily during aging, reflecting the high calory intake. C5 siRNA did not affect the 
weight gain in the two groups (Fig. 3.27 C).  
In order to determine whether C5 siRNA affected blood cell counts in ApoE-/- mice in 
a high-fat diet condition, complete blood was obtained after 20 weeks of C5 siRNA 
injections and analyzed with a complete blood cell counter. In both the liver-specific 
C5 siRNA and the control group mice, blood cells numbers, concentrations and other 
parameters were not changed after the high-fat diet period (Fig. 3.27 D-F).  
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Figure 3.27 Liver-specific C5 siRNA does not impact blood lipid levels, body weight gain, blood cell 
concentration and leukocyte percentage of 32 weeks old ApoE-/- mice on a high-fat diet. (A-B) Blood 
lipid level. Plasma was collected after 18 weeks of siRNA treatment. Chol and TG levels were measured 
by our collaborators, Prof. Daniel Teupser and Wolfgang Wilfert. Chol: cholesterol; TG: triglyceride. 
HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very low-density lipoprotein. C. 
Body weight gain. Body weight was weighed before treatment and every 2 weeks after treatment. (D-
E) Blood cell concentration and leukocyte percentage. Data represent means ± SEM; two-tailed 
Student´s t-test, n.s.: no significant difference; C5 siRNA-treated mice: n=10; control siRNA treated mice: 
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n=11. HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular 
hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red blood cell distribution 
width; MPV: mean platelet volume. WBCs: white blood cells; RBC: red blood cells; PLT: platelets; LYM: 
lymphocytes; MO: monocytes; and GRA: granulocytes. 
 
Figure 3.28 C5 siRNA did not affect leukocyte subsets in the circulation of 32 weeks old ApoE-/- 
mice on a high-fat diet, part A. Flow cytometric analysis of leukocytes from 32 weeks old C5 siRNA 
and control siRNA treated ApoE-/- mice. A. Gating strategies: CD4+ T cells (CD45+CD4+ gate), CD8+ 
T cells (CD45+CD8+ gate), CD4+ Th0 (CD45+CD4+CD62LhiCD44lo gate), CD4+ TEM 
(CD45+CD4+CD62LloCD44hi gate), CD4+ TCM (CD45+CD4+CD62hiCD44hi gate), CD8+ Th0 
(CD45+CD8+CD62LhiCD44lo gate), CD8+ TEM (CD45+CD8+CD62LloCD44hi gate), CD8 TCM 
(CD45+CD8+CD62hiCD44hi gate), B cells (CD45+B220+ gate). B. The frequencies of CD4+ T cells, CD8+ 
T cells and B cells were compared in circulation in high-fat diet fed 32 weeks old ApoE-/- mice treated 
with C5 siRNA and control siRNA. The bar graph shows the percentages of CD4+ T cells, CD8+ T cells 
and B cells in CD45+ leucocytes. C. The frequencies of CD4+ Th0, TEM and TCM were compared in 
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circulation in high-fat diet fed 32 weeks old ApoE-/- mice treated with C5 siRNA and control siRNA. The 
bar graph shows the percentages of Th0, TEM and TCM in CD4+ T cells. D. The frequencies of CD8+ 
Th0, TEM and TCM were compared in circulation in high-fat diet fed 32 weeks old ApoE-/- mice treated 
with C5 siRNA and control siRNA. The bar graph shows the percentages of Th0, TEM and TCM in 
CD8+ T cells. Data represent means ± SEM; Student’s-t test, n.s.: no significant difference, * p<0.05; C5 
treated mice: n=8; control siRNA treated mice: n=6. 
  
Figure 3.29 C5 siRNA did not affect leukocyte subsets in the circulation of 32 weeks old ApoE-/- 
mice on a high-fat diet, part B. FACS analyses of leukocytes from high-fat diet fed 32 weeks old 
ApoE-/- mice treated with the C5 siRNA and control siRNA. A. Gating strategies: Treg cells 
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(CD45+CD4+Foxp3+ gate), CD11b-CD11c+ cells (CD45+CD4-CD11b-CD11c+ gate), CD11b+CD11chi 
cells (CD45+CD4-CD11b+CD11chi gate), CD11b+CD11cint cells (CD45+CD4-CD11b+CD11cint gate), 
CD11b-CD11c- cells (CD45+CD4-CD11b-CD11c- gate), CD11bintCD11c- cells (CD45+CD4-
CD11bintCD11c- gate), CD11bhiCD11c- cells (CD45+CD4-CD11bhiCD11c- gate). B. The frequencies of 
Treg cells were compared within circulation in high-fat diet fed 32 weeks old ApoE-/- mice treated with 
the liver-specific C5 siRNA and control siRNA. C. The frequencies of CD11b-CD11c+ cells, 
CD11b+CD11c+ cells, CD11b-CD11c- cells, CD11b+CD11cdim, and CD11b+CD11c- cells were compared 
within circulation in high-fat diet fed 32 weeks old ApoE-/- mice treated with liver-specific C5 siRNA 
and control siRNA. Data represent means ± SEM; Student’s-t test, n.s.: no significant difference; liver-
specific C5 siRNA-treated mice: n=8 mice; control siRNA-treated mice: n=6 mice.  
3.4.3 Liver-specific C5 inhibition does not change the blood leukocytes subsets in 
young ApoE-/- mice on a high-fat diet 
The data above showed that the C5 siRNA did not affect circulating leukocytes subsets 
in young and aged ApoE-/- mice on a normal diet (Fig. 3.5, 3.6, 3.7, 3.16, 3.17, 3.18). 
In order to determine whether C5 siRNA influence the leukocyte subsets in the 
circulation in the ApoE-/- mice in the high-fat diet condition, the leukocyte 
concentrations in the blood were also analyzed with FACS (Fig. 3.28 A and Fig. 3.29 
A).  
C5 siRNA did not influence the concentration of CD45+CD4+ T cells, CD45+CD8+ T 
cells, CD45+B220+ B cells (Fig. 3.28 B), CD45+CD4+ Th0, CD45+CD4+ TEM, 
CD45+CD4+ TCM (Fig. 3.28 C), CD45+CD8+ Th0, CD45+CD8+TEM, CD45+CD8+ 
TCM (Fig. 3.28 D), CD45+ Treg cells (Fig. 3.29 B), CD45+CD4-CD11b-CD11c+ cells, 
CD45+CD4-CD11b+CD11chi cells, CD45+CD4-CD11b+CD11cint cells, CD45+CD4-
CD11b-CD11c- cells, CD45+CD4-CD11bintCD11c- cells, and CD45+CD4-
CD11bhiCD11c- cells (Fig. 3.29 C). But in the CD4+ T cells, the Th0 and TEM were 
changed. The concentration of CD4+ Th0 was reduced, and CD4+ TEM were increased 
in the C5 siRNA group compared to the control (Fig. 3.28 C). 
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3.4.4 C5 siRNA did not affect atherosclerosis plaque burden in young ApoE-/- mice 
on a high-fat diet 
In order to explore whether the C5 siRNA affected atherosclerotic plaque development 
in the ApoE-/- mice under high-fat diet conditions after 20 weeks siRNA treatment, 
whole aortas were examined with the en-face analysis (Fig. 3.30 A). The Sudan IV 
positive plaque areas in the whole aortas (Fig. 3.30 B), thoracic aorta parts (Fig. 3.30 
C) and abdominal aorta parts (Fig. 3.30 D) were similar in the siRNA group versus the 
control group.  
 
Figure 3.30 C5 siRNA did not affect atherosclerotic lesion sizes in aortas of 32 weeks old high-fat 
diet fed ApoE-/- mice. A. en-face Sudan IV staining. Total aortas were pinned and stained with Sudan 
IV. Representative aortas from mice treated with control siRNA and liver-specific C5 siRNA; Scale bar: 
500 μm. B. The percent Sudan IV staining of the total aortic surface. C. The percent Sudan IV staining 
of the thoracic aorta. D. The percent Sudan IV staining of the abdominal aorta. Data represent means ± 
SEM; Student’s-t test, n.s.: no significant difference; liver-specific C5 siRNA treated mice: n=10; control 
siRNA treated mice: n=11.  
To evaluate the effect of C5 siRNA in plaque composition, we stained 10μm fresh 
frozen aortic root sections with ORO/HE staining (Fig. 3.31 A) and quantified the 
plaque size. The plaque areas were not significantly different in the C5 siRNA and 
control groups (Fig. 3.31 B). 
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Figure 3.31 Liver-specific C5 mediated regression of atherosclerotic lesions in aortic roots of 32 
weeks old high-fat diet fed ApoE-/- mice. A. Aortic root plaque from high-fat diet fed 32 weeks old C5 
siRNA and control siRNA treated ApoE-/- mice. 10 μm fresh frozen sections of the aortic root were 
stained with ORO/HE staining. Scale bar: 100μm. B. Mean plaque sizes of the individual cross-sections 
of the aortic root. Data are represented as the mean ± SEM, Two-way ANOVA, n.s.: no significant 
difference; liver-specific C5 siRNA-treated mice: n=5; control siRNA-treated mice: n=5. 
3.4.5 C5 siRNA does not influence macrophage/DC and T cell infiltration in 
atherosclerosis in young ApoE-/- mice on a high-fat diet 
In order to determine the CD68+ macrophage/DCs and CD3e+ T cells infiltration, the 
aortic root sections were stained with immunofluorescence CD68 and CD3e antibodies 
staining (Fig. 3.32 A and Fig. 3.33 A). 
The fraction of the CD68+ macrophage/dendritic areas and CD3e+ T cell numbers in the 
atherosclerotic plaques were not significantly different in the C5 siRNA and control 
siRNA groups (Fig. 3.32 B and Fig. 3.33 B). 
 
Figure 3.32 C5 did not affect CD68+ macrophage/DC infiltration in atherosclerotic plaque of 32 
weeks old ApoE-/- mice on a high-fat diet. A. Aortic root plaque from high-fat diet-fed 32 weeks old 
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C5 siRNA and control siRNA-treated ApoE-/- mice. 10 μm fresh frozen sections of the aortic root were 
stained with CD68+ macrophages/DCs immunofluorescence staining. Scale bars: 100 μm. B. 
Quantification of CD68+ area in aortic root plaque. Data represent the means ± SEM, two-way ANOVA, 
n.s.: no significant difference; C5 siRNA-treated mice: n=4; control siRNA treated mice: n=4. 
 
Figure 3.33 C5 did not affect CD3e+ T cells in atherosclerotic plaques of 32 weeks old ApoE-/- mice 
on a high-fat diet. A. Aortic root plaques from high-fat diet fed 32 weeks old C5 siRNA and control 
siRNA treated ApoE-/- mice. 10 μm fresh frozen sections of the aortic root were stained with CD3e+ T 
cell immunofluorescence staining. Scale bars: 100 μm. B. Quantification of CD3e+ numbers in aortic 
root plaque. Data represent the means ± SEM, two-way ANOVA, n.s.: no significant difference; liver-
specific C5 siRNA-treated mice: n=4; control siRNA-treated mice: n=4. 
3.4.6 Effect of C5 siRNA on complement protein activation and deposition in high-
fat diet fed 32 weeks old ApoE-/- mice 
In both the normal diet fed young and aged ApoE-/- mice, C5 siRNA reduced the C5 
deposition in the plaques from them (Fig. 3.12 and Fig. 3.23), but did not affect the C3 
or C4 deposition. Next, I examined complement protein deposition in the aortic root 
plaques from the high-fat diet fed 32 weeks ApoE-/- mice with immunofluorescence 
staining. There was no apparent difference of C3, C4 (Fig. 3.35), and C5 (Fig. 3.34) 
deposition in the aortic root plaques between the C5 siRNA and control siRNA group. 
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Figure 3.34 C5 siRNA reduced C5 deposition in atherosclerotic plaque of the high-fat diet fed 32 
weeks old ApoE-/- mice. (A-B) Aortic root plaque from the high-fat diet fed 32 weeks old C5 siRNA- 
and control siRNA-treated ApoE-/- mice. 10 μm fresh frozen sections of the aortic root were examined 
by C5 antibody immunofluorescence staining (right). Left pictures show the ORO/HE-stained sections 
next to the sections stained with C5-antibody. Scale bars: 100 μm.  
 
Figure 3.35 C3 and C4 deposition in atherosclerotic plaque of the high-fat diet fed 32 weeks old 
ApoE-/- mice. (A-B) Aortic root plaque from the high-fat diet fed 32 weeks old C5 siRNA and control 
siRNA-treated ApoE-/- mice. 10 μm fresh frozen sections of the aortic root were examined by C3 and C4 
antibody immunofluorescence staining. Left pictures show the ORO/HE-stained sections next to the 
sections stained with C3 and C4 antibody. Scale bars: 100 μm. The green area in the pictures shows the 
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autofluorescence. 
3.4.7 C5 siRNA does not affect atherosclerotic plaque burden in young ApoE-/- 
mice on a short-term high-fat diet 
In order to explore whether the C5-mediated complement system only plays a role in 
early atherosclerosis, we selected 4 weeks high-fat diet during early atherosclerosis (Fig. 
3.36).  
 
Figure 3.36 Experimental design. 12 weeks old male ApoE-/- mice (liver-specific C5 siRNA treated 
mice: n=4; control siRNA treated mice: n=4), were treated with C5 or control siRNA every two weeks 
for 4 weeks and were given water and high-fat chow ad libitum. 
After 4 weeks of siRNA treatment and a high-fat diet, the total aortas were analyzed 
with the en-face analysis (Fig. 3.37 A). The atherosclerotic plaques in these mice were 
much less than 16w long-term high-fat diet mice and as less as normal diet fed young 
mice. However, C5 siRNA still did not reduce early atherosclerosis during a period of 
four weeks of high-fat diet (Fig. 3.37 B).  
 
Figure 3.37 Liver-specific C5 did not affect atherosclerotic lesion sizes in aortas of 12 weeks old 
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high-fat diet fed ApoE-/- mice. A. en-face Sudan IV staining. Total aortas were pinned and stained with 
Sudan IV. Representative aortas from mice treated with control siRNA and liver-specific C5 siRNA; 
Scale bar: 500 μm. B. The percent Sudan IV staining of the total aortic surface. C. The percent Sudan IV 
staining of the thoracic aorta. D. The percent Sudan IV staining of the abdominal aorta. Data represent 
means ± SEM; Student’s t-test, n.s.: no significant difference; C5 siRNA-treated mice: n=4; control 
siRNA-treated mice: n=4.  
3.5. Classical complement cascade activation in human atherosclerosis 
In human pathology, in 1962, Lachmann et al. observed complement protein (beta-1-C 
globulin) deposition in the vascular walls of malignant nephrosclerosis and in certain 
collagenous diseases. Atherosclerosis is viewed as the embodiment of chronic 
inflammatory disease now. The plaque progresses from the early stage of fatty streaks 
to a more complex advanced stage exemplified by a necrotic core. Complement protein 
deposition is a characteristic feature of human atherosclerotic lesions102-104. In order to 
explore whether the complement system is activated during human atherosclerosis 
progression, human atherosclerosis samples from carotid endarterectomy were 
classified into healthy arteries, early stage and advanced atherosclerotic plaques based 
on one of the American Heart Association classifications followed by quantification. 
Five healthy control arteries on autopsy (type 0-I), six early (type II-III) and nine 
advanced atherosclerotic plaques (type V-VII)105 from carotid endarterectomy 
specimens were stained for CD68+ macrophages/DCs, C1q, ApoE, and C5 (Fig. 3.38 
A). These quantificational illustrations show CD68+ macrophage infiltration, and C1q, 
ApoE, and C5 protein deposits increased in early and advanced plaques compared with 
control arteries (Fig. 3.38 B, C). 
These data indicated that human atherosclerotic plaques are contained CD68+ 
macrophages/DCs, and C1q, ApoE, and C5 protein deposition. Thus, the complement 
cascades are activated in human plaques. This section presented here was published95. 
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Figure 3.38 Classical complement cascade activation in human atherosclerosis. A. Human carotid 
artery sections were stained for Alcian, EvG, CD68, C1q, ApoE, and C5 by DAB and hematoxylin. 
Representative images from B and C. B. CD68, C1q, ApoE, and C5 signals in the intima were quantified. 
C. CD68, C1q, ApoE, and C5 signals in the media were quantified. CD68, C1q, ApoE, and C5 signals 
were quantified as described in Methods. Data represent means ± SEM; one-way ANOVA, n.s.: no 
significant difference, * p<0.05, ** p<0.01, ***: p<0.005; healthy control: n = 5 (independent samples), 
early plaque: n = 6, advanced plaque: n = 9.
Intima Media 
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4. DISCUSSION 
4.1 Discovery of an ApoE-complement C5 axis which controls 
atherosclerosis in mice 
ApoE has traditionally been viewed as a lipid-binding glycoprotein whose major 
function is to clear remnants of chylomicrons and VLDL from the circulation. Previous 
studies had shown that ApoE-/- mice had five times normal plasma cholesterol and 
developed foam cell-rich depositions in their proximal aortas by the age of 3 months27. 
However, importantly, ApoE has also been recognized to be a multifunctional protein 
whose impact on tissue homeostasis extends beyond lipid transport. Thus, ApoE has 
been implicated in brain diseases as varied as Alzheimer´s disease106 and Parkinson´s 
disease107. Moreover, the apolipoprotein has been implicated in affecting chronic 
inflammatory diseases, including several infectious diseases108. Its role in the regulation 
of immune responses has been discussed, but no molecular mechanism has been 
proposed. Yin et al.,95 in our group recently demonstrated that ApoE forms a high-
affinity complex with the complement-initiating molecule C1q and thereby dampens 
the activity of the CCC in vitro but - of particular interest - also in vivo. These studies 
were performed using a variety of mouse models to dissect the role of ApoE in tissue 
inflammation as varied as atherosclerosis (the current thesis) and choroid plexus 
inflammation and Alzheimer´s disease. When these studies using translational studies 
into human atherosclerosis and diseased human brains are taken together with the data 
presented here, a major general and possibly ubiquitous role of ApoE in various 
unresolvable inflammatory diseases deserves attention.  
The time window of liver-specific C5 siRNA treatment that I used to examine 
atherosclerosis in ApoE-/- mice (12 weeks to 32 weeks) covered the critical period 
during atherosclerosis initiation. A principal finding of my study is that the extent of 
total aortic atherosclerosis was markedly attenuated in aortas from normal chow-fed 
young C5 siRNA-treated mice. 
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A second important finding of the present study is that C5 siRNA not only attenuated 
the size of the atherosclerotic lesions but that it also affected the cellularity of the plaque. 
Thus, CD68+ macrophages/DCs were reduced in lesions from experimental mice versus 
their control brethren. Moreover, CD3e+ T cells were also reduced in C5 siRNA-treated 
mice. This finding implies that liver-derived C5 associated-complement activation 
promotes changes that are associated with an inflammatory response in the initiation of 
atherosclerotic plaques. Of note, complement protein C5 contributes to the progression 
of atherosclerosis by two distinctive ways: C5a is an activated biologically powerful 
anaphylatoxin generated by cleavage of the C5 protein by protease C5-convertase. 
However, C5b is another degradation product of C5 forming MAC, resulting in cell 
lysis. Our data cannot distinguish between the specific effects of these two C5 
degradation products on atherosclerosis.  
C5a acts as a powerful chemoattractant that can modulate the activity of the myeloid 
lineage, such as eosinophils, basophils and neutrophils, monocytes and most tissue 
macrophage subtypes, T cells and B cells47. Previous studies had shown that C5a 
promotes migration and adherence of neutrophils and monocytes to vessel walls, and 
initiates accumulation of complement and phagocytic cells at sites of infection109. In 
our chow-fed young mice, the reduction of the atherosclerotic lesion and the 
macrophage and T cell infiltration may, therefore, be caused by the absence of C5a in 
the treatment group rather than a reduction of MAC. MAC deposition is a typical 
feature of human plaques, however. The results of several studies suggested that MAC 
might also play an important role in the development of atherosclerosis110-112. Further 
studies are clearly needed to determine the distinctive contributions of the two C5 
degradation products on atherosclerosis during the various stages of the disease, i.e., 
initiation, progression, and the late clinically significant stages.  
In conclusion, we have demonstrated that the initiation of atherosclerosis in mice 
depends in part on the presence of liver-specific C5 mediated-complement activation. 
Our data indicate that the complement system needs to be considered when assessing 
the mechanisms of other inflammatory parameters related to atherosclerosis. 
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4.2 C5-targeted therapy aims to reduce atherosclerosis 
We have demonstrated that C5 had the most prominent effects during the initiation of 
the lesion via increasing macrophage and T cell migration. Therefore, this study also 
suggested a causal role for liver-specific C5 in advanced atherosclerotic plaque in aged 
ApoE-/- mice. Normal chow-fed 58 weeks old ApoE-/- mice had already developed 
advanced plaques27. After 18 weeks liver-specific C5 siRNA treatment, however, 
neither the plaque size nor the macrophage content were changed.  
The used siRNA has a GalNAc adduct, which specifically binds to and is taken up by 
the ASGPR, which is selectively and strongly expressed on hepatocytes. In the 
circulation, the majority of C5 protein is synthesized by the liver, though to a lesser 
degree it is also produced by tissue macrophages, blood monocytes113, and epithelial 
cells of the lung, the genitourinary system, and the intestine114. Advanced plaques 
contain macrophages. We hypothesize that C5 protein might be produced by 
macrophages locally which is consistent with our observation that C5 staining in aortic 
root sections showed that C5 was expressed in plaques in both the C5 treatment and 
control groups.  
C5a is a powerful chemoattractant and is also involved in recruiting inflammatory cells 
via CD88. CD88 (the canonical C5a receptor) is expressed by most of the cell types 
observed in human atherosclerotic plaque, i.e. macrophages, ECs, SMCs115, and T cells. 
In our aged animals, the majority of C5 was reduced by liver-specific C5 siRNA. 
However, the expression of CD88 might be up-regulated by a compensatory reaction. 
Previous studies showed that in the inflamed human central nervous system, reactive 
astrocytes, microglia cells, and ECs expressed more CD88116. This would further 
explain why inhibition of C5 in aged ApoE-/- mice had no effect on macrophage 
infiltration. Further studies are needed to uncover the age-dependent effects of our 
treatment. A combination of C5 siRNA and inhibition of CD88 may clarify some of 
these open issues.  
Atherosclerosis is strongly associated with aging117, as atherosclerotic plaques show 
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evidence of cellular senescence described by reduced vascular SMC proliferation, 
increased collagen deposition and decrease in arterial elastin content118, which promote 
vascular stiffness119 and hypertension120; irreversible growth arrest and apoptosis occur 
in ECs, vascular SMCs and macrophages121, DNA damage, epigenetic modifications, 
and telomere shortening, and dysfunction observed in plaque vascular SMCs122 and 
ECs123. Growing evidence further showed that cellular senescence promotes 
atherosclerosis124-126.  
Mechanisms of the lack of impact of liver-specific C5 inhibition on atherosclerosis in 
aged ApoE-/- mice remains to be clearly defined. Several possibilities exist. a) Different 
stages of atherosclerotic plaques: In young ApoE-/- mice on chow diet, the C5 siRNA 
treatment was started at 12 weeks, and the mice did not develop visible plaques in the 
aorta at this point in time. There was no pre-existing inflammation in the aorta when 
we started the C5 siRNA treatment. After 20 weeks of treatment, C5 siRNA strongly 
reduced atherosclerotic plaque size and inflammation. These data support the 
conclusion that a presumed lipid-complement-inflammation axis promotes early 
atherosclerosis development. In aged ApoE-/- mice, the C5 siRNA treatment was started 
at 58 weeks when the mice had already developed atherosclerotic plaques. In advanced 
plaques, other pre-existing inflammatory triggers, i.e., crystal, macrophage-form cells 
or necrotic cores may trigger other pro-inflammatory pathways including 
inflammasome127. The immunofluorescence staining confirmed that those complement 
proteins were deposited in advanced plaques, while C5 siRNA treatment indeed 
reduced C5 deposited in advanced plaques in aged ApoE-/- mice fed with chow diet 
(Figure 3.23 -3.24). But the plaque size was not significantly reduced after C5 siRNA 
treatment in advanced plaques analyzed by en-face staining. Further studies are 
required to examine whether C5 siRNA treatment altered plaque stabilization; (b) C5 
siRNA targeted liver-produced C5, but not locally produced C5. In aged ApoE-/- mice 
fed with chow diet, locally produced C5 by infiltrated T cells and monocytes may 
compensate C5 siRNA treatment which silenced serum C5; (c) the time period needed 
for C5 siRNA in the present study in aged mice may have been too short to yield 
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statistically significant data; (d) different age windows and consequently variability in 
plaque sizes may require larger mouse cohorts to proof an effect of complement 
inhibition in advanced atherosclerosis; (e) C5 may not be involved in advanced plaque 
progression. These two different models may represent early and advanced stages of 
atherosclerotic plaques in human diseases. However, cautions are required when 
interpreting murine data in view of a possible relevance for human diseases. 
Nevertheless, we confirmed that complement proteins and inflammation is present in 
human atherosclerotic plaques. In addition, our murine data strongly suggest that 
atherosclerotic plaques in young and aged ApoE-/- mice are suitable models to study the 
impact of complement activation in atherosclerosis. 
4.3 Possible effect of high-fat diet on C5-dependent atherosclerosis 
Why C5 inhibition reduces plaque size and alters the cellular composition of plaques in 
ApoE-/- mice on a normal diet but not on a high-fat diet remains an important unresolved 
question. Our data show that 20 weeks of C5 siRNA treatment reduced atherosclerosis 
in 32 weeks old ApoE-/- mice on chow diet, while, 20 weeks of C5 siRNA treatment did 
not reduce atherosclerosis in 32 weeks old ApoE-/- mice on 16 weeks high-fat diet. In 
both mouse models, we used liver-specific C5 siRNA. It is possible that 16 weeks high-
fat diet leads to a higher CD68 macrophage content in atherosclerotic plaques, which 
produced higher local concentrations of C5 to compensate for the lack of serum C5. 
However, we cannot exclude other possibilities, for example, that high-fat diet triggered 
the reprogramming of myeloid blood cells, which may enter the plaque independent of 
complement activation, as evidenced by our finding that C5 siRNA treatment or C5 
knockout63 does not reduce plaque size in ApoE-/- mice on high-fat diet.  
Hence, we propose that there may be two mechanisms to initiate atherosclerotic plaque 
inflammation: (i) complement C5-dependent initiation of atherosclerosis; (ii) 
complement C5-independent initiation of atherosclerosis. Further studies are clearly 
required to address this important unresolved question in the future. These data 
indicated that atherosclerosis might respond to anti-complement therapeutic approaches 
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depending on the diet whereby the extreme levels of hyperlipidemia in high-fat diet fed 
mice may overwhelm the innate immune system, which, in turn, becomes dysfunctional. 
We have pointed out previously that the immune system may be dysfunctional when 
lipid levels reach unphysiological extreme levels in ApoE-/- mice8. 
Indeed, the observation that high-fat diet versus normal chow diet leads to two different 
outcomes in murine complement inhibition studies suggests that complement 
activation-dependent atherosclerosis in normal chow diet versus complement 
activation-independent atherosclerosis in high-fat diet are mechanistically distinct. The 
impact of high-fat diet on the immune system has been studied by several groups: 
(a)Hedrick CC et al. reported that the high-fat diet might create intensive oxidative 
stress and alter apolipoproteins in the circulation, which may evoke immunologic 
responses when compared to mice on chow diet128; (b) Dansky et al. studied the role of 
the recombinase activating gene 1 (Rag-1) gene (important for T and B cell 
development) in ApoE-/- mice on a chow diet versus high-fat diet. Rag-1-/-ApoE-/- mice 
showed a significant decrease in atherosclerotic plaque size compared to ApoE-/- mice 
under chow diet at 16 weeks of age, while there was no significant difference in plaque 
size when the mice were of high-fat diet. These data support the hypothesis that high 
fat diet triggers atherosclerosis independent of T and B cells129; (c) Murphy et al. 
reported that high-fat diet induced myeloid cell proliferation in the bone marrow of 
ApoE-/- mice, compared to chow diet-treated ApoE-/- mice130; (d) Christ et al. reported 
that high-fat diet triggers inflammasome activation, transcriptomic, and epigenomic 
reprogramming of myeloid progenitor cells, which leads to more pro-inflammatory 
cytokine expression by myeloid cells131. 
4.4 Is the C5-dependent effect on atherosclerosis only the tip of an 
iceberg of a broader and possibly ubiquitous role of C5 and ApoE in 
unresolvable inflammation?  
The present data, together with those of Yin et al.95, show that two other and very 
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distinct types of unresolvable inflammation, i.e., in choroid plexus inflammation and 
Alzheimer´s disease, are linked to ApoE. Moreover, the translational work in Yin et al. 
suggest that the experimental mouse data may be applicable to the respective human 
diseases. In view of the discovery of the ApoE-C1q complex and its presence in distinct 
diseased tissues, we propose that other diseases including chronic inflammatory 
diseases caused by persistent bacterial and other infections as well as inflammatory 
types of cancer should be studied to examine a broader role of the complex in chronic 
inflammation.  
4.5 Liver-derived complement component C5 vs. local produced C5 in 
atherosclerosis 
Complement mRNAs, i.e. C1q, C2, C3, C4 and C5 have been reported in human 
atherosclerotic plaques as analyzed by PCR55,56,132. These data revealed that some 
complement proteins are transcribed locally rather than being derived from the liver. 
Complement C5 protein localized with macrophages indicating that macrophages may 
produce C5 protein locally. Whaley et al. and Hetland et al. detected complement C3, 
factor B (fB), factor D (fD), C2, C4 and C5 mRNA expression from human blood 
monocyte-derived macrophages or macrophages in vitro indicating that the mRNAs of 
these complement components are derived from immune cells, i.e. macrophages, in 
atherosclerotic plaques 113,133,134. Meanwhile, C5 mRNA (but not that of C1q or C3) 
was below the detection threshold by microarray in atherosclerotic plaque indicating 
that the great majority of C5 is serum-derived and is recruited into inflammatory sites; 
this finding made it possible to target liver-specific C5 (which is shown in the present 
work to decrease serum C5 by >95%) without compromising locally produced C5. Our 
data, therefore, provide the first evidence that liver-produced C5 promote 
atherosclerosis development in young ApoE-/- mice. Whether macrophage-derived C5 
plays the same role in atherosclerosis, however, is still unclear. 
Moreover, recent research has shown that complement can influence the adaptive 
immune response by modulating DC function and thus regulating antigen-specific T 
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cell responses. In addition, local production and activation of complement have been 
suggested to be critical for DC development135,136. 
4.6 Complement studies in other atherosclerotic mouse models  
4.6.1 Complement component C5 in atherosclerosis 
Patel S et al. 2001 knocked out the C5 gene in ApoE-/- mice, then maintained the mice 
on a high-fat diet for 18 weeks. There was no significant difference in atherosclerotic 
plaque size in the aortic root when compared to ApoE-/- control. The content of 
macrophage-derived foam cells in atherosclerotic plaque was also not different63. This 
study of global C5 knockout is inconclusive, however, as it does not distinguish 
between liver- versus local complement expression and because it does rely on 
unphysiologically high cholesterol concentrations which are known to be little affected 
by immune cells. Manthey H et al. 2011 blocked the C5a receptor CD88 by injecting 
the CD88 antagonist - PMX53 - in ApoE-/- mice maintained on a normal chow diet for 
25 weeks. PMX53 treatment significantly reduced atherosclerotic plaque size in the 
brachiocephalic artery at the age of 30 weeks48. CD88 expression has been shown to be 
expressed by endothelial cells, smooth muscle cells and macrophages in plaques, 
suggesting that PMX53 treatment blocked the binding of C5a to CD88 in plaques. 
These data support a detrimental role of activated complement cascades in 
atherosclerosis. The apparent contradictory observations between Patel S et al. 2001 
and Manthey H et al. 2011 may due to several reasons: knockout C5 versus C5a 
receptors; high-fat diet versus normal chow diet; advanced atherosclerosis plaques in 
ApoE-/- mice fed with 18 weeks high-fat diet versus early atherosclerotic plaques in 30 
weeks old ApoE-/- mice maintained on a chow diet. In the present work, liver-specific 
C5 siRNA was used to treat 4 experimental groups of mice, in particular (i) 76 weeks 
old ApoE-/- mice on normal chow diet; (ii) 32 weeks old ApoE-/- mice fed with normal 
chow diet; (iii) 32 weeks old ApoE-/- mice fed with 16 weeks high-fat diet; (iv) 16 weeks 
old ApoE-/- mice fed with 4 weeks high-fat diet. Therefore, a broad strategy was used 
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to clarify important unresolved issues regarding the role of C5 in atherogenesis. We 
conclude that C5 inhibition did not reduce atherosclerosis in ApoE-/- mice on a high-fat 
diet (group iii). Thus, my data provide evidence that different diet conditions are critical 
to understanding atherosclerosis inflammation as related to C5. 
4.6.2 Complement activation studies on atherosclerosis in ApoE-/- mice 
In mouse atherosclerosis, the roles of complement pathways in atherosclerosis are not 
fully understood as several complement components, i.e. C1q and C3, are not only 
involved in complement activation but also involved in the control of other forms of 
tissue homeostasis137. However, blocking the complement activation products, i.e. C3a 
and C5a receptors, prevents atherosclerosis (Table 4.1).  
4.6.3 Complement activation on atherosclerosis in LDLr-/- mice  
Several previous studies have suggested a role of complement cascade activation in the 
pathogenesis of atherosclerosis using the LDLr-/- mouse model. LDLr-/- mice fed a high-
fat diet showed a significant increase in the mRNA expression of complement C3, 
factor D and properdin in the liver compared to LDLr-/- mice on normal chow, 
suggesting that complement pathway activation may be important in LDLr-/- mice138. 
LDLr-/- mice deficient in C1qa on a normal diet were shown to develop threefold larger 
aortic root lesions than C1qa-sufficient animals, but no differences were observed when 
mice were maintained on a high-fat diet61. In addition, increased en-face atherosclerotic 
lesion size was reported in C3-/-LDLr-/- mice compared to LDLr-/- controls on high-fat 
diet139. These data may reflect the protective role of complement cascade activation in 
the atherogenesis of LDLr-/- mice.  
However, experiments on the decay-accelerating factor (Daf), CD55, which prevents 
the formation of the C3 convertases, and on another inhibitor, i.e. CD59, which regulate 
the formation of TCC, showed both that Daf-/-LDLr-/- mice142 and aCD59-/-LDLr-/- 
mice143 developed more extensive en-face lesions of the aorta than LDLr-/- mice on both 
low- and high-fat diet. Bf-/-LDLr-/- mice also had significantly decreased cross-sectional 
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aortic root lesion fraction areas and reduced lesion complexity compared with LDLr-/- 
mice after a 12-week period of high-fat diet140. These data indicate the disparate effects 
of upstream and terminal complement components; the deficiency of the complement 
system may protect the development of atherosclerosis in LDLr-/- mice (Table 4.1). 
Table 4.1 Complement proteins in experimental atherosclerosis models 
Increased atherosclerosis 
Animal model Diet Effect on atherosclerotic plaque size Reference 
C1q-/-LDLr-/- mice Normal chow Increased aortic root plaque size. 61 
C3-/-ApoE-/-LDLr-/- 
mice 
Normal chow Increased aortic en-face plaque size. 62 
C3-/-LDLr-/- mice High-fat diet Increased aortic en-face and aortic arch plaque 
size. 
139 
Decreased atherosclerosis 
Animal model Diet Effect on atherosclerotic plaque size Reference 
Factor B-/-LDLr-/- 
mice 
High-fat diet Decreased aortic root plaque size 140 
C3aR-/-ApoE-/- mice Normal chow Decreased aortic root plaque size in females but 
not in males 
141 
Anti C5 antibody treat 
mCd59ab-/-ApoE-/- 
mice 
High-fat diet Reduced aortic en-face and aortic arch plaque 
size 
112 
C5aR antagonist on 
ApoE-/-mice 
Normal chow Reduced brachiocephalic arteries plaque 
burden 
48 
C6-/-ApoE-/- mice High-fat diet Decreased brachiocephalic artery plaque size 60 
Daf-/-LDLr-/- mice High-fat diet Increased aortic en-face stained lesion size 142 
Low-fat diet Increased aortic en-face stained lesion size; 
Increased aortic root size and complexity 
aCD59-/-LDLr-/- mice High-fat diet Increased aortic en-face stained lesion size 143 
Low-fat diet Increased aortic en-face stained lesion size; 
Increased aortic root size and complexity 
No difference on atherosclerosis 
Animal model Diet Effect on atherosclerotic plaque size Reference 
C1q-/-LDLr-/- mice High-fat diet No difference in aortic root plaque size 61 
Factor B-/-LDLr-/- 
mice 
Normal chow No difference in aortic root plaque size 140 
Factor B-/-ApoE-/-
LDLr-/- mice 
Normal chow No differences in aortic en-face and aortic root 
plaque size 
62 
C5-/-ApoE-/- mice High-fat diet No differences in aortic root plaque size 63 
Daf-/-LDLr-/- mice High-fat diet No differences in aortic root lesion size 142 
aCD59-/-LDLr-/- mice High-fat diet No differences in aortic root lesion size 143 
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The LDLr-/- mice are different from the ApoE-/- mouse model, which were used in our 
atherosclerosis study. In LDLr-/- mice, atherosclerotic lesions do not develop 
spontaneously as in ApoE-/- animals, but are inducible under high-fat diet. 
4.7 Can C5-dependent atherogenesis in mice be translated to human 
atherosclerosis? 
Human atherosclerosis is a chronic and complex disease of large and medium-sized 
arteries3. It takes decades to form atherosclerotic plaques in human arteries, and it is an 
age-dependent disease3. Human atherosclerotic plaques are heterogeneous containing 
multiple pathologies. Wild type mice do not develop atherosclerosis on a chow diet and 
only minimally on high-fat diet144. Several murine models have been used to mimic 
human atherosclerotic pathologies145,146. In mice, atherosclerotic plaques develop 
within a few weeks to few months, and the pathological features in murine models 
reproduce features of human atherosclerotic plaques. Yet, caution is warranted when 
data obtained in mice are translated to humans. I reported that lipid deposits in 
atherosclerosis plaque activated the complement cascades, which in turn triggered 
chronic inflammation in ApoE-/- mice. We reported that ApoE acts as endogenous 
complement inhibitor95, which may provide mechanistic insight for this observation. In 
order to validate whether lipid-complement-inflammation axis contributes to human 
atherosclerosis, we decided to stain complement C1q, ApoE, and C5 and CD68 using 
different stages of atherosclerotic plaques (Fig. 3.38). My data supported the 
conclusion that complement activation may indeed contribute to atherosclerosis 
inflammation in human atherosclerosis. However, complement-independent 
inflammation also contributes to atherosclerosis development in mice (ApoE-/- mice on 
high-fat diet). I hypothesize that human atherosclerotic plaques consist of both 
complement-triggered inflammation and complement-independent inflammation. Thus, 
more studies are required to clarify whether patients with cardiovascular diseases will 
benefit from complement C5 siRNA treatment. Based on these data, we believe that 
diets did not affect the efficiency of C5 siRNA in vivo. Moreover, in a phase 1/2 clinical 
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study, N-acetylgalactosamine-conjugated C5 siRNA (target human C5 mRNA, ALN-
CC5, Alnylam® Pharmaceuticals) showed safety in healthy adult volunteers and 
patients with paroxysmal nocturnal hemoglobinuria (PNH) (clinicaltrials.gov; 
NCT02352493), and several clinical trials to treat complement-mediated diseases are 
ongoing (clinicaltrials.gov; NCT03841448, NCT03999840). These data support the 
concept that our approach in mice may be translatable to human patients with 
complement-mediated diseases including atherosclerosis. 
4.8 Young and aged ApoE-/- mice are suitable murine models to study 
of the roles of complement cascades in atherosclerosis  
Young ApoE-/- mice and aged ApoE-/- mice were used to study the different stages of 
atherosclerotic plaques. In young ApoE-/- mice on chow diet, the C5 siRNA treatment 
was started from the age of 12 weeks, when the mice had not yet developed visible 
plaques. After 20 weeks of treatment, C5 siRNA strongly reduced atherosclerotic plaque 
size and inflammation, supporting the conclusion that a presumed lipid-complement-
inflammation axis promotes early atherosclerosis development. In aged ApoE-/- mice, 
the C5 siRNA treatment was started at the age of 58 weeks, when the mice had already 
developed atherosclerotic plaques. In advanced plaques, other pre-existing 
inflammatory triggers, i.e., cholesterol crystal, macrophage-foam cells or necrotic cores 
may trigger other pro-inflammatory pathways including inflammasomes127. We also 
performed immunofluorescence staining to confirm that those complement proteins are 
deposited in advanced plaques, and C5 siRNA treatment indeed reduced C5 deposited 
in advanced plaques in aged ApoE-/- mice fed with chow diet (Figures 3.23-3.24). 
However, the plaque size was not significantly reduced after C5 siRNA treatment in 
advanced plaques by en-face staining. Further studies are required to examine whether 
C5 siRNA treatment altered plaque stability. 
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As discussed above, C5 siRNA targeted liver-produced C5, but not locally produced C5. 
In aged ApoE-/- mice on chow diet, locally produced C5 by infiltrated T cells and 
monocytes may compensate C5 siRNA treatment which silenced serum C5 selectively.  
These two different models may be regarded to represent early and advanced stages of 
atherosclerotic plaques in human diseases, respectively, and caution is required before 
translating murine data to human diseases. Complement proteins and inflammation 
have been observed in human atherosclerotic plaques, supporting those atherosclerotic 
plaques in young and aged ApoE-/- mice are adequate murine models to study the impact 
the roles of complement activation in atherosclerosis.
SUMMARY 
88 
 
5. SUMMARY 
Atherosclerosis can be viewed as an age-dependent chronic inflammatory disease of 
arteries which constitutes the leading cause of deaths worldwide. Complement cascades 
are major constituents of innate immunity and also significantly contribute to adaptive 
immune responses. Complement components have been found in human atherosclerotic 
plaques, but their roles in disease progression have been found to yield 
often contradictory outcomes. In the current study, the roles of liver-derived 
complement C5 during different stages of atherosclerosis using ApoE-deficient mice at 
various ages as experimental models for human age-related chronic inflammatory 
diseases were explored. C5 constitutes a final protein product of all three complement 
cascades which undergoes a final cleavage reaction to yield highly active molecules in 
innate immunity. Under normal chow, we chose to study atherosclerosis in young 
versus aged mice, which represent early and advanced stages of atherosclerosis, 
respectively. When we challenged ApoE-/- mice with a high-fat diet, the development 
of atherosclerotic plaque was exacerbated under conditions of extreme hyperlipidemia. 
Our data are consistent with the possibility that there are two distinct mechanisms 
underlying the progression of atherosclerosis depending on the dietary condition: One 
which is dependent on complement and the other which is independent on complement 
C5 under extreme hyperlipidemia. Moreover, our observation of a strict age-
dependency of the effect of C5 siRNA on disease outcome uncovers the involvement 
of C5 in early but not advanced atherosclerosis. When taken together, the current study 
allows studying the roles of complement inhibition during different stages and different 
types of dietary conditions. These data are likely to encourage future studies into the 
molecular mechanisms of complement-sensitive pro-atherosclerotic events, which in 
turn may lead to new therapeutic approaches to treat and/or prevent atherosclerosis.
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6. ZUSAMMENFASSUNG  
Atherosklerose kann als eine altersabhängige chronische Entzündung der Arterienwand 
angesehen werden, die als Ursache für die weltweit führende Todesursache gilt. 
Komplementkaskaden sind wesentlich an angeborenen Immunreaktionen beteiligt und 
spielen auch wichtige Rollen an den Schnittstellen zwischen angeborenen und 
adaptiven Immunreaktionen. Ihre Proproteine und aktive Konstituenten wurden bereits 
früher in atherosklerotischen Plaques beobachtet. Allerdings haben Untersuchungen 
ihrer Funktion kontroverse Ergebnisse gezeigt. In dieser Promotionsarbeit wurde die 
Rolle des in der Leber synthetisierten Komplementproteins C5 in murinen Modellen 
der Atherosklerose untersucht, d.h. der ApoE-defizienten Maus. C5 wird vor allem in 
der Leber produziert und stellt ein Proprotein am Ende aller drei Komplementkaskaden 
dar. Unter normalen Diätbedingungen (normales Mausfutter) konnte gezeigt werden, 
dass die Inhibition der C5 Transkription durch ein Leber-spezifisches C5 siRNA 
Molekül zu einer signifikanten Reduktion der Progression der Atherosclerose in jungen 
ApoE-defizienten Mäusen führt, während die Effekte des gleichen Moleküls in alten 
Mäusen nicht zu beobachten waren. C5 siRNA hatte ebenfalls keine Effekte auf die 
Ausprägung der Erkrankung in Untersuchungen von ApoE-defizienten Mäusen, die 
einer hochkalorischen Nahrung mit einem hohen Fettgehalt (der Western Diät) 
unterzogen wurden. Diese Ergebnisse deuten an, dass es zwei distinkte altersabhängige 
Formen der Atherosklerose gibt: Eine frühe Form, die auf eine Therapie mit C5 
Therapeutika anspricht und einer fortgeschrittenen Form, die resistent gegen diese 
Therapeutika ist. Die Daten zeigen auch, dass die klassische Komplementkaskade eine 
Rolle unter Bedingungen der moderaten nicht aber der extremen Hyperlipidämie, wie 
sie durch eine hochkalorische Diät mit einem hohen Fettgehalt erreicht wird, spielt. 
Diese Ergebnisse können als Grundlage dienen, die molekularen Mechanismen des C5 
Proteins in einer prototypischen chronisch entzündlichen Erkrankung, der 
Atherosklerose, aufzudecken, um neue Therapiestrategien dieser kausal nicht 
therapierbaren Erkrankung zu entwickeln. 
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9. SUPPLEMENT 
Table S1. Probe sets of total aortas up and down-regulated transcripts in Wt and ApoE-/- mice during aging. 
Differential expression of probe sets was determined as described in Material and Methods for different complement system related Gene Ontology terms: A. 
innate immune response (GO: 0045087), B. classical complement pathway (GO: 0006958), C. alternative complement pathway (GO: 0006957), D. regulation 
of complement activation (GO: 0030449). E. Leukocyte migration (GO: 0050900), meloid leukocyte migration (GO: 0097529), F. Phagocytosis (GO: 0006909), 
G. Cellular response to lipid (GO: 0071396). Further data are displayed as heat maps in Fig. 3.1 and Fig. 3.2. Probe sets are ordered according to fold change 
between aorta from 78 weeks old ApoE-/- mice versus 6 weeks. Columns of the mean value for each gene show signal intensity without normalization. 
A. Innate immune response (GO: 0045087) 
 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1421792_s_at Trem2 triggering receptor
expressed on myeloid cells
2
83433 22 25 27 22 707 1816 83.52 2.00E-07
1424305_at Igj immunoglobulin joining 16069 117 207 664 206 314 13650 66.11 6.00E-05
1427747_a_at Lcn2 lipocalin 2 16819 70 98 145 66 3505 3726 56.51 5.00E-07
1460188_at Ptpn6 protein tyrosine
phosphatase, non-receptor
type 6
15170 37 51 198 46 567 1324 28.96 6.00E-06
1449858_at Cd86 CD86 antigen 12524 15 8 21 11 107 296 25.86 0.001
1426808_at Lgals3 lectin, galactose binding,
soluble 3
16854 652 822 1038 693 9961 13992 20.2 2.00E-08
Gene name p ANOVA
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
SUPPLEMENT 
105 
 
 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1420699_at Clec7a C-type lectin domain family
7, member a
56644 238 388 461 273 3319 5253 19.26 9.00E-08
1418126_at Ccl5 chemokine (C-C motif) 20304 24 73 420 67 406 1222 18.28 0.009
1438858_x_at H2-Aa histocompatibility 2, class II 14960 523 1020 1766 544 4473 9321 17.13 5.00E-06
1443783_x_at H2-Aa histocompatibility 2, class II
antigen A, alpha
14960 94 219 391 111 942 1563 14.02 8.00E-06
1460204_at Tec tec protein tyrosine kinase 21682 98 34 200 64 335 874 13.74 1.00E-04
1429947_a_at Zbp1 Z-DNA binding protein 1 58203 36 66 40 41 160 565 13.67 7.00E-05
1425477_x_at H2-Ab1 histocompatibility 2, class II
antigen A, beta 1
14961 279 361 491 263 1416 3555 13.53 8.00E-06
1429525_s_at Myo1f myosin IF 17916 84 146 152 73 486 990 13.51 5.00E-06
1452279_at Cfp complement factor
properdin
18636 232 130 281 112 733 1502 13.42 0.008
1449195_s_at Cxcl16 chemokine (C-X-C motif)
ligand 16
66102 190 164 238 146 1008 1929 13.18 7.00E-07
1420804_s_at Clec4d C-type lectin domain family
4, member d
17474 153 166 152 142 716 1741 12.23 5.00E-06
1436778_at Cybb cytochrome b-245, beta
polypeptide
13058 329 376 637 312 1584 3259 10.45 6.00E-07
1452431_s_at H2-Aa histocompatibility 2, class II
antigen A, alpha
14960 612 862 1303 606 2998 6322 10.42 2.00E-05
1416871_at Adam8 a disintegrin and
metallopeptidase domain 8
11501 195 215 174 181 1113 1881 10.42 9.00E-07
1451721_a_at H2-Ab1 histocompatibility 2, class II
antigen A, beta 1
14961 457 616 941 514 2144 5102 9.93 1.00E-06
1420380_at Ccl2 chemokine (C-C motif)
ligand 2
20296 99 49 126 95 414 915 9.65 1.00E-04
1429524_at Myo1f myosin IF 17916 79 145 184 115 491 1106 9.65 4.00E-06
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1422932_a_at Vav1 vav 1 oncogene 22324 31 68 22 46 230 431 9.41 4.00E-04
1435226_at Rnf19b ring finger protein 19B 75234 339 398 397 55 367 509 9.3 0.003
1422903_at Ly86 lymphocyte antigen 86 17084 417 477 693 421 1743 3863 9.18 2.00E-06
1449049_at Tlr1 toll-like receptor 1 21897 78 97 100 84 339 711 8.45 3.00E-05
1450648_s_at H2-Ab1 histocompatibility 2, class II
antigen A, beta 1
14961 780 1005 1459 782 2234 6399 8.19 1.00E-05
1425951_a_at Clec4n C-type lectin domain family
4, member n
56620 37 106 112 65 311 510 7.81 0.002
1418718_at Cxcl16 chemokine (C-X-C motif)
ligand 16
66102 462 481 623 437 1456 3219 7.36 8.00E-07
1417063_at C1qb complement component 1, q
subcomponent, beta
polypeptide
12260 1347 1154 1506 1169 5621 8251 7.06 5.00E-07
1417876_at Fcgr1 Fc receptor, IgG, high
affinity I
14129 156 174 234 153 627 1066 6.96 2.00E-06
1417025_at H2-Eb1 histocompatibility 2, class II
antigen E beta
14969 1013 1729 2610 1222 4520 8317 6.8 3.00E-06
1419627_s_at Clec4n C-type lectin domain family
4, member n
56620 142 179 272 152 559 1027 6.77 6.00E-05
1451987_at Arrb2 arrestin, beta 2 216869 170 188 174 147 568 986 6.71 2.00E-05
1447621_s_at Tmem17
3
transmembrane protein 173 72512 111 120 160 83 332 552 6.67 4.00E-05
1420715_a_at Pparg peroxisome proliferator
activated receptor gamma
19016 29 476 171 60 375 400 6.65 0.002
1418261_at Syk spleen tyrosine kinase 20963 311 375 517 281 875 1860 6.63 7.00E-06
1436779_at Cybb cytochrome b-245, beta
polypeptide
13058 262 334 357 246 864 1603 6.52 2.00E-06
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1425519_a_at Cd74 CD74 antigen (invariant
polypeptide of major
histocompatibility complex,
class II antigen-associated)
16149 1634 2699 4537 1955 7675 11699 5.98 4.00E-06
1449401_at C1qc complement component 1, q
subcomponent, C chain
12262 1942 1677 2435 1819 8204 10753 5.91 7.00E-07
1427368_x_at Fes feline sarcoma oncogene 14159 74 198 187 117 320 671 5.76 2.00E-05
1457753_at Tlr13 toll-like receptor 13 279572 136 153 141 136 496 758 5.59 1.00E-07
1423166_at Cd36 CD36 antigen 12491 794 3237 1578 835 4019 4649 5.57 8.00E-06
1418776_at Gbp8 guanylate-binding protein 8 76074 23 75 100 46 122 258 5.54 8.00E-04
1417346_at Pycard PYD and CARD domain
containing
66824 399 333 506 335 802 1825 5.44 7.00E-06
1452948_at Tnfaip8l
2
tumor necrosis factor,
alpha-induced protein 8-like
2
69769 173 135 45 99 360 533 5.39 6.00E-05
1434815_a_at Mapkapk
3
mitogen-activated protein
kinase-activated protein
kinase 3
102626 119 228 235 87 267 468 5.35 9.00E-04
1421525_a_at Naip5 NLR family, apoptosis
inhibitory protein 5
17951 99 123 146 113 349 594 5.26 1.00E-05
1434653_at Ptk2b PTK2 protein tyrosine
kinase 2 beta
19229 261 463 424 263 748 1346 5.12 1.00E-06
1452410_a_at Fes feline sarcoma oncogene 14159 138 141 164 118 341 597 5.07 2.00E-05
1418262_at Syk spleen tyrosine kinase 20963 149 133 185 133 404 664 4.98 2.00E-05
1420499_at Gch1 GTP cyclohydrolase 1 14528 108 102 176 97 271 475 4.9 8.00E-05
1419609_at Ccr1 chemokine (C-C motif)
receptor 1
12768 92 149 166 125 365 604 4.85 7.00E-05
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1435290_x_at H2-Aa histocompatibility 2, class II
antigen A, alpha
14960 2113 4191 5680 2340 8604 11007 4.7 7.00E-06
1427691_a_at Ifnar2 i terferon (alpha and beta)
receptor 2
15976 77 175 47 93 296 435 4.69 0.005
1423768_at Unc93b1 un -93 homolog B1 (C.
elegans)
54445 629 694 766 561 1301 2623 4.67 2.00E-06
1417268_at Cd14 CD14 antigen 12475 577 649 838 605 1254 2776 4.59 2.00E-06
1437726_x_at C1qb complement component 1, q
subcomponent, beta
12260 1568 1745 1897 1774 7646 8089 4.56 7.00E-07
1451174_at Nrros negative regulator of
reactive oxygen species
224109 263 327 389 293 744 1334 4.56 7.00E-06
1417381_at C1qa complement component 1, q
subcomponent, alpha
12259 1952 1766 1881 1925 6761 8373 4.35 1.00E-07
1422978_at Cybb cytochrome b-245, beta
polypeptide
13058 193 211 199 204 619 883 4.33 7.00E-06
1424560_at Pstpip1 proline-serine-threonine
phosphatase-interacting
protein 1
19200 160 92 120 158 365 681 4.31 5.00E-04
1417378_at Cadm1 cell adhesion molecule 1 54725 353 320 421 290 608 1230 4.24 9.00E-06
1423954_at C3 complement component 3 12266 1929 4798 3722 2416 8194 10023 4.15 2.00E-06
1460231_at Irf5 interferon regulatory factor
5
27056 176 214 293 189 462 764 4.04 5.00E-05
1460273_a_at Naip2 NLR family, apoptosis
inhibitory protein 2
17948 80 138 136 110 293 444 4.03 2.00E-05
1420361_at Slc11a1 solute carrier family 11
(proton-coupled divalent
metal ion transporters),
member 1
18173 662 704 802 668 1645 2664 3.99 1.00E-06
1460245_at Klrd1 killer cell lectin-like
receptor, subfamily D,
member 1
16643 121 156 170 139 230 541 3.89 1.00E-04
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1450883_a_at Cd36 CD36 antigen 12491 1224 4327 1699 1492 5328 5773 3.87 1.00E-05
1429527_a_at Plscr1 phospholipid scramblase 1 22038 113 162 147 112 346 430 3.85 1.00E-05
1426239_s_at Arrb2 arrestin, beta 2 216869 426 477 568 505 857 1941 3.84 1.00E-05
1449455_at Hck hemopoietic cell kinase 15162 304 332 451 317 658 1215 3.84 9.00E-06
1429831_at Pik3ap1 phosphoinositide-3-kinase
adaptor protein 1
83490 194 184 278 161 299 614 3.82 3.00E-06
1420653_at Tgfb1 transforming growth factor,
beta 1
21803 516 538 551 440 1292 1670 3.79 8.00E-07
1425902_a_at Nfkb2 nuclear factor of kappa light
polypeptide gene enhancer
in B cells 2, p49/p100
18034 188 112 258 129 204 487 3.78 8.00E-04
1425396_a_at Lck lymphocyte protein tyrosine
kinase
16818 126 176 244 168 188 623 3.71 3.00E-04
1421366_at Clec5a C-type lectin domain family
5, member a
23845 52 70 96 79 168 281 3.58 0.001
1424254_at Ifitm1 interferon induced
transmembrane protein 1
68713 148 284 244 202 369 723 3.58 3.00E-04
1437176_at Nlrc5 NLR family, CARD domain
containing 5
434341 168 236 265 207 314 737 3.56 2.00E-04
1454268_a_at Cyba cytochrome b-245, alpha
polypeptide
13057 2532 2330 3388 2574 5556 9049 3.52 2.00E-06
1447927_at Gbp6 guanylate binding protein 6 100702 244 375 398 190 524 667 3.52 0.004
1422013_at Clec4a2 C-type lectin domain family
4, member a2
26888 197 248 276 169 397 592 3.49 2.00E-05
1417470_at Apobec3 apolipoprotein B mRNA
editing enzyme, catalytic
polypeptide 3
80287 207 217 330 299 496 1023 3.42 2.00E-04
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
SUPPLEMENT 
110 
 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1419879_s_at Trim25 tripartite motif-containing
25
217069 403 462 645 407 917 1377 3.38 3.00E-06
1419873_s_at Csf1r colony stimulating factor 1
receptor
12978 1231 1391 1675 1179 3013 3981 3.38 3.00E-05
1419526_at Fgr Gardner-Rasheed feline
sarcoma viral (Fgr)
oncogene homolog
14191 184 254 418 227 569 763 3.37 1.00E-04
1425289_a_at Cr2 complement receptor 2 12902 132 161 241 118 135 396 3.35 0.02
1417376_a_at Cadm1 cell adhesion molecule 1 54725 233 253 273 241 443 802 3.33 4.00E-05
1453181_x_at Plscr1 phospholipid scramblase 1 22038 120 158 169 132 314 439 3.32 1.00E-05
1419569_a_at Isg20 interferon-stimulated protein 57444 257 340 589 270 311 883 3.27 0.01
1434366_x_at C1qb complement component 1, q
subcomponent, beta
polypeptide
12260 1499 1543 1546 1518 5822 4861 3.2 1.00E-05
1417377_at Cadm1 cell adhesion molecule 1 54725 70 106 76 97 176 303 3.13 0.03
1435040_at Irak3 interleukin-1 receptor-
associated kinase 3
73914 131 212 264 133 427 394 2.97 8.00E-05
1419394_s_at S100a8 S100 calcium binding
protein A8 (calgranulin A)
20201 140 528 792 402 628 1182 2.94 0.007
1456694_x_at Ptpn6 protein tyrosine
phosphatase, non-receptor
type 6
15170 449 549 568 367 660 1075 2.93 0.001
1419132_at Tlr2 toll-like receptor 2 24088 329 398 499 378 713 1099 2.91 1.00E-05
1421358_at H2-M3 histocompatibility 2, M
region locus 3
14991 727 816 1169 671 1076 1924 2.87 3.00E-05
1420404_at Cd86 CD86 antigen 12524 160 152 167 141 232 402 2.85 6.00E-04
1421547_at Cd180 CD180 antigen 17079 223 279 274 219 599 621 2.84 5.00E-05
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1450783_at Ifit1 interferon-induced protein
with tetratricopeptide
repeats 1
15957 148 201 310 181 427 504 2.78 3.00E-05
1434438_at Samhd1 SAM domain and HD
domain, 1
56045 689 971 1146 696 1035 1897 2.73 0.002
1440481_at Stat1 signal transducer and
activator of transcription 1
20846 104 104 103 117 165 316 2.71 0.002
1453281_at Pik3cd phosphatidylinositol 3-
kinase catalytic delta
polypeptide
18707 228 201 252 235 350 630 2.69 5.00E-04
1426415_a_at Trim25 tripartite motif-containing
25
217069 107 105 62 112 231 299 2.67 2.00E-04
1436625_at Fcgr1 Fc receptor, IgG, high
affinity I
14129 150 172 282 182 348 484 2.65 0.001
1440169_x_at Ifnar2 interferon (alpha and beta)
receptor 2
15976 356 463 580 456 915 1196 2.62 2.00E-04
1428696_at Rftn1 raftlin lipid raft linker 1 76438 760 731 1117 982 1315 2457 2.5 7.00E-06
1420915_at Stat1 signal transducer and
activator of transcription 1
20846 300 422 402 313 628 778 2.49 2.00E-05
1448756_at S100a9 S100 calcium binding
protein A9 (calgranulin B)
20202 109 442 600 261 459 648 2.48 0.01
1418240_at Gbp2 guanylate binding protein 2 14469 721 912 1200 778 1313 1913 2.46 3.00E-04
1419042_at Iigp1 interferon inducible GTPase
1
60440 366 623 582 414 855 1011 2.44 0.006
1435906_x_at Gbp2 guanylate binding protein 2 14469 713 996 1131 750 1395 1828 2.44 2.00E-04
1450884_at Cd36 CD36 antigen 12491 147 624 269 200 508 484 2.42 4.00E-05
1417244_a_at Irf7 interferon regulatory factor
7
54123 253 302 393 266 425 633 2.38 4.00E-04
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1436199_at Trim14 tripartite motif-containing
14
74735 134 164 226 172 273 406 2.36 7.00E-05
1453196_a_at Oasl2 2'-5' oligoadenylate
synthetase-like 2
23962 303 274 360 232 554 547 2.35 3.00E-04
1416118_at Trim59 tripartite motif-containing
59
66949 173 92 126 143 137 331 2.31 3.00E-04
1429692_s_at Gch1 GTP cyclohydrolase 1 14528 140 136 136 123 199 282 2.29 0.001
1448550_at Lbp lipopolysaccharide binding
protein
16803 931 1284 1276 998 1934 2268 2.27 5.00E-05
1425065_at Oas2 2'-5' oligoadenylate
synthetase 2
246728 142 109 185 145 232 330 2.27 0.05
1433699_at Tnfaip3 tumor necrosis factor,
alpha-induced protein 3
21929 569 683 845 643 1032 1441 2.24 1.00E-04
1434903_s_at Il1rl2 interleukin 1 receptor-like 2 107527 148 148 142 125 200 278 2.23 0.001
1449130_at Cd1d1 CD1d1 antigen 12479 257 983 341 225 818 497 2.21 5.00E-05
1432478_a_at Rnf19b ring finger protein 19B 75234 233 245 168 224 329 485 2.16 0.001
1418392_a_at Gbp3 guanylate binding protein 3 55932 365 502 404 348 716 747 2.15 0.001
1450033_a_at Stat1 signal transducer and
activator of transcription 1
20846 462 539 381 447 740 951 2.12 8.00E-04
1442804_at Fgr Gardner-Rasheed feline
sarcoma viral (Fgr)
oncogene homolog
14191 207 237 399 263 407 559 2.12 0.001
1425974_a_at Trim25 tripartite motif-containing
25
217069 543 468 535 456 737 952 2.09 8.00E-05
1449874_at Ly96 lymphocyte antigen 96 17087 393 259 353 296 403 617 2.08 8.00E-04
1417856_at Relb avian reticuloendotheliosis
viral (v-rel) oncogene
related B
19698 178 192 280 178 219 370 2.08 0.007
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1426276_at Ifih1 interferon induced with
helicase C domain 1
71586 463 477 581 444 747 919 2.07 1.00E-05
1433803_at Jak1 Janus kinase 1 16451 755 904 1113 847 1208 1745 2.06 1.00E-04
1423518_at Csk c-src tyrosine kinase 12988 492 500 676 473 535 962 2.03 5.00E-04
1453913_a_at Tap2 transporter 2, ATP-binding
cassette, sub-family B
(MDR/TAP)
21355 242 429 486 285 458 565 1.98 5.00E-05
1450829_at Tnfaip3 tumor necrosis factor,
alpha-induced protein 3
21929 50 77 119 133 144 239 1.8 0.01
1422781_at Tlr3 toll-like receptor 3 142980 221 279 223 184 459 325 1.77 0.02
1449131_s_at Cd1d1 CD1d1 antigen 12479 536 1490 801 531 1176 930 1.75 7.00E-05
1438676_at Gbp6 guanylate binding protein 6 100702 129 273 180 166 316 265 1.6 5.00E-04
1457664_x_at C2 complement component 2
(within H-2S)
12263 357 255 619 365 420 573 1.57 0.002
1418666_at Ptx3 pentraxin related gene 19288 137 133 104 152 277 239 1.57 0.02
1427911_at Tmem17
3
transmembrane protein 173 72512 415 434 241 527 773 820 1.55 0.001
1449935_a_at Dnaja3 DnaJ (Hsp40) homolog,
subfamily A, member 3
83945 472 955 505 470 812 707 1.5 9.00E-04
1423285_at Coch coagulation factor C
homolog (Limulus
polyphemus)
12810 313 356 613 213 274 272 1.28 0.004
1439364_a_at Mmp2 matrix metallopeptidase 2 17390 3914 2827 2177 3996 3443 4990 1.25 2.00E-04
1416136_at Mmp2 matrix metallopeptidase 2 17390 5328 3177 2750 5567 4910 6603 1.19 7.00E-06
1423153_x_at Cfh complement component
factor h
12628 4181 6155 3959 4945 8564 4094 -1.21 6.00E-04
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1442511_at Ipo7 importin 7 233726 188 95 145 203 94 150 -1.35 0.001
1433804_at Jak1 Janus kinase 1 16451 260 134 123 299 225 196 -1.52 0.001
1421907_at Med1 mediator complex subunit 1 19014 1092 681 497 1138 844 722 -1.58 0.05
1455095_at Hist2h2b
e
histone cluster 2, H2be 319190 579 844 496 591 693 343 -1.72 1.00E-04
1452961_at Tril TLR4 interactor with
leucine-rich repeats
66873 277 404 319 316 414 179 -1.77 0.03
1450743_s_at Syncrip synaptotagmin binding,
cytoplasmic RNA
interacting protein
56403 483 180 73 423 266 228 -1.85 0.007
1422102_a_at Stat5b signal transducer and
activator of transcription 5B
20851 326 292 265 404 190 213 -1.89 0.002
1422769_at Syncrip synaptotagmin binding,
cytoplasmic RNA
interacting protein
56403 511 226 172 442 313 227 -1.95 1.00E-05
1447854_s_at Hist2h2b
e
histone cluster 2, H2be 319190 813 854 735 929 749 448 -2.08 0.001
1422216_at Mid2 midline 2 23947 633 452 474 585 412 275 -2.13 3.00E-04
1451773_s_at Polr3f polymerase (RNA) III
(DNA directed) polypeptide
F
70408 262 148 113 203 194 93 -2.19 0.002
1442827_at Tlr4 toll-like receptor 4 21898 413 183 137 320 208 142 -2.26 9.00E-04
1437673_at Wnt5a wingless-type MMTV
integration site family,
member 5A
22418 246 284 183 201 226 85 -2.37 0.003
1427646_a_at Arhgef2 rho/rac guanine nucleotide
exchange factor (GEF) 2
16800 707 443 469 802 425 336 -2.39 0.01
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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B. Classical complement pathway (GO: 0006958) 
  
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1421042_at Arhgef2 rho/rac guanine nucleotide
exchange factor (GEF) 2
16800 1304 849 791 1487 796 594 -2.5 7.00E-04
1436791_at Wnt5a wingless-type MMTV
integration site family,
member 5A
22418 706 850 713 786 717 241 -3.26 2.00E-05
1448152_at Igf2 insulin-like growth factor 2 16002 648 786 721 668 582 195 -3.43 0.004
1448818_at Wnt5a wingless-type MMTV
integration site family,
member 5A
22418 653 606 253 721 519 140 -5.14 8.00E-06
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1417063_at C1qb complement component 1, q
subcomponent, beta
polypeptide
12260 1347 1154 1506 1169 5621 8251 7.06 5.00E-07
1449401_at C1qc complement component 1, q
subcomponent, C chain
12262 1942 1677 2435 1819 8204 10753 5.91 7.00E-07
1437726_x_at C1qb complement component 1, q
subcomponent, beta
polypeptide
12260 1568 1745 1897 1774 7646 8089 4.56 7.00E-07
1417381_at C1qa complement component 1, q
subcomponent, alpha
polypeptide
12259 1952 1766 1881 1925 6761 8373 4.35 1.00E-07
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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C. Alternative complement pathway (GO: 0006957)  
 
 
 
 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1423954_at C3 complement component 3 12266 1929 4798 3722 2416 8194 10023 4.15 2.00E-06
1425289_a_at Cr2 complement receptor 2 12902 132 161 241 118 135 396 3.35 0.02
1434366_x_at C1qb complement component 1, q
subcomponent, beta
polypeptide
12260 1499 1543 1546 1518 5822 4861 3.2 1.00E-05
1457664_x_at C2 complement component 2
(within H-2S)
12263 357 255 619 365 420 573 1.57 0.002
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1452279_at Cfp
complement factor
properdin
18636 232 130 281 112 733 1502 13.42 0.008
1423954_at C3 complement component 3 12266 1929 4798 3722 2416 8194 10023 4.15 2.00E-06
1423153_x_at Cfh
complement component
factor h
12628 4181 6155 3959 4945 8564 4094 -1.21 6.00E-04
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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D. Regulation of complement activation (GO: 0030449) 
 
E. Leukocyte migration (GO: 0050900) 
 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1423954_at C3 complement component 3 12266 1929 4798 3722 2416 8194 10023 4.15 2.00E-06
1423153_x_at Cfh complement component
factor h
12628 4181 6155 3959 4945 8564 4094 -1.21 6.00E-04
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1449254_at Spp1 secreted phosphoprotein 1 20750 46 93 326 76 13398 13789 180.67 3.00E-05
1418457_at Cxcl14 chemokine (C-X-C motif)
ligand 14
57266 5 4 3 5 48 299 63.89 3.00E-05
1419561_at Ccl3 chemokine (C-C motif)
ligand 3
20302 6 18 9 12 212 597 48.71 5.00E-06
1419282_at Ccl12 chemokine (C-C motif)
ligand 12
20293 83 27 134 23 374 926 40.66 4.00E-05
1418652_at Cxcl9 chemokine (C-X-C motif)
ligand 9
17329 15 65 42 20 72 601 30.5 2.00E-04
1417851_at Cxcl13 chemokine (C-X-C motif)
ligand 13
55985 79 91 272 83 330 1980 23.92 2.00E-06
1426808_at Lgals3 lectin, galactose binding,
soluble 3
16854 652 822 1038 693 9961 13992 20.2 2.00E-08
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1442082_at C3ar1 complement component 3a
receptor 1
12267 162 203 280 175 2019 3522 20.11 6.00E-08
1418126_at Ccl5 chemokine (C-C motif)
ligand 5
20304 24 73 420 67 406 1222 18.28 0.009
1450678_at Itgb2 integrin beta 2 16414 274 540 582 384 2879 6211 16.19 7.00E-07
1418340_at Fcer1g Fc receptor, IgE, high
affinity I, gamma
polypeptide
14127 507 690 889 382 2708 5707 14.95 2.00E-05
1419483_at C3ar1 complement component 3a
receptor 1
12267 342 353 423 332 2266 4841 14.58 5.00E-07
1419209_at Cxcl1 chemokine (C-X-C motif)
ligand 1
14825 110 172 157 103 1157 1394 13.59 6.00E-06
1442082_at C3ar1 complement component 3a
receptor 1
12267 162 203 280 175 2019 3522 20.11 6.00E-08
1418126_at Ccl5 chemokine (C-C motif)
ligand 5
20304 24 73 420 67 406 1222 18.28 0.009
1450678_at Itgb2 integrin beta 2 16414 274 540 582 384 2879 6211 16.19 7.00E-07
1418340_at Fcer1g Fc receptor, IgE, high
affinity I, gamma
polypeptide
14127 507 690 889 382 2708 5707 14.95 2.00E-05
1419483_at C3ar1 complement component 3a
receptor 1
12267 342 353 423 332 2266 4841 14.58 5.00E-07
1419209_at Cxcl1 chemokine (C-X-C motif)
ligand 1
14825 110 172 157 103 1157 1394 13.59 6.00E-06
1449195_s_at Cxcl16 chemokine (C-X-C motif)
ligand 16
66102 190 164 238 146 1008 1929 13.18 7.00E-07
1436003_at Vcam1 vascular cell adhesion
molecule 1
22329 158 178 297 146 1348 1865 12.8 1.00E-07
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1430700_a_at Pla2g7 phospholipase A2, group
VII (platelet-activating
factor acetylhydrolase,
plasma)
27226 219 238 169 164 1438 2061 12.53 2.00E-04
1455269_a_at Coro1a coronin, actin binding
protein 1A
12721 169 336 625 275 1527 3332 12.12 1.00E-05
1419482_at C3ar1 complement component 3a
receptor 1
12267 235 228 335 252 1530 2963 11.78 1.00E-06
1416246_a_at Coro1a coronin, actin binding
protein 1A
12721 334 325 498 336 1586 3943 11.75 1.00E-05
1421712_at Sele selectin, endothelial cell 20339 20 48 83 34 184 362 10.78 7.00E-04
1416871_at Adam8 a disintegrin and
metallopeptidase domain 8
11501 195 215 174 181 1113 1881 10.42 9.00E-07
1428787_at Nckap1l NCK associated protein 1
like
105855 130 86 249 159 779 1589 10 7.00E-05
1420380_at Ccl2 chemokine (C-C motif)
ligand 2
20296 99 49 126 95 414 915 9.65 1.00E-04
1448620_at Fcgr3 Fc receptor, IgG, low
affinity III
14131 324 357 399 369 1881 3536 9.58 3.00E-06
1422932_a_at Vav1 vav 1 oncogene 22324 31 68 22 46 230 431 9.41 4.00E-04
1422445_at Itga6 integrin alpha 6 16403 356 738 578 308 1476 2682 8.7 1.00E-04
1418930_at Cxcl10 chemokine (C-X-C motif)
ligand 10
15945 84 92 98 48 185 403 8.33 5.00E-04
1418204_s_at Aif1 allograft inflammatory
factor 1
11629 166 234 394 191 676 1456 7.63 8.00E-07
1418718_at Cxcl16 chemokine (C-X-C motif)
ligand 16
66102 462 481 623 437 1456 3219 7.36 8.00E-07
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1435903_at Cd300a CD300A antigen 217303 214 236 244 184 720 1349 7.35 1.00E-06
1421186_at Ccr2 chemokine (C-C motif)
receptor 2
12772 154 154 132 130 619 939 7.21 3.00E-05
1418261_at Syk spleen tyrosine kinase 20963 311 375 517 281 875 1860 6.63 7.00E-06
1448162_at Vcam1 vascular cell adhesion
molecule 1
22329 1927 2139 2776 1455 7397 8838 6.07 1.00E-07
1425519_a_at Cd74 CD74 antigen (invariant
polypeptide of major
histocompatibility complex,
class II antigen-associated)
16149 1634 2699 4537 1955 7675 11699 5.98 4.00E-06
1428786_at Nckap1l NCK associated protein 1
like
105855 283 375 583 364 896 2157 5.92 2.00E-06
1451314_a_at Vcam1 vascular cell adhesion
molecule 1
22329 902 949 1671 857 3474 5052 5.89 1.00E-06
1417346_at Pycard PYD and CARD domain
containing
66824 399 333 506 335 802 1825 5.44 7.00E-06
1449127_at Selplg selectin, platelet (p-
selectin) ligand
20345 254 336 457 279 728 1495 5.36 5.00E-05
1415803_at Cx3cl1 chemokine (C-X3-C motif)
ligand 1
20312 262 349 622 278 772 1458 5.24 1.00E-06
1434653_at Ptk2b PTK2 protein tyrosine
kinase 2 beta
19229 261 463 424 263 748 1346 5.12 1.00E-06
1417620_at Rac2 RAS-related C3 botulinum
substrate 2
19354 366 467 503 475 1376 2369 4.99 3.00E-06
1418262_at Syk spleen tyrosine kinase 20963 149 133 185 133 404 664 4.98 2.00E-05
1451374_x_at Cklf chemokine-like factor 75458 152 119 140 75 198 365 4.85 7.00E-04
1419609_at Ccr1 chemokine (C-C motif)
receptor 1
12768 92 149 166 125 365 604 4.85 7.00E-05
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1460302_at Thbs1 thrombospondin 1 21825 1405 897 1318 1466 3249 7044 4.81 2.00E-06
1448859_at Cxcl13 chemokine (C-X-C motif)
ligand 13
55985 344 292 521 366 506 1742 4.76 3.00E-04
1422444_at Itga6 integrin alpha 6 16403 140 214 185 130 501 611 4.71 0.005
1422046_at Itgam integrin alpha M 16409 128 116 120 118 435 542 4.6 4.00E-05
1448449_at Ripk3 receptor-interacting serine-
threonine kinase 3
56532 98 72 104 80 174 365 4.59 4.00E-05
1417574_at Cxcl12 chemokine (C-X-C motif)
ligand 12
20315 577 562 615 474 1216 2174 4.58 1.00E-05
1415989_at Vcam1 vascular cell adhesion
molecule 1
22329 1174 1182 1475 1035 3424 4723 4.56 4.00E-07
1422823_at Eps8 epidermal growth factor
receptor pathway substrate
8
13860 247 296 317 207 683 922 4.45 5.00E-05
1427892_at Myo1g myosin IG 246177 229 319 418 289 623 1236 4.28 7.00E-06
1421187_at Ccr2 chemokine (C-C motif)
receptor 2
12772 59 71 18 57 218 244 4.27 1.00E-04
1439902_at C5ar1 complement component 5a
receptor 1
12273 128 130 163 108 287 460 4.24 7.00E-05
1434069_at Prex1 phosphatidylinositol-3,4,5-
trisphosphate-dependent
Rac exchange factor 1
277360 329 307 310 286 624 1159 4.06 1.00E-05
1449984_at Cxcl2 chemokine (C-X-C motif)
ligand 2
20310 67 97 113 78 179 306 3.94 1.00E-04
1419728_at Cxcl5 chemokine (C-X-C motif)
ligand 5
20311 36 46 74 36 200 136 3.73 7.00E-04
1417676_a_at Ptpro protein tyrosine 19277 240 281 311 226 530 822 3.64 7.00E-06
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1449925_at Cxcr3 chemokine (C-X-C motif)
receptor 3
12766 156 151 234 164 194 595 3.62 8.00E-05
1422824_s_at Eps8 epidermal growth factor
receptor pathway substrate
8
13860 281 335 416 234 637 846 3.61 2.00E-07
1450377_at Thbs1 thrombospondin 1 21825 717 476 570 799 1329 2712 3.39 1.00E-06
1450414_at Pdgfb platelet derived growth
factor, B polypeptide
18591 315 569 533 320 676 1084 3.38 9.00E-06
1417751_at Stk10 serine/threonine kinase 10 20868 328 238 642 299 598 1006 3.37 0.01
1415804_at Cx3cl1 chemokine (C-X3-C motif)
ligand 1
20312 67 134 123 78 315 258 3.3 0.003
1425357_a_at Grem1 gremlin 1 23892 130 147 161 112 178 358 3.21 4.00E-04
1424495_a_at Cklf chemokine-like factor 75458 249 241 266 185 347 584 3.16 7.00E-04
1424067_at Icam1 intercellular adhesion
molecule 1
15894 715 772 949 690 1677 2170 3.14 1.00E-06
1418806_at Csf3r colony stimulating factor 3
receptor (granulocyte)
12986 134 206 247 133 326 417 3.13 0.02
1452050_at Camk1d calcium/calmodulin-
dependent protein kinase ID
227541 114 215 189 143 292 436 3.04 6.00E-05
1419394_s_at S100a8 S100 calcium binding
protein A8 (calgranulin A)
20201 140 528 792 402 628 1182 2.94 0.007
1419132_at Tlr2 toll-like receptor 2 24088 329 398 499 378 713 1099 2.91 1.00E-05
1418252_at Padi2 peptidyl arginine deiminase,
type II
18600 126 178 252 166 226 482 2.9 5.00E-04
1421188_at Ccr2 chemokine (C-C motif) 12772 167 187 236 166 349 465 2.81 2.00E-04
1419480_at Sell selectin, lymphocyte 20343 150 187 285 194 187 527 2.72 0.002
1422190_at C5ar1 complement component 5a
receptor 1
12273 195 215 240 175 354 473 2.71 0.003
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1424208_at Ptger4 prostaglandin E receptor 4
(subtype EP4)
19219 470 631 955 533 1065 1426 2.68 2.00E-04
1449399_a_at Il1b interleukin 1 beta 16176 154 248 277 264 306 701 2.66 9.00E-04
1425863_a_at Ptpro protein tyrosine
phosphatase, receptor type,
O
19277 102 107 114 87 203 218 2.52 9.00E-04
1417122_at Vav3 vav 3 oncogene 57257 150 247 205 178 308 447 2.51 0.001
1448756_at S100a9 S100 calcium binding
protein A9 (calgranulin B)
20202 109 442 600 261 459 648 2.48 0.01
1420558_at Selp selectin, platelet 20344 1203 955 966 882 1883 2152 2.44 9.00E-05
1457644_s_at Cxcl1 chemokine (C-X-C motif)
ligand 1
14825 652 678 472 530 1301 1276 2.41 0.003
1421073_a_at Ptger4 prostaglandin E receptor 4
(subtype EP4)
19219 112 115 133 96 219 228 2.37 7.00E-04
1450357_a_at Ccr6 chemokine (C-C motif)
receptor 6
12458 182 215 239 211 189 496 2.35 0.02
1421578_at Ccl4 chemokine (C-C motif)
ligand 4
20303 369 367 586 386 521 885 2.29 0.003
1448550_at Lbp lipopolysaccharide binding
protein
16803 931 1284 1276 998 1934 2268 2.27 5.00E-05
1425860_x_at Cklf chemokine-like factor 75458 438 380 438 373 470 841 2.25 3.00E-04
1416371_at Apod apolipoprotein D 11815 474 1606 1672 607 1712 1358 2.24 2.00E-06
1419481_at Sell selectin, lymphocyte 20343 165 161 206 213 197 463 2.17 0.002
1448600_s_at Vav3 vav 3 oncogene 57257 212 366 305 250 365 542 2.17 6.00E-04
1438643_at Camk1d calcium/calmodulin-
dependent protein kinase ID
227541 145 174 133 160 282 340 2.12 0.009
1441855_x_at Cxcl1 chemokine (C-X-C motif)
ligand 1
14825 580 592 713 590 1086 1251 2.12 8.00E-04
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1425733_a_at Eps8 epidermal growth factor
receptor pathway substrate
8
13860 241 257 253 231 392 488 2.12 3.00E-05
1448823_at Cxcl12 chemokine (C-X-C motif)
ligand 12
20315 5885 5864 6394 5182 8384 10772 2.08 7.00E-06
1450020_at Cx3cr1 chemokine (C-X3-C motif)
receptor 1
13051 104 116 64 146 283 302 2.06 3.00E-04
1419300_at Flt1 FMS-like tyrosine kinase 1 14254 228 351 441 267 371 540 2.03 7.00E-04
1435495_at Adora1 adenosine A1 receptor 11539 149 258 96 89 185 158 1.77 0.004
1436037_at Itga4 integrin alpha 4 16401 583 457 457 585 753 1018 1.74 0.002
1417789_at Ccl11 chemokine (C-C motif)
ligand 11
20292 246 801 630 296 713 495 1.67 3.00E-04
1437347_at Ednrb endothelin receptor type B 13618 604 655 708 488 1040 812 1.66 0.04
1418456_a_at Cxcl14 chemokine (C-X-C motif)
ligand 14
57266 253 309 174 279 395 454 1.63 2.00E-05
1449528_at Figf c-fos induced growth factor 14205 1234 2306 2562 1309 2829 2009 1.53 8.00E-04
1449906_at Selp selectin, platelet 20344 205 146 102 180 454 273 1.52 0.002
1422474_at Pde4b phosphodiesterase 4B,
cAMP specific
18578 496 1257 1183 659 1373 860 1.3 4.00E-04
1451803_a_at Vegfb vascular endothelial growth
factor B
22340 344 743 629 422 723 544 1.29 0.001
1421857_at Adam17 a disintegrin and
metallopeptidase domain 17
11491 849 443 318 746 452 556 -1.34 3.00E-04
1425587_a_at Ptprj protein tyrosine
phosphatase, receptor type,
J
19271 246 175 106 214 226 156 -1.37 0.01
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1430630_at Itgb1 integrin beta 1 (fibronectin
receptor beta)
16412 196 165 96 169 160 108 -1.56 5.00E-04
1422102_a_at Stat5b signal transducer and
activator of transcription 5B
20851 326 292 265 404 190 213 -1.89 0.002
1423503_at Jam3 junction adhesion molecule
3
83964 1694 1509 1630 1718 1241 853 -2.01 2.00E-05
1425091_at Rarres2 retinoic acid receptor
responder (tazarotene
induced) 2
71660 294 255 223 284 238 141 -2.02 2.00E-04
1423444_at Rock1 Rho-associated coiled-coil
containing protein kinase 1
19877 6804 4986 5060 6358 4734 3121 -2.04 2.00E-05
1423445_at Rock1 Rho-associated coiled-coil
containing protein kinase 1
19877 5911 5987 5146 6020 4999 2765 -2.18 5.00E-06
1454824_s_at Mtus1 mitochondrial tumor
suppressor 1
102103 2794 2882 2177 2573 2180 1131 -2.28 2.00E-05
1449396_at Aoc3 amine oxidase, copper
containing 3
11754 3675 3868 3401 4108 3563 1730 -2.37 8.00E-05
1437673_at Wnt5a wingless-type MMTV
integration site family,
member 5A
22418 246 284 183 201 226 85 -2.37 0.003
1436501_at Mtus1 mitochondrial tumor
suppressor 1
102103 2086 1613 1415 1767 1376 721 -2.45 3.00E-06
1436502_at Mtus1 mitochondrial tumor
suppressor 1
102103 923 579 442 654 443 240 -2.72 3.00E-04
1436791_at Wnt5a wingless-type MMTV
integration site family,
member 5A
22418 706 850 713 786 717 241 -3.26 2.00E-05
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
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F. Meloid leukocyte migration (GO: 0097529)  
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1431693_a_at Il17b interleukin 17B 56069 348 145 345 295 38 89 -3.32 0.002
1438533_at Myo9b myosin IXb 17925 240 99 60 204 114 58 -3.53 0.003
1415900_a_at Kit kit oncogene 16590 224 229 153 266 226 74 -3.58 0.03
1460729_at Rock1 Rho-associated coiled-coil
containing protein kinase 1
19877 1233 366 564 965 389 266 -3.63 2.00E-06
1450029_s_at Itga9 integrin alpha 9 104099 1853 1428 1011 1932 1276 518 -3.73 1.00E-05
1439713_at Itga1 integrin alpha 1 109700 410 304 118 425 278 92 -4.61 2.00E-04
1427771_x_at Itgb1 integrin beta 1 (fibronectin
receptor beta)
16412 1680 2297 732 2442 1692 505 -4.83 0.001
1460285_at Itga9 integrin alpha 9 104099 3458 2214 1617 3486 1844 695 -5.01 2.00E-05
1448818_at Wnt5a wingless-type MMTV
integration site family,
member 5A
22418 653 606 253 721 519 140 -5.14 8.00E-06
1420860_at Itga9 integrin alpha 9 104099 789 476 286 742 398 114 -6.49 3.00E-05
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1449254_at Spp1 secreted phosphoprotein 1 20750 46 93 326 76 13398 13789 180.67 3.00E-05
1419561_at Ccl3 chemokine (C-C motif)
ligand 3
20302 6 18 9 12 212 597 48.71 5.00E-06
1419282_at Ccl12 chemokine (C-C motif)
ligand 12
20293 83 27 134 23 374 926 40.66 4.00E-05
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1426808_at Lgals3 lectin, galactose binding,
soluble 3
16854 652 822 1038 693 9961 13992 20.2 2.00E-08
1442082_at C3ar1 complement component 3a
receptor 1
12267 162 203 280 175 2019 3522 20.11 6.00E-08
1418126_at Ccl5 chemokine (C-C motif)
ligand 5
20304 24 73 420 67 406 1222 18.28 0.009
1450678_at Itgb2 integrin beta 2 16414 274 540 582 384 2879 6211 16.19 7.00E-07
1418340_at Fcer1g Fc receptor, IgE, high
affinity I, gamma
polypeptide
14127 507 690 889 382 2708 5707 14.95 2.00E-05
1419483_at C3ar1 complement component 3a
receptor 1
12267 342 353 423 332 2266 4841 14.58 5.00E-07
1419209_at Cxcl1 chemokine (C-X-C motif)
ligand 1
14825 110 172 157 103 1157 1394 13.59 6.00E-06
1430700_a_at Pla2g7 phospholipase A2, group
VII (platelet-activating
factor acetylhydrolase,
plasma)
27226 219 238 169 164 1438 2061 12.53 2.00E-04
1419482_at C3ar1 complement component 3a
receptor 1
12267 235 228 335 252 1530 2963 11.78 1.00E-06
1416871_at Adam8 a disintegrin and
metallopeptidase domain 8
11501 195 215 174 181 1113 1881 10.42 9.00E-07
1428787_at Nckap1l NCK associated protein 1
like
105855 130 86 249 159 779 1589 10 7.00E-05
1420380_at Ccl2 chemokine (C-C motif)
ligand 2
20296 99 49 126 95 414 915 9.65 1.00E-04
1448620_at Fcgr3 Fc receptor, IgG, low
affinity III
14131 324 357 399 369 1881 3536 9.58 3.00E-06
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
SUPPLEMENT 
128 
 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1422932_a_at Vav1 vav 1 oncogene 22324 31 68 22 46 230 431 9.41 4.00E-04
1418930_at Cxcl10 chemokine (C-X-C motif)
ligand 10
15945 84 92 98 48 185 403 8.33 5.00E-04
1418204_s_at Aif1 allograft inflammatory
factor 1
11629 166 234 394 191 676 1456 7.63 8.00E-07
1435903_at Cd300a CD300A antigen 217303 214 236 244 184 720 1349 7.35 1.00E-06
1421186_at Ccr2 chemokine (C-C motif)
receptor 2
12772 154 154 132 130 619 939 7.21 3.00E-05
1418261_at Syk spleen tyrosine kinase 20963 311 375 517 281 875 1860 6.63 7.00E-06
1425519_a_at Cd74 CD74 antigen (invariant
polypeptide of major
histocompatibility complex,
class II antigen-associated)
16149 1634 2699 4537 1955 7675 11699 5.98 4.00E-06
1428786_at Nckap1l NCK associated protein 1
like
105855 283 375 583 364 896 2157 5.92 2.00E-06
1415803_at Cx3cl1 chemokine (C-X3-C motif)
ligand 1
20312 262 349 622 278 772 1458 5.24 1.00E-06
1434653_at Ptk2b PTK2 protein tyrosine
kinase 2 beta
19229 261 463 424 263 748 1346 5.12 1.00E-06
1417620_at Rac2 RAS-related C3 botulinum
substrate 2
19354 366 467 503 475 1376 2369 4.99 3.00E-06
1418262_at Syk spleen tyrosine kinase 20963 149 133 185 133 404 664 4.98 2.00E-05
1451374_x_at Cklf chemokine-like factor 75458 152 119 140 75 198 365 4.85 7.00E-04
1419609_at Ccr1 chemokine (C-C motif)
receptor 1
12768 92 149 166 125 365 604 4.85 7.00E-05
1460302_at Thbs1 thrombospondin 1 21825 1405 897 1318 1466 3249 7044 4.81 2.00E-06
1422046_at Itgam integrin alpha M 16409 128 116 120 118 435 542 4.6 4.00E-05
1417574_at Cxcl12 chemokine (C-X-C motif)
ligand 12
20315 577 562 615 474 1216 2174 4.58 1.00E-05
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1419300_at Flt1 FMS-like tyrosine kinase 1 14254 228 351 441 267 371 540 2.03 7.00E-04
1417789_at Ccl11 chemokine (C-C motif)
ligand 11
20292 246 801 630 296 713 495 1.67 3.00E-04
1437347_at Ednrb endothelin receptor type B 13618 604 655 708 488 1040 812 1.66 0.04
1449528_at Figf c-fos induced growth factor 14205 1234 2306 2562 1309 2829 2009 1.53 8.00E-04
1422474_at Pde4b phosphodiesterase 4B,
cAMP specific
18578 496 1257 1183 659 1373 860 1.3 4.00E-04
1451803_a_at Vegfb vascular endothelial growth
factor B
22340 344 743 629 422 723 544 1.29 0.001
1425587_a_at Ptprj protein tyrosine
phosphatase, receptor type,
J
19271 246 175 106 214 226 156 -1.37 0.01
1422102_a_at Stat5b signal transducer and
activator of transcription 5B
20851 326 292 265 404 190 213 -1.89 0.002
1423503_at Jam3 junction adhesion molecule
3
83964 1694 1509 1630 1718 1241 853 -2.01 2.00E-05
1425091_at Rarres2 retinoic acid receptor
responder (tazarotene
induced) 2
71660 294 255 223 284 238 141 -2.02 2.00E-04
1454824_s_at Mtus1 mitochondrial tumor
suppressor 1
102103 2794 2882 2177 2573 2180 1131 -2.28 2.00E-05
1436501_at Mtus1 mitochondrial tumor
suppressor 1
102103 2086 1613 1415 1767 1376 721 -2.45 3.00E-06
1436502_at Mtus1 mitochondrial tumor
suppressor 1
102103 923 579 442 654 443 240 -2.72 3.00E-04
1431693_a_at Il17b interleukin 17B 56069 348 145 345 295 38 89 -3.32 0.002
1438533_at Myo9b myosin IXb 17925 240 99 60 204 114 58 -3.53 0.003
1415900_a_at Kit kit oncogene 16590 224 229 153 266 226 74 -3.58 0.03
p ANOVA
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
Gene name
Mean
Wt  aorta
6 weeks
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G. Phagocytosis (GO: 0006909) 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1450029_s_at Itga9 integrin alpha 9 104099 1853 1428 1011 1932 1276 518 -3.73 1.00E-05
1439713_at Itga1 integrin alpha 1 109700 410 304 118 425 278 92 -4.61 2.00E-04
1460285_at Itga9 integrin alpha 9 104099 3458 2214 1617 3486 1844 695 -5.01 2.00E-05
1420860_at Itga9 integrin alpha 9 104099 789 476 286 742 398 114 -6.49 3.00E-05
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1420699_at Clec7a C-type lectin domain family
7, member a
56644 238 388 461 273 3319 5253 19.26 9.00E-08
1438097_at Rab20 RAB20, member RAS
oncogene family
19332 8 7 46 12 77 184 15.09 5.00E-05
1418340_at Fcer1g Fc receptor, IgE, high
affinity I, gamma
polypeptide
14127 507 690 889 382 2708 5707 14.95 2.00E-05
1455269_a_at Coro1a coronin, actin binding
protein 1A
12721 169 336 625 275 1527 3332 12.12 1.00E-05
1416246_a_at Coro1a coronin, actin binding
protein 1A
12721 334 325 498 336 1586 3943 11.75 1.00E-05
1422808_s_at Dock2 dedicator of cyto-kinesis 2 94176 132 177 262 124 559 1417 11.48 1.00E-06
1428787_at Nckap1l NCK associated protein 1
like
105855 130 86 249 159 779 1589 10 7.00E-05
1420380_at Ccl2 chemokine (C-C motif)
ligand 2
20296 99 49 126 95 414 915 9.65 1.00E-04
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1448620_at Fcgr3 Fc receptor, IgG, low
affinity III
14131 324 357 399 369 1881 3536 9.58 3.00E-06
1422932_a_at Vav1 vav 1 oncogene 22324 31 68 22 46 230 431 9.41 4.00E-04
1448452_at Irf8 interferon regulatory factor
8
15900 80 70 93 86 464 726 8.46 3.00E-04
1418204_s_at Aif1 allograft inflammatory
factor 1
11629 166 234 394 191 676 1456 7.63 8.00E-07
1435903_at Cd300a CD300A antigen 217303 214 236 244 184 720 1349 7.35 1.00E-06
1416714_at Irf8 interferon regulatory factor
8
15900 194 249 333 209 705 1523 7.3 7.00E-06
1421186_at Ccr2 chemokine (C-C motif)
receptor 2
12772 154 154 132 130 619 939 7.21 3.00E-05
1417876_at Fcgr1 Fc receptor, IgG, high
affinity I
14129 156 174 234 153 627 1066 6.96 2.00E-06
1420715_a_at Pparg peroxisome proliferator
activated receptor gamma
19016 29 476 171 60 375 400 6.65 0.002
1418261_at Syk spleen tyrosine kinase 20963 311 375 517 281 875 1860 6.63 7.00E-06
1428786_at Nckap1l NCK associated protein 1
like
105855 283 375 583 364 896 2157 5.92 2.00E-06
1416985_at Sirpa signal-regulatory protein
alpha
19261 927 971 1137 930 3410 5382 5.78 9.00E-07
1424987_at 5430435
G22Rik
RIKEN cDNA 5430435G22
gene
226421 313 302 408 330 886 1891 5.73 1.00E-06
1423166_at Cd36 CD36 antigen 12491 794 3237 1578 835 4019 4649 5.57 8.00E-06
1435477_s_at Fcgr2b Fc receptor, IgG, low
affinity IIb
14130 736 720 1048 705 2176 3922 5.56 4.00E-06
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1417346_at Pycard PYD and CARD domain
containing
66824 399 333 506 335 802 1825 5.44 7.00E-06
1451941_a_at Fcgr2b Fc receptor, IgG, low
affinity IIb
14130 549 458 690 506 1472 2594 5.13 1.00E-05
1435830_a_at 5430435
G22Rik
RIKEN cDNA 5430435G22
gene
226421 117 132 73 99 290 505 5.11 0.009
1418262_at Syk spleen tyrosine kinase 20963 149 133 185 133 404 664 4.98 2.00E-05
1460302_at Thbs1 thrombospondin 1 21825 1405 897 1318 1466 3249 7044 4.81 2.00E-06
1455332_x_at Fcgr2b Fc receptor, IgG, low
affinity IIb
14130 254 277 421 334 907 1444 4.32 3.00E-05
1427892_at Myo1g myosin IG 246177 229 319 418 289 623 1236 4.28 7.00E-06
1421187_at Ccr2 chemokine (C-C motif)
receptor 2
12772 59 71 18 57 218 244 4.27 1.00E-04
1423954_at C3 complement component 3 12266 1929 4798 3722 2416 8194 10023 4.15 2.00E-06
1420361_at Slc11a1 solute carrier family 11
(proton-coupled divalent
metal ion transporters),
member 1
18173 662 704 802 668 1645 2664 3.99 1.00E-06
1433678_at Pld4 phospholipase D family,
member 4
104759 284 345 354 270 714 1069 3.96 1.00E-05
1450883_a_at Cd36 CD36 antigen 12491 1224 4327 1699 1492 5328 5773 3.87 1.00E-05
1449455_at Hck hemopoietic cell kinase 15162 304 332 451 317 658 1215 3.84 9.00E-06
1420653_at Tgfb1 transforming growth factor,
beta 1
21803 516 538 551 440 1292 1670 3.79 8.00E-07
1450377_at Thbs1 thrombospondin 1 21825 717 476 570 799 1329 2712 3.39 1.00E-06
1419526_at Fgr Gardner-Rasheed feline
sarcoma viral (Fgr)
oncogene homolog
14191 184 254 418 227 569 763 3.37 1.00E-04
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1452050_at Camk1d calcium/calmodulin-
dependent protein kinase ID
227541 114 215 189 143 292 436 3.04 6.00E-05
1421840_at Abca1 ATP-binding cassette, sub-
family A (ABC1), member 1
11303 1805 2970 2438 3039 7715 8828 2.9 8.00E-07
1421839_at Abca1 ATP-binding cassette, sub-
family A (ABC1), member 1
11303 406 422 385 673 1638 1913 2.84 5.00E-06
1448534_at Sirpa signal-regulatory protein
alpha
19261 542 445 509 554 1153 1569 2.83 2.00E-05
1421188_at Ccr2 chemokine (C-C motif)
receptor 2
12772 167 187 236 166 349 465 2.81 2.00E-04
1421385_a_at Myo7a myosin VIIA 17921 228 269 272 241 408 673 2.79 3.00E-05
1416986_a_at Sirpa signal-regulatory protein
alpha
19261 231 248 141 266 618 734 2.76 1.00E-05
1449399_a_at Il1b interleukin 1 beta 16176 154 248 277 264 306 701 2.66 9.00E-04
1436625_at Fcgr1 Fc receptor, IgG, high
affinity I
14129 150 172 282 182 348 484 2.65 0.001
1435220_s_at Cdc42se
2
CDC42 small effector 2 72729 483 400 376 403 612 1057 2.63 4.00E-05
1439787_at P2rx7 purinergic receptor P2X,
ligand-gated ion channel, 7
18439 335 463 522 352 719 922 2.62 2.00E-06
1419238_at Abca7 ATP-binding cassette, sub-
family A (ABC1), member 7
27403 225 303 419 226 346 586 2.6 2.00E-04
1458683_at Sirpb1a signal-regulatory protein
beta 1A
320832 160 87 154 170 200 440 2.59 0.02
1450884_at Cd36 CD36 antigen 12491 147 624 269 200 508 484 2.42 4.00E-05
1419853_a_at P2rx7 purinergic receptor P2X,
ligand-gated ion channel, 7
18439 138 186 113 129 250 300 2.33 0.002
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1448550_at Lbp lipopolysaccharide binding
protein
16803 931 1284 1276 998 1934 2268 2.27 5.00E-05
1450392_at Abca1 ATP-binding cassette, sub-
family A (ABC1), member 1
11303 164 150 115 272 596 580 2.14 8.00E-06
1422651_at Adipoq adiponectin, C1Q and
collagen domain containing
11450 2602 6562 3968 2524 5547 5362 2.12 0.001
1438643_at Camk1d calcium/calmodulin-
dependent protein kinase ID
227541 145 174 133 160 282 340 2.12 0.009
1442804_at Fgr Gardner-Rasheed feline
sarcoma viral (Fgr)
oncogene homolog
14191 207 237 399 263 407 559 2.12 0.001
1423518_at Csk c-src tyrosine kinase 12988 492 500 676 473 535 962 2.03 5.00E-04
1457664_x_at C2 complement component 2
(within H-2S)
12263 357 255 619 365 420 573 1.57 0.002
1418666_at Ptx3 pentraxin related gene 19288 137 133 104 152 277 239 1.57 0.02
1441248_at Clcn3 chloride channel 3 12725 133 79 240 167 115 249 1.49 0.005
1422553_at Pten phosphatase and tensin
homolog
19211 1496 1011 617 1534 1229 973 -1.58 0.006
1428816_a_at Gata2 GATA binding protein 2 14461 317 363 391 301 360 176 -1.71 0.007
1451939_a_at Srpx sushi-repeat-containing
protein
51795 1194 526 566 1007 679 540 -1.87 6.00E-05
1432004_a_at Dnm2 dynamin 2 13430 392 371 174 429 440 208 -2.07 8.00E-05
1421198_at Itgav integrin alpha V 16410 791 365 315 593 363 282 -2.1 4.00E-04
1453771_at Gulp1 GULP, engulfment adaptor
PTB domain containing 1
70676 1522 1384 1185 1500 1242 658 -2.28 1.00E-07
1420925_at Tub tubby candidate gene 22141 1457 1557 1616 1506 1087 433 -3.48 2.00E-04
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
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H. Cellular response to lipid (GO: 0071396) 
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1417752_at Coro1c coronin, actin binding
protein 1C
23790 1030 947 443 1219 818 334 -3.65 7.00E-06
1432092_a_at Gulp1 GULP, engulfment adaptor
PTB domain containing 1
70676 402 199 187 455 227 100 -4.53 0.03
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1421792_s_at Trem2 triggering receptor
expressed on myeloid cells
2
83433 22 25 27 22 707 1816 83.52 2.00E-07
1419282_at Ccl12 chemokine (C-C motif)
ligand 12
20293 83 27 134 23 374 926 40.66 4.00E-05
1450297_at Il6 interleukin 6 16193 21 10 57 21 290 523 24.46 1.00E-04
1418126_at Ccl5 chemokine (C-C motif)
ligand 5
20304 24 73 420 67 406 1222 18.28 0.009
1449195_s_at Cxcl16 chemokine (C-X-C motif)
ligand 16
66102 190 164 238 146 1008 1929 13.18 7.00E-07
1420380_at Ccl2 chemokine (C-C motif)
ligand 2
20296 99 49 126 95 414 915 9.65 1.00E-04
1422903_at Ly86 lymphocyte antigen 86 17084 417 477 693 421 1743 3863 9.18 2.00E-06
1445882_at Cd300lb CD300 antigen like family
member B
217304 170 165 219 139 694 1201 8.67 1.00E-06
1448452_at Irf8 interferon regulatory factor
8
15900 80 70 93 86 464 726 8.46 3.00E-04
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1418930_at Cxcl10 chemokine (C-X-C motif)
ligand 10
15945 84 92 98 48 185 403 8.33 5.00E-04
1418718_at Cxcl16 chemokine (C-X-C motif)
ligand 16
66102 462 481 623 437 1456 3219 7.36 8.00E-07
1416714_at Irf8 interferon regulatory factor
8
15900 194 249 333 209 705 1523 7.3 7.00E-06
1420715_a_at Pparg peroxisome proliferator
activated receptor gamma
19016 29 476 171 60 375 400 6.65 0.002
1425225_at Fcgr4 Fc receptor, IgG, low
affinity IV
246256 145 232 360 298 877 1955 6.56 2.00E-06
1426858_at Inhbb inhibin beta-B 16324 197 496 510 218 618 1219 5.6 1.00E-06
1423166_at Cd36 CD36 antigen 12491 794 3237 1578 835 4019 4649 5.57 8.00E-06
1417346_at Pycard PYD and CARD domain
containing
66824 399 333 506 335 802 1825 5.44 7.00E-06
1447643_x_at Snai2 snail family zinc finger 2 20583 733 428 1253 398 856 2082 5.24 0.04
1434653_at Ptk2b PTK2 protein tyrosine
kinase 2 beta
19229 261 463 424 263 748 1346 5.12 1.00E-06
1418099_at Tnfrsf1b tumor necrosis factor
receptor superfamily,
member 1b
21938 300 400 416 308 986 1555 5.05 6.00E-06
1417268_at Cd14 CD14 antigen 12475 577 649 838 605 1254 2776 4.59 2.00E-06
1460273_a_at Naip2 NLR family, apoptosis
inhibitory protein 2
17948 80 138 136 110 293 444 4.03 2.00E-05
1449310_at Ptger2 prostaglandin E receptor 2
(subtype EP2)
19217 60 77 87 65 151 255 3.95 1.00E-04
1450883_a_at Cd36 CD36 antigen 12491 1224 4327 1699 1492 5328 5773 3.87 1.00E-05
1420653_at Tgfb1 transforming growth factor,
beta 1
21803 516 538 551 440 1292 1670 3.79 8.00E-07
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1447927_at Gbp6 guanylate binding protein 6 100702 244 375 398 190 524 667 3.52 0.004
1420425_at Prdm1 PR domain containing 1,
with ZNF domain
12142 144 169 175 159 193 463 2.92 0.002
1421840_at Abca1 ATP-binding cassette, sub-
family A (ABC1), member 1
11303 1805 2970 2438 3039 7715 8828 2.9 8.00E-07
1421839_at Abca1 ATP-binding cassette, sub-
family A (ABC1), member 1
11303 406 422 385 673 1638 1913 2.84 5.00E-06
1421547_at Cd180 CD180 antigen 17079 223 279 274 219 599 621 2.84 5.00E-05
1440481_at Stat1 signal transducer and
activator of transcription 1
20846 104 104 103 117 165 316 2.71 0.002
1449399_a_at Il1b interleukin 1 beta 16176 154 248 277 264 306 701 2.66 9.00E-04
1420992_at Ankrd1 ankyrin repeat domain 1
(cardiac muscle)
107765 360 408 520 408 418 1054 2.58 0.001
1416303_at Litaf LPS-induced TN factor 56722 2048 1894 2430 2047 3700 5169 2.53 3.00E-06
1420915_at Stat1 signal transducer and
activator of transcription 1
20846 300 422 402 313 628 778 2.49 2.00E-05
1438091_a_at H2afz H2A histone family,
member Z
51788 2221 2211 2803 1710 2651 4222 2.47 5.00E-05
1418240_at Gbp2 guanylate binding protein 2 14469 721 912 1200 778 1313 1913 2.46 3.00E-04
1435906_x_at Gbp2 guanylate binding protein 2 14469 713 996 1131 750 1395 1828 2.44 2.00E-04
1416304_at Litaf LPS-induced TN factor 56722 1054 720 953 1013 1704 2463 2.43 9.00E-05
1450884_at Cd36 CD36 antigen 12491 147 624 269 200 508 484 2.42 4.00E-05
1448550_at Lbp lipopolysaccharide binding
protein
16803 931 1284 1276 998 1934 2268 2.27 5.00E-05
1438092_x_at H2afz H2A histone family,
member Z
51788 2062 2204 2383 1732 2584 3909 2.26 3.00E-05
1433699_at Tnfaip3 tumor necrosis factor,
alpha-induced protein 3
21929 569 683 845 643 1032 1441 2.24 1.00E-04
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1417932_at Il18 interleukin 18 16173 266 241 362 270 475 594 2.2 0.004
1450392_at Abca1 ATP-binding cassette, sub-
family A (ABC1), member 1
11303 164 150 115 272 596 580 2.14 8.00E-06
1450033_a_at Stat1 signal transducer and
activator of transcription 1
20846 462 539 381 447 740 951 2.12 8.00E-04
1425214_at P2ry6 pyrimidinergic receptor
P2Y, G-protein coupled, 6
233571 646 940 826 828 1292 1737 2.1 4.00E-04
1449874_at Ly96 lymphocyte antigen 96 17087 393 259 353 296 403 617 2.08 8.00E-04
1418744_s_at Tesc tescalcin 57816 177 572 509 152 403 316 2.07 0.001
1420991_at Ankrd1 ankyrin repeat domain 1
(cardiac muscle)
107765 393 368 562 463 354 916 1.98 8.00E-04
1435458_at Pim1 proviral integration site 1 18712 562 1097 507 694 950 1334 1.92 2.00E-05
1434185_at Acaca acetyl-Coenzyme A
carboxylase alpha
107476 753 2742 1470 1006 2047 1815 1.8 0.004
1450829_at Tnfaip3 tumor necrosis factor,
alpha-induced protein 3
21929 50 77 119 133 144 239 1.8 0.01
1422678_at Dgat2 diacylglycerol O-
acyltransferase 2
67800 968 4122 2231 1527 3277 2664 1.74 3.00E-04
1424950_at Sox9 SRY (sex determining
region Y)-box 9
20682 72 134 46 113 313 192 1.71 8.00E-04
1438676_at Gbp6 guanylate binding protein 6 100702 129 273 180 166 316 265 1.6 5.00E-04
1416958_at Nr1d2 nuclear receptor subfamily
1, group D, member 2
353187 1849 4023 3301 1701 3317 2679 1.57 0.002
1416041_at Sgk1 serum/glucocorticoid
regulated kinase 1
20393 4259 2102 2122 2774 3162 4106 1.48 0.003
1423086_at Npc1 Niemann-Pick type C1 18145 576 494 344 499 693 725 1.45 0.005
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1431292_a_at Twf2 twinfilin, actin-binding
protein, homolog 2
(Drosophila)
23999 311 331 170 266 334 381 1.43 0.008
1418167_at Tfap4 transcription factor AP4 83383 140 276 285 177 227 248 1.4 0.006
1422474_at Pde4b phosphodiesterase 4B,
cAMP specific
18578 496 1257 1183 659 1373 860 1.3 4.00E-04
1439364_a_at Mmp2 matrix metallopeptidase 2 17390 3914 2827 2177 3996 3443 4990 1.25 2.00E-04
1417273_at Pdk4 pyruvate dehydrogenase
kinase, isoenzyme 4
27273 1340 4010 1390 1020 2303 1252 1.23 1.00E-04
1422677_at Dgat2 diacylglycerol O-
acyltransferase 2
67800 735 2221 987 922 1797 1127 1.22 2.00E-04
1419415_a_at Rarg retinoic acid receptor,
gamma
19411 736 1213 854 574 1209 698 1.22 0.004
1416136_at Mmp2 matrix metallopeptidase 2 17390 5328 3177 2750 5567 4910 6603 1.19 7.00E-06
1436026_at Zfp703 zinc finger protein 703 353310 674 1672 1251 1128 1541 1279 1.13 0.01
1426464_at Nr1d1 nuclear receptor subfamily
1, group D, member 1
217166 503 1455 1219 638 1230 634 -1.01 0.004
1437064_at Ar androgen receptor 11835 496 815 1038 657 700 592 -1.11 0.001
1457721_at Ppara peroxisome proliferator
activated receptor alpha
19013 152 433 210 182 313 141 -1.3 0.003
1436475_at Nr2f2 nuclear receptor subfamily
2, group F, member 2
11819 457 720 910 552 624 421 -1.31 0.001
1448076_at Ctr9 Ctr9, Paf1/RNA polymerase
II complex component,
homolog (S. cerevisiae)
22083 192 142 87 174 150 133 -1.31 0.009
1448395_at Sfrp1 secreted frizzled-related
protein 1
20377 1584 999 626 1162 1758 870 -1.33 3.00E-04
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1421907_at Med1 mediator complex subunit 1 19014 1092 681 497 1138 844 722 -1.58 0.05
1416594_at Sfrp1 secreted frizzled-related
protein 1
20377 476 46 81 379 384 230 -1.64 7.00E-06
1436326_at Rora RAR-related orphan
receptor alpha
19883 1392 760 671 1244 696 699 -1.78 8.00E-06
1424034_at Rora RAR-related orphan
receptor alpha
19883 2711 1328 1522 2238 1085 1240 -1.8 7.00E-06
1439107_a_at Kmt2e lysine (K)-specific
methyltransferase 2E
69188 833 656 310 969 920 520 -1.87 0.006
1460647_a_at Nr2f6 nuclear receptor subfamily
2, group F, member 6
13864 548 268 250 589 280 292 -2.01 6.00E-04
1425014_at Nr2c2 nuclear receptor subfamily
2, group C, member 2
22026 240 193 131 236 205 117 -2.02 0.01
1426997_at Thra thyroid hormone receptor
alpha
21833 943 1034 1176 1328 998 657 -2.02 0.005
1424035_at Rora RAR-related orphan
receptor alpha
19883 289 153 146 329 133 156 -2.11 8.00E-04
1455165_at Rora RAR-related orphan
receptor alpha
19883 1506 1025 992 1296 785 602 -2.15 3.00E-04
1425991_a_at Kank2 KN motif and ankyrin repeat
domains 2
235041 785 835 563 1050 866 483 -2.17 0.01
1420583_a_at Rora RAR-related orphan
receptor alpha
19883 2192 981 1052 1729 829 794 -2.18 1.00E-05
1434766_at Prkaa2 protein kinase, AMP-
activated, alpha 2 catalytic
subunit
108079 979 1180 867 982 830 448 -2.19 4.00E-05
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVAGene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1442827_at Tlr4 toll-like receptor 4 21898 413 183 137 320 208 142 -2.26 9.00E-04
1443823_s_at Atp1a2 ATPase, Na+/K+
transporting, alpha 2
polypeptide
98660 4204 4898 4399 4678 3867 2059 -2.27 0.002
1434893_at Atp1a2 ATPase, Na+/K+
transporting, alpha 2
polypeptide
98660 1696 2456 2107 2034 2020 882 -2.31 2.00E-04
1416487_a_at Yap1 yes-associated protein 1 22601 502 332 207 413 267 174 -2.38 3.00E-04
1426057_a_at Epha3 Eph receptor A3 13837 354 175 106 275 185 114 -2.41 2.00E-05
1421028_a_at Mef2c myocyte enhancer factor 2C 17260 1504 712 697 1362 767 561 -2.43 5.00E-05
1439527_at Pgr progesterone receptor 18667 1070 1270 1283 1023 564 415 -2.46 2.00E-04
1451927_a_at Mapk14 mitogen-activated protein
kinase 14
26416 266 222 119 287 224 113 -2.53 9.00E-05
1429463_at Prkaa2 protein kinase, AMP-
activated, alpha 2 catalytic
subunit
108079 1407 1460 827 1475 1117 580 -2.54 5.00E-04
1425575_at Epha3 Eph receptor A3 13837 1622 1172 800 1599 964 625 -2.56 1.00E-04
1427465_at Atp1a2 ATPase, Na+/K+
transporting, alpha 2
polypeptide
98660 1924 1820 1671 2017 1459 784 -2.57 6.00E-04
1429003_at Snw1 SNW domain containing 1 66354 524 402 177 511 418 196 -2.61 1.00E-05
1421866_at Nr3c1 nuclear receptor subfamily
3, group C, member 1
14815 726 301 383 682 476 257 -2.65 2.00E-04
1425574_at Epha3 Eph receptor A3 13837 550 193 247 534 236 189 -2.82 4.00E-05
1458129_at Rora RAR-related orphan
receptor alpha
19883 783 531 348 754 409 262 -2.87 7.00E-06
1422264_s_at Klf9 Kruppel-like factor 9 16601 363 330 165 395 255 136 -2.91 0.003
Gene name
Mean
Wt  aorta
6 weeks
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
Apoe
-/-
 aorta
32 weeks
Mean
Apoe
-/-
 aorta
78 weeks
p ANOVA
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Fold change
Affymetrix Gene Entrez Apoe
-/-
 aorta
Probe set ID symbol Gene ID 78 weeks
vs. 6 weeks
1421027_a_at Mef2c myocyte enhancer factor 2C 17260 2673 1597 972 2514 1694 854 -2.94 2.00E-05
1451569_at Nr2c2 nuclear receptor subfamily
2, group C, member 2
22026 346 153 121 331 233 104 -3.18 0.006
1451022_at Lrp6 low density lipoprotein
receptor-related protein 6
16974 207 120 45 199 131 58 -3.46 2.00E-04
1459372_at Npas4 neuronal PAS domain
protein 4
225872 320 122 62 200 51 45 -4.43 0.04
1453860_s_at Nr3c1 nuclear receptor subfamily
3, group C, member 1
14815 227 81 46 174 103 20 -8.62 0.005
1449998_at Nkx3-1 NK-3 transcription factor,
locus 1 (Drosophila)
18095 605 403 563 719 319 28 -26.12 1.00E-05
p ANOVA
Mean
Wt  aorta
32 weeks
Mean
Wt  aorta
78 weeks
Mean
Apoe
-/-
 aorta
6 weeks
Mean
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-/-
 aorta
32 weeks
Mean
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Gene name
Mean
Wt  aorta
6 weeks
